

RIDOUT & MAYBEE

Patent & Trade Mark Agents

Our Ref: 36541-0005

October 6, 2000

DELIVERED**THE COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231**

Dear Sir:

We enclose the documents identified below in respect of a patent application in the name of **Harold A. Robertson and Eileen M. Donovan-Wright** for an invention entitled **"GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND COMPOUNDS FOR MODULATING SAME"** to be filed on receipt.

Enclosed are:

- Specification, Claims & Abstract
- Declaration, Power of Attorney
- 41 Sheets of Drawings
- Small Entity Declaration
- Cover Letter
- Assignment
- Assignment Recordation Form Cover Sheet
- Sequence listings on diskette
- Response Card

	CLAIMS FILED		BASIC FEE
	Number	Excess	
	Rate		\$ 355.00
Total claims	19 - 20 =	x	
Independent claims	4 - 3 = 1	x 40	\$ 40.00
Multiple dependencies			
	Total filing fees		\$ 395.00

P. Lwan McArdle
B.Sc. (Mech. Eng.)

W. Charles Kent
B.Sc. (Eng. Chem.) LL.B., F.R.S.

J. Douglas Wilson
B.Sc., LL.B.

William R. Edgar
B.Sc. (Chem. Eng.) LL.B.

Richard A.R. Parsons
B.A. (Hons.) LL.B.

Philip K. Holland
LL.B. (Hons.)

James R. Lake
Ph.D. (Chem. Chem.) LL.B.

Randall S. Mitchell
Ph.D. (Polymer Chem.) LL.B.

P. Scott Maclean
B.Sc., LL.B.

Lynn S. Cassan
B.Sc. Eng. LL.B.

Janet M. Fuhler
LL.B.

Marcus T. Galla
B.Sc., LL.B.

William B. Voss
B.Sc. (Eng. Eng.) LL.M., F.R.S.

Robert G. Hiron
B.Sc. (Hons. Chem.)

Kim A. Brull
B.A.

Mary L. MacVean

Lynda E.E. Dwyer

Roland H. Joachim
B.Sc. (Chem.) LL.B.

Mitchell B. Charness
B.A. Sc. (Mech. Eng.) LL.B.

Ian G. McMillan
B.Sc. (Mech. Chem.) LL.B.

David J. Heller
B.Sc. (Sci. Chem.) LL.B.

Margaret H. McKay
M.Sc. (Biochem.) LL.B.

Consultants

Malcolm S. Johnston, Q.C.

William L. Rayhurst

Godfrey P. Orleans

Kenneth M. Gouret

Jana Parsons

One Queen St. East
Suite 2400, Toronto
Canada, M5C 3B1

Telephone 416 368 1462
Facsimile 416 362 0823
Email info@ridoutmaybee.com

Agents for the
Government of Canada
Patent Office

JC841 U.S. PTO
09/680208
10/06/00

RIDOUT & MAYBEE PTO 8

JC841 U.S. PTO
09/680208



10/06/00

Page 2
October 6, 2000
The Commissioner of Patents and Trademarks

Please deduct the amount of **\$395.00 U.S.** from our Deposit Account No. 13-2400. Please also deduct the amount of **\$40.00 U.S.** from our Deposit Account to cover the assignment recordation fee. Please deduct any additional fees required from our deposit account. An additional signed copy of this letter is attached.

Should any Patent and Trademark Office Official want to telephone, the call should be made to Mr. David J. Heller (Registration No. 43,384) at (416) 868-1482.

Yours very truly,

De

David J. Heller
(Registration No. 43,384)

DJH:lc
Encls.

Applicant or Patentee: NovaNeuron Inc. Attorney's
Serial or Patent No.: N/A Docket No:
Filed or Issued: N/A 36541-0004
Title: GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND
COMPOUNDS FOR MODULATING SAME

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS -
(37 CFR 1.9(f) & 1.27(c)).. SMALL BUSINESS CONCERN

I hereby declare that I am

 the owner of the small business concern identified below:
X an official of the small business concern empowered to act on
behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN NovaNeuron Inc.
ADDRESS OF SMALL BUSINESS CONCERN Room 15 D 7, Tupper Building
Halifax, N.S. B3H 4H7
Canada

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND COMPOUNDS FOR MODULATING SAME by inventor(s) Harold A. Robertson et al. described in

x the specification filed herewith
 application serial no. filed
 patent no. issued

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor(s), who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27).

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Neil H. Ritchie
TITLE OF PERSON IF OTHER THAN OWNER President, NovaNeuron Inc.
ADDRESS OF PERSON SIGNING 40 NovaNeuron
3859 University Avenue
Sir Charles Tupper Medical Bldg.
Room 15D7
Halifax, Nova Scotia B3H 4H7 Canada

SIGNATURE  DATE Oct. 4/00

Gene Necessary for Striatal Function, Uses Thereof, and
Compounds for Modulating Same

CROSS-REFERENCE

This patent claims priority from US provisional application no. 60/158,043 filed October 7, 1999 and US provisional application no. 60/217,765 filed July 12, 2000, entitled Gene Necessary for Striatal Function, Uses Thereof, and Compounds for Modulating Same.

FIELD OF THE INVENTION

The present invention relates to a polynucleotide, PDE10A, which is down-regulated during the development of CAG repeat disorders, such as Huntington's disease. The present invention also describes compounds that modulate CAG repeat disorders, processes for expressing PDE10A, and its agonists and antagonists, and uses of PDE10A, and its variants, derivatives, agonists and antagonists.

BACKGROUND OF THE INVENTION

Very few if any effective treatments exist for neurological disorders characterized by progressive cell loss, known as neurodegenerative diseases, as well as those involving acute cell loss, such as stroke and trauma.

Huntington's disease (HD) is an inherited neurological disorder that is transmitted in

autosomal dominant fashion. HD results from genetically programmed degeneration of neurons in certain areas of the brain. Huntington's disease is caused by a mutation of the gene *IT-15* that codes for the protein huntingtin. The huntingtin gene contains a polymorphic stretch of repeated CAG trinucleotides that encode a polyglutamine tract within huntingtin. If this tract exceeds 35 in number, Huntington's disease results. Huntington's disease is only one of a number of neurological diseases which are characterised by these polyglutamine repeats (Ross, 1997). Schizophrenia, Alzheimer's disease, stroke, trauma, and Parkinson's disease also affect the basal ganglia.

Huntingtin has no sequence similarity to known proteins (Group THDCR, 1993; Sisodia, 1998). The function of the normal or mutated HD form of huntingtin has not been defined by the prior art. It is evident, however, that the expression of the HD form of huntingtin leads to progressive and selective neuronal loss. It has been demonstrated that the GABA- and enkephalin-containing medium spiny projection neurons of the caudate-putamen eventually die as a result of HD (Richfield et al., 1994). Patients with minimal cell loss, however, still present with motor and cognitive symptoms suggesting that neuronal dysfunction, and not simply cell loss, contribute to the symptoms of HD. The motor symptoms of HD include the development of chorea, dystonia, bradykinesia and tremors (Young et al., 1986). Voluntary movements may also be affected such that there may be disturbances in speech (Ludlow et al., 1987) and degradation of fine motor co-ordination (Young et al., 1986). In addition to motor decline, emotional disturbances and cognitive loss are also evident during the progression of HD (Caine et al., 1978).

Despite the fact that huntingtin is ubiquitously expressed, HD specifically affects cells of the

basal ganglia, structures deep within the brain that have a number of important functions, including co-ordinating movement. The basal ganglia includes the caudate nucleus, the putamen, the nucleus accumbens and the olfactory tubercle. HD also affects the brain's outer surface, or cortex, which controls thought, perception, and memory. The mechanism by which only a small group of neurons in the striatum and cortex are rendered vulnerable to this ubiquitously expressed mutant protein is not known. There are no effective treatments for Huntington's disease.

Huntington's disease is widely believed to be a gain-of function disorder but neither the normal function nor the gained function of huntingtin is known. Because the function for huntingtin is not known, there is little insight into the disease process. It was believed that huntingtin was related to neuronal intranuclear inclusions (NII). However, recent results have cast doubt on our understanding of the role of the NII in Huntington's disease (Saudou et al., 1998) or in other CAG repeat disorders (Klement et al., 1998; see also commentary by Sisodia, 1998).

The development of a mouse carrying the 5' end of the human Huntington's disease gene (the promoter and first exon; Mangiarini et al., 1996) was an important step in the development of the tools that will allow us to understand the function (and gain-of-function) associated with huntingtin. R6/2 mice exhibit a rapidly progressing neurological phenotype with onset at about 8 weeks. This phenotype includes a movement disorder characterised by shuddering, resting tremor, epileptic seizures and stereotyped behaviour. These symptoms suggest that the function of the basal ganglia is affected by the expression of the human exon 1 transgene prior to neuronal cell death. By 12 weeks the affected mice have significantly reduced brain

weights and they die by about 13 weeks of age. Neuronal intranuclear inclusions (NII) develop at about 4 weeks (Davies et al., 1997). As is observed in human Huntington's disease patient, the R6/2 mice show changes in neuronal receptors (Cha et al., 1998). The present inventors have also demonstrated that changes in the expression of DARPP-32 and cannabinoid receptors change over time in HD mice; such changes have also been observed in human Huntington's disease patients (unpublished results). The loss of the cannabinoid receptor is one of the earliest documented changes that occur prior to neuronal degeneration in human HD patients. The R6/2 model, therefore, mimics the early phases of HD; a point in disease development where intervention would be most appropriate.

Human PDE10 was recently identified by identification of cDNA fragments published on the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) database (Loughney et al., WO99/42596). While PDE10 was found to share homology with known PDEs, no function could be identified for PDE10.

SUMMARY OF THE INVENTION

The present invention provides the function and uses of a nucleotide segment, PDE10A, and compounds which inhibit or promote the development of CAG repeat disorders such as Huntington's Disease.

The invention teaches a method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of: (a) selecting a control animal having PDE10A and a test animal having PDE10A; (b) treating said test animal using a compound; and (c)

determining the relative quantity of RNA corresponding to PDE10A, as between said animals. In an embodiment, the animal is a mammal, preferably a mouse, and preferably a transgenic mouse. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention also teaches a method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of: (a) selecting a host cell containing PDE10A; (b) cloning said host cell and separating said clones into a test group and a control group; (c) treating said test group using a compound; and (c) determining the relative quantity of RNA corresponding to PDE10A, as between said test group and said control group. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention further teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder, said method comprising determining the level of expression of RNA corresponding to PDE10A in an individual relative to a predetermined control level of expression, wherein a decreased expression of said RNA as compared to said control is indicative of a CAG repeat disorder. Preferably, the expression is measured by in situ hybridization, fluorescent in situ hybridization, polymerase chain reaction, or DNA fingerprinting technique. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention further teaches compositions for treating a CAG repeat disorder comprising a compound which modulates PDE10 expression and a pharmaceutically acceptable carrier. The compound can be selected from the group consisting of: quinpirole, alloxan, miconazole nitrate, MDL-12330A and tetracycline derivatives such as demeclocycline. The compound

may be selected from the group consisting of: (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and (3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, or from the group consisting of: KS-505, IC224, SCH 51866, IBMX and Dipyridamole. The disorder can be HD.

The invention also teaches the use of a composition which modulates PDE10 for treating a CAG repeat disorder comprising administering the composition to a subject in need of such treatment, and such use of the composition which modulates PDE10 for treating HD.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a portion of an autoradiogram of the differential display reaction identifying PDE10A in mouse brain mRNA.

FIG. 2 is a northern blot confirming that PDE10A has a lower steady-state level of expression in the striatum of transgenic HD mice.

FIG. 3 is a nucleotide sequence of the differential display cDNA fragment of pPDE10A.

FIG. 4 shows the *in situ* hybridization of probe 1 to coronal and sagittal brain sections of 10 week-old wild-type and HD mice.

FIG. 5 shows the *in situ* hybridization corresponding to spatial and temporal expression of PDE10A in brain sections of wild-type and HD mice over the period of time that the HD mice develop abnormal movements and postures.

FIG. 6 shows the *in situ* hybridization corresponding to expression of PDE10A in brain sections of one day old wild-type and HD mice.

FIG. 7 shows the *in situ* hybridization corresponding to distribution of the mRNA of PDE10A in mouse striatal neurons.

FIG. 8 is the *in situ* hybridization corresponding to mRNA distribution of the rat homologue of PDE10A in rat brain tissue.

FIG. 9 shows a Southern blot analysis of DNA from wild-type and transgenic HD mice hybridized to the pPDE10A cDNA probe.

FIG. 10 is a nucleotide sequence of cPDE10-1, and corresponds to SEQ ID NO. 1.

FIG. 11 is a restriction map of cPDE10-1.

FIG. 12 is a nucleotide sequence of cPDE10-2, and corresponds to SEQ ID NO. 2.

FIG. 13 is a restriction map of cPDE10-2.

FIG. 14 is a schematic diagram showing the alignment of cPDE10-1 and -2 and the regions that are identical and unique between the two clones.

FIG. 15 is a nucleotide sequence of cPDE10A and RACEs, corresponding to SEQ ID NO. 11.

FIG. 16 is a map of PDE10A coding sequence and restriction sites.

FIG. 17 is a map of PDE10A coding sequence and features.

FIG. 18 is a restriction map of PDE10A.

FIG. 19 is a nucleotide sequence of cPDE10A and corresponds to SEQ ID NO. 12.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

The following illustrative explanations are provided to facilitate understanding of certain terms used frequently herein. The explanations are provided as a convenience and are not limitative of the invention.

"Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

"Identity", "similarity" or "homologous", as used in the art, are relationships between two or

more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Both identity and similarity can be readily calculated (Lesk, A. M., 1988; Smith, D. W., 1993; Griffin, A. M., and Griffin, H. G., 1994; von Heinje, G., 1987; and Gribskov, M. and Devereux, J., 1991). While there exist a number of methods to measure identity and similarity between two polynucleotide sequences, both terms are well known to skilled artisans (von Heinje, G., 1987; Gribskov, M. and Devereux, 1991; and Carillo, H., and Lipman, D., 1988). Methods commonly employed to determine identity or similarity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D. (1988). Methods to determine identity and similarity are codified in computer programs. Computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., 1984), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., 1990).

"Isolated" means altered "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring polynucleotide naturally present in a living organism in its natural state is not "isolated," but the same polynucleotide separated from coexisting materials of its natural state is "isolated", as the term is employed herein. As part of or following isolation, such polynucleotides can be joined to other polynucleotides, such as DNA, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated polynucleotides, alone or joined to other polynucleotides such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in

culture or in whole organisms, such DNA still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the polynucleotides may occur in a composition, such as a media formulations, solutions for introduction of polynucleotides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated polynucleotides within the meaning of that term as it is employed herein.

“Plasmids”. Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well known, published procedures. Many plasmids and other cloning and expression vectors that can be used in accordance with the present invention are well known and readily available to those of skill in the art. Moreover, those of skill readily may construct any number of other plasmids suitable for use in the invention.

“Polynucleotides(s)” of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The DNA may be double-stranded or single-stranded. Single-stranded polynucleotides may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand. Polynucleotides generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-,

double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double-stranded regions. In addition, polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term polynucleotide also includes DNA or DNA that contain one or more modified bases. Thus, DNA or DNA with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNA or DNA comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia. Polynucleotides embraces short polynucleotides often referred to as oligonucleotide(s). It will also be appreciated that RNA made by transcription of this doubled stranded nucleotide sequence, and an antisense strand of a nucleic acid molecule of the invention or an oligonucleotide fragment of the nucleic acid molecule, are contemplated within the scope of the invention. An antisense sequence is constructed by inverting the sequence of a nucleic acid molecule of the invention, relative to its normal presentation for transcription. Preferably, an antisense sequence is

constructed by inverting a region preceding the initiation codon or an unconserved region.

The antisense sequences may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.

“Stringent hybridization conditions” are those which are stringent enough to provide specificity, reduce the number of mismatches and yet are sufficiently flexible to allow formation of stable hybrids at an acceptable rate. Such conditions are known to those skilled in the art and are described, for example, in Sambrook, et al, (1989). By way of example only, stringent hybridization with short nucleotides may be carried out at 5-10° below the T_M using high concentrations of probe such as 0.01-1.0 pmole/ml. Preferably, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.

“Variant(s)” of polynucleotides are polynucleotides that differ in nucleotide sequence from another, reference polynucleotide. Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical. Changes in the nucleotide sequence of the variant may be silent. That is, they may not alter the amino acids encoded by the polynucleotide. Where alterations are limited to silent changes of this type a variant will encode a polypeptide or polynucleotide with the same amino acid sequence as the reference. Changes in the nucleotide sequence of the variant may alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Such nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide or polynucleotide encoded by the reference sequence.

As hereinbefore mentioned, the present inventors have identified and sequenced a DNA sequence encoding PDE10A. The DNA sequence is shown in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11.

It will be appreciated that the invention includes nucleotide or amino acid sequences which have substantial sequence homology with the nucleotide sequences shown in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11. The term "sequences having substantial sequence homology" means those nucleotide and amino acid sequences which have slight or inconsequential sequence variations from the sequences disclosed in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11; i.e. the homologous sequences function in substantially the same manner to produce substantially the same polypeptides as the actual sequences. The variations may be attributable to local mutations or structural modifications. It is expected that a sequence having 85-90% sequence homology with the DNA sequence of the invention will provide a functional PDE10 polypeptide.

As used herein, "PDE10A" comprises a polynucleotide sequence which is down regulated in the course of CAG repeat disorders selected from the group consisting of: (a) a sequence comprising SEQ ID NO:1; (b) a sequence comprising SEQ ID NO:2; (c) a sequence comprising SEQ ID NO:11; (d) a sequence comprising nucleotides 257 to 2596 of SEQ ID NO:11; (e) a sequence which is at least 90% homologous with a sequence of (a), (b), (c) or (d), and; (f) a sequence which hybridizes to (a), (b), (c) or (d) under stringent conditions. In an embodiment, the isolated polynucleotide segment is cDNA. The invention also teaches an isolated polynucleotide segment, which retains substantially the same biological function or

activity as the polynucleotide encoded by the polynucleotide sequence.

Further embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding PDE10 polypeptide or polynucleotide, and polynucleotides which are complementary to such polynucleotides. Other embodiments are polynucleotides that comprise a region that is at least 80% identical over their entire length to a polynucleotide encoding PDE10 of SEQ ID NO.11 and polynucleotides complementary thereto. This includes polynucleotides at least 90% identical over their entire length to the same, and among these embodiments are polynucleotides with at least 95%. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

The polynucleotides of the present invention may be employed as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein.

Analysis of the complete nucleotide and amino acid sequences of the protein of the invention using the procedures of Sambrook et al., supra, have been used to determine the expressed region, initiation codon and untranslated sequences of the PDE10A gene. The transcription regulatory sequences of the gene are determined by analyzing fragments of the DNA for their ability to express a reporter gene such as the bacterial gene lacZ.

The nucleic acid molecules of the invention allow those skilled in the art to construct

nucleotide probes for use in the detection of nucleotide sequences in biological materials. As shown in FIG. 11, 13, 15 and 16, a number of unique restriction sequences for restriction enzymes are incorporated in the nucleic acid molecule identified in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11, and these provide access to nucleotide sequences which code for polypeptides unique to the PDE10A polypeptide of the invention. Nucleotide sequences unique to PDE10A or isoforms thereof, can also be constructed by chemical synthesis and enzymatic ligation reactions carried out by procedures known in the art.

A nucleotide probe may be labeled with a detectable marker such as a radioactive label which provides for an adequate signal and has sufficient half-life such as ^{32}P , ^3H , ^{14}C or the like. Other detectable markers which may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and chemiluminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. The nucleotide probes may be used to detect genes related to or analogous to PDE10A of the invention.

Accordingly, the present invention also provides a method of detecting the presence of nucleic acid molecules encoding a polypeptide related to or analogous to PDE10A in a sample comprising contacting the sample under hybridization conditions with one or more of the nucleotide probes of the invention labeled with a detectable marker, and determining the degree of hybridization between the nucleic acid molecule in the sample and the nucleotide probes.

Hybridization conditions which may be used in the method of the invention are known in the art and are described for example in Sambrook J, et al., *supra*. The hybridization product may be assayed using techniques known in the art. The nucleotide probe may be labeled with a detectable marker as described herein and the hybridization product may be assayed by detecting the detectable marker or the detectable change produced by the detectable marker.

The nucleic acid molecule of the invention also permits the identification and isolation, or synthesis of nucleotide sequences which may be used as primers to amplify a polynucleotide molecule of the invention, for example in polymerase chain reaction (PCR). The length and bases of the primers for use in the PCR are selected so that they will hybridize to different strands of the desired sequence and at relative positions along the sequence such that an extension product synthesized from one primer when it is separated from its template can serve as a template for extension of the other primer into a nucleic acid of defined length.

Primers which may be used in the invention are oligonucleotides i.e. molecules containing two or more deoxyribonucleotides of the nucleic acid molecule of the invention which occur naturally as in a purified restriction endonuclease digest or are produced synthetically using techniques known in the art such as, for example, phosphotriester and phosphodiester methods (See Good et al, 1977) or automated techniques (see, for example, Conolly, B. A., 1987). The primers are capable of acting as a point of initiation of synthesis when placed under conditions which permit the synthesis of a primer extension product which is complementary to the DNA sequence of the invention e.g. in the presence of nucleotide substrates, an agent for polymerization such as DNA polymerase and at suitable temperature and pH. Preferably, the primers are sequences that do not form secondary structures by base

pairing with other copies of the primer or sequences that form a hair pin configuration. The primer may be single or double-stranded. When the primer is double-stranded it may be treated to separate its strands before using it to prepare amplification products. The primer preferably contains between about 7 and 25 nucleotides.

The primers may be labeled with detectable markers which allow for detection of the amplified products. Suitable detectable markers are radioactive markers such as P-32, S-35, I-125, and H-3, luminescent markers such as chemiluminescent markers, preferably luminol, and fluorescent markers, preferably dansyl chloride, fluorescein-5-isothiocyanate, and 4-fluor-7-nitrobenz-2-oxa-1,3 diazole, enzyme markers such as horseradish peroxidase, alkaline phosphatase, .beta.-galactosidase, acetylcholinesterase, or biotin.

It will be appreciated that the primers may contain non-complementary sequences provided that a sufficient amount of the primer contains a sequence which is complementary to a nucleic acid molecule of the invention or oligonucleotide sequence thereof, which is to be amplified. Restriction site linkers may also be incorporated into the primers allowing for digestion of the amplified products with the appropriate restriction enzymes facilitating cloning and sequencing of the amplified product.

Thus, a method of determining the presence of a nucleic acid molecule having a sequence encoding PDE10A or a predetermined oligonucleotide fragment thereof in a sample, is provided comprising treating the sample with primers which are capable of amplifying the nucleic acid molecule or the predetermined oligonucleotide fragment thereof in a polymerase chain reaction to form amplified sequences, under conditions which permit the formation of

amplified sequences and, assaying for amplified sequences.

The polymerase chain reaction refers to a process for amplifying a target nucleic acid sequence as generally described in Innis et al, Academic Press, 1989, in Mullis et al., U.S. Pat. No. 4,863,195 and Mullis, U.S. Pat. No. 4,683,202 which are incorporated herein by reference. Conditions for amplifying a nucleic acid template are described in M. A. Innis and D. H. Gelfand, 1989, which is also incorporated herein by reference.

The amplified products can be isolated and distinguished based on their respective sizes using techniques known in the art. For example, after amplification, the DNA sample can be separated on an agarose gel and visualized, after staining with ethidium bromide, under ultra violet (UV) light. DNA may be amplified to a desired level and a further extension reaction may be performed to incorporate nucleotide derivatives having detectable markers such as radioactive labeled or biotin labeled nucleoside triphosphates. The primers may also be labeled with detectable markers. The detectable markers may be analyzed by restriction and electrophoretic separation or other techniques known in the art.

The conditions which may be employed in the methods of the invention using PCR are those which permit hybridization and amplification reactions to proceed in the presence of DNA in a sample and appropriate complementary hybridization primers. Conditions suitable for the polymerase chain reaction are generally known in the art. For example, see M. A. Innis and D. H. Gelfand, 1989, which is incorporated herein by reference. Preferably, the PCR utilizes polymerase obtained from the thermophilic bacterium *Thermus aquaticus* (Taq polymerase, GeneAmp Kit, Perkin Elmer Cetus) or other thermostable polymerase may be used to amplify

DNA template strands.

It will be appreciated that other techniques such as the Ligase Chain Reaction (LCR) and Nucleic-Acid Sequence Based Amplification (NASBA) may be used to amplify a nucleic acid molecule of the invention. In LCR, two primers which hybridize adjacent to each other on the target strand are ligated in the presence of the target strand to produce a complementary strand (Barney, 1991 and European Published Application No. 0320308, published Jun. 14, 1989). NASBA is a continuous amplification method using two primers, one incorporating a promoter sequence recognized by an RNA polymerase and the second derived from the complementary sequence of the target sequence to the first primer (U.S. Ser. No. 5,130,238 to Malek).

The present invention also teaches vectors which comprise a polynucleotide or polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polynucleotides of the invention by recombinant techniques.

In accordance with this aspect of the invention the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector. In certain embodiments in this regard, the vectors provide for specific expression. Such specific expression may be inducible expression or expression only in certain types of cells or both inducible and cell-specific. Particular among inducible vectors are vectors that can be induced for expression by environmental factors that are easy to manipulate, such as temperature and nutrient additives. A variety of vectors suitable to this

aspect of the invention, including constitutive and inducible expression vectors for use in prokaryotic and eukaryotic hosts, are well known and employed routinely by those of skill in the art. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids, all may be used for expression in accordance with this aspect of the present invention.

The following vectors, which are commercially available, are provided by way of example. Among vectors for use in bacteria are pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia, and pBR322 (ATCC 37017). Among eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. These vectors are listed solely by way of illustration of the many commercially available and well known vectors that are available to those of skill in the art for use in accordance with this aspect of the present invention. It will be appreciated that any other plasmid or vector suitable for, for example, introduction, maintenance, propagation or expression of a polynucleotide or polypeptide of the invention in a host may be used in this aspect of the invention. Generally, any vector suitable to maintain, propagate or express polynucleotides to express a polypeptide or polynucleotide in a host may be used

for expression in this regard.

The appropriate DNA sequence may be inserted into the vector by any of a variety of well-known and routine techniques. In general, expression constructs will contain sites for transcription initiation and termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at the end of the polynucleotide to be translated.

The DNA sequence in the expression vector is operatively linked to appropriate expression control sequence(s), including, for instance, a promoter to direct mRNA transcription. Promoter regions can be selected from any desired gene using vectors that contain a reporter transcription unit lacking a promoter region, such as a chloramphenicol acetyl transferase ("CAT") transcription unit, downstream of restriction site or sites for introducing a candidate promoter fragment; i.e., a fragment that may contain a promoter. As is well known, introduction into the vector of a promoter-containing fragment at the restriction site upstream of the cat gene engenders production of CAT activity, which can be detected by standard CAT assays. Vectors suitable to this end are well known and readily available, such as pKK232-8 and pCM7. Promoters for expression of polynucleotides of the present invention include not only well known and readily available promoters, but also promoters that readily may be obtained by the foregoing technique, using a reporter gene. Among known prokaryotic promoters suitable for expression of polynucleotides and polypeptides in accordance with the present invention are the E. coli lacI and lacZ and promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR, PL promoters and the trp promoter. Among

known eukaryotic promoters suitable in this regard are the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Vectors for propagation and expression generally will include selectable markers and amplification regions, such as, for example, those set forth in Sambrook et al., supra.

As hereinbefore mentioned, the present invention also teaches host cells which are genetically engineered with vectors of the invention.

Polynucleotide constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. The PDE10A polynucleotide or polypeptide products or isoforms or parts thereof, may be obtained by expression in a suitable host cell using techniques known in the art. Suitable host cells include prokaryotic or eukaryotic organisms or cell lines, for example bacterial, mammalian, yeast, or other fungi, viral, plant or insect cells. Methods for transforming or transfecting cells to express foreign DNA are well known in the art (See for example, Itakura et al., U.S. Pat. No. 4,704,362; Hinnen et al., 1978; Murray et al., U.S. Pat. No. 4,801,542; Upshall et al., U.S. Pat. No. 4,935,349; Hagen et al., U.S. Pat. No. 4,784,950; Axel et al., U.S. Pat. No. 4,399,216; Goeddal et al., U.S. Pat. No. 4,766,075; and Sambrook et al, 1989, all of which are incorporated herein by reference). Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2

and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

Host cells can be genetically engineered to incorporate polynucleotides and express polynucleotides of the present invention. Introduction of polynucleotides into the host cell can be affected by calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al. (1986) and Sambrook et al. (1989).

As hereinbefore mentioned, the present invention also teaches the production of polynucleotides of the invention by recombinant techniques.

The PDE10 polynucleotides encode a polypeptide which is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case in vivo, the additional amino acids may be processed away from the mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed

such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the present invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences which are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

The polypeptides of the invention may be prepared by culturing the host/vector systems described above, in order to express the recombinant polypeptides. Recombinantly produced PDE10A based protein or parts thereof, may be further purified using techniques known in the art such as commercially available protein concentration systems, by salting out the protein followed by dialysis, by affinity chromatography, or using anion or cation exchange resins.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using DNA derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., *supra*.

Polynucleotides of the invention, encoding the heterologous structural sequence of a

polynucleotide or polypeptide of the invention generally will be inserted into a vector using standard techniques so that it is operably linked to the promoter for expression. The polynucleotide will be positioned so that the transcription start site is located appropriately 5' to a ribosome binding site. The ribosome binding site will be 5' to the AUG that initiates translation of the polynucleotide or polypeptide to be expressed. Generally, there will be no other open reading frames that begin with an initiation codon, usually AUG, and lie between the ribosome binding site and the initiation codon. Also, generally, there will be a translation stop codon at the end of the expressed polynucleotide and there will be a polyadenylation signal in constructs for use in eukaryotic hosts. Transcription termination signal appropriately disposed at the 3' end of the transcribed region may also be included in the polynucleotide construct.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polynucleotide or polypeptide. These signals may be endogenous to the polynucleotide or they may be heterologous signals. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art. PDE10A polynucleotide or polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for

purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polynucleotide is denatured during isolation and or purification.

In an embodiment, a nucleic acid molecule of the invention may be cloned into a glutathione S-transferase (GST) gene fusion system for example the pGEX-1 T, pGEX-2T and pGEX-3X of Pharmacia. The fused gene may contain a strong lac promoter, inducible to a high level of expression by IPTG, as a regulatory element. Thrombin or factor Xa cleavage sites may be present which allow proteolytic cleavage of the desired polypeptide from the fusion product. The glutathione S-transferase-PDE10A fusion protein may be easily purified using a glutathione sepharose 4B column, for example from Pharmacia. The 26 kd glutathione S-transferase polypeptide can be cleaved by thrombin (pGEX-1 or pGEX-2T) or factor Xa (pGEX-3X) and resolved from the using the polypeptide using the same affinity column. Additional chromatographic steps can be included if necessary, for example Sephadex or DEAE cellulose. The two enzymes may be monitored by protein and enzymatic assays and purity may be confirmed using SDS-PAGE.

The PDE10A protein or parts thereof may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964) or synthesis in homogenous solution (Houbenweyl, 1987).

Within the context of the present invention, PDE10A polypeptide includes various structural forms of the primary protein which retain biological activity. For example, PDE10A polypeptide may be in the form of acidic or basic salts or in neutral form. In addition,

individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions or additions may be made to the amino acid or nucleic acid sequences, the net effect being that biological activity of PDE10A is retained. Due to code degeneracy, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the C- or N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, fusion proteins may be added to the polynucleotide or polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polynucleotide or polypeptide. The addition of peptide moieties to polynucleotide or polypeptides to engender secretion or excretion, to improve stability or to facilitate purification, among others, are familiar and routine techniques in the art. In drug discovery, for example, proteins have been fused with antibody Fc portions for the purpose of high-throughput screening assays to identify antagonists (see Bennett et al., 1995, and Johanson et al., 1995).

Detecting Presence of or Predisposition for CAG Repeat Disorders

This invention is also related to the use of the PDE10A polynucleotides to detect complementary polynucleotides as a diagnostic reagent. Detection of the level of expression of PDE10A in a eukaryote, particularly a mammal, and especially a human, will provide a

method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, exhibiting decreased levels of PDE10A may be detected by a variety of techniques. Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as the striatum, nucleus accumbens and olfactory tubercle. RNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki et al., 1986) prior to analysis. As an example, PCR primers complementary to the nucleic acid encoding PDE10A can be used to identify and analyze PDE10A presence and/or expression. Using PCR, characterization of the level of PDE10A present in the individual may be made by comparative analysis.

The invention thus provides a process for detecting disease by using methods known in the art and methods described herein to detect decreased expression of PDE10 polynucleotide. For example, decreased expression of PDE10 polynucleotide can be measured using any one of the methods well known in the art for the quantification of polynucleotides, such as, for example, PCR, RT-PCR, DNase protection, northern blotting and other hybridization methods. Thus, the present invention provides a method for detecting triplet-repeat disorders, and a method for detecting a genetic pre-disposition for triplet-repeat disorders and other disorders of the basal ganglia including schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease (AD). More generally, the present invention provides a method for detecting a genetic pre-disposition for neurological disorders characterized by progressive cell loss.

Drug Screening Assays

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of PDE10 polypeptides or polynucleotides, such as its interaction with PDE10-binding molecules. The identification of mutations in specific genes in inherited neurodegenerative disorders, combined with advances in the field of transgenic methods, provides those of skill in the art with the information necessary to further study human diseases. This is extraordinarily useful in modeling familial forms of triplet-repeat disorders and other disorders of the basal ganglia including schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease (AD). More generally, the present invention is useful for modeling neurological disorders characterized by progressive cell loss, as well as those involving acute cell loss, such as stroke and trauma.

For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds PDE10. The preparation is incubated with labeled PDE10 in the absence or the presence of a candidate molecule which may be a PDE10 agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labeled ligand.

PDE10-like effects of potential agonists and antagonists may be measured, for instance, by determining activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of PDE10 or molecules that elicit the same effects as PDE10. Reporter systems that may be useful in this

regard include, but are not limited to, colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in PDE10 activity, and binding assays known in the art.

Another example of an assay for PDE10 antagonists is a competitive assay that combines PDE10 and a potential antagonist with membrane-bound PDE10-binding molecules, recombinant PDE10 binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. PDE10 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of PDE10 molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing PDE10-induced activities, thereby preventing the action of PDE10 by excluding PDE10 from binding.

Potential antagonists include a small molecule which binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, 1988, for a description of these molecules).

Potential antagonists include compounds related to and derivatives of PDE10.

Developing modulators of the biological activities of specific PDEs requires differentiating PDE isozymes present in a particular assay preparation. The classical enzymological approach of isolating PDEs from natural tissue sources and studying each new isozyme may be used. Another approach has been to identify assay conditions which might favor the contribution of one isozyme and minimize the contribution of others in a preparation. Still another approach has been the separation of PDEs by immunological means. Each of the foregoing approaches for differentiating PDE isozymes is time consuming. As a result many attempts to develop selective PDE modulators have been performed with preparations containing more than one isozyme. Moreover, PDE preparations from natural tissue sources are susceptible to limited proteolysis and may contain mixtures of active proteolytic products that have different kinetic, regulatory and physiological properties than the full length PDEs.

Recombinant PDE10 polypeptide products of the invention greatly facilitate the development of new and specific PDE10 modulators. The need for purification of an isozyme can be avoided by expressing it recombinantly in a host cell that lacks endogenous phosphodiesterase activity (e.g., yeast strain YKS45 deposited as ATCC 74225). Once a compound that modulates the activity of the PDE10 is discovered, its selectivity can be evaluated by comparing its activity on the PDE10 to its activity on other PDE isozymes. Thus, the combination of the recombinant PDE10 products of the invention with other recombinant PDE products in a series of independent assays provides a system for developing selective modulators of PDE10. Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to the PDE10 or PDE10 nucleic acid,

oligonucleotides which specifically bind to the PDE10 (see Patent Cooperation Treaty International Publication No. WO93/05182 published Mar. 18, 1993 which describes methods for selecting oligonucleotides which selectively bind to target biomolecules) or PDE10 nucleic acid (e.g., antisense oligonucleotides) and other non-peptide natural or synthetic compounds which specifically bind to the PDE10 or PDE10 nucleic acid. Mutant forms of the PDE10 which alter the enzymatic activity of the PDE10 or its localization in a cell are also contemplated. Crystallization of recombinant PDE10 alone and bound to a modulator, analysis of atomic structure by X-ray crystallography, and computer modelling of those structures are methods useful for designing and optimizing non-peptide selective modulators. See, for example, Erickson et al., *Ann. Rep. Med. Chem.*, 27: 271-289 (1992) for a general review of structure-based drug design.

Targets for the development of selective modulators include, for example: (1) the regions of the PDE10 which contact other proteins and/or localize the PDE10 within a cell, (2) the regions of the PDE10 which bind substrate, (3) the allosteric cGMP-binding site(s) of PDE10, (4) the metal-binding regions of the PDE10, (5) the phosphorylation site(s) of PDE10 and (6) the regions of the PDE10 which are involved in dimerization of PDE10 subunits.

Thus, the present invention provides a method for screening and selecting compounds which promote triplet-repeat disorders, and a method for screening and selecting compounds which treat or inhibit triplet-repeat disorders, as well as schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease. More generally, the present invention provides a method for screening and selecting compounds which promote or inhibit neurological disorders characterized by progressive cell loss, as well as those involving acute cell loss, such as

stroke and trauma.

The selected antagonists and agonists may be administered, for instance, to inhibit progressive and acute neurological disorders, such as Huntington's disease, Parkinson's disease, schizophrenia, Alzheimer's disease (AD), stroke or trauma.

Antagonists and agonists and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds. The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by direct microinjection into the affected area, or by intravenous or other routes. These compositions of the present invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of antagonists or agonists of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation is prepared to suit the mode of administration.

Inhibition of PDE10A will be highly detrimental to striatal brain function. The progressive decline in PDE10A mRNA levels in HD may lead to dysregulation of cAMP levels and neuronal dysfunction. Up-regulation of PDE10A will be effective in combating such neuronal dysfunction.

Gene Therapy

A variety of gene therapy approaches may be used in accordance with the invention to modulate expression of the PDE10A gene in vivo. For example, antisense DNA molecules may be engineered and used to block translation of PDE10A mRNA in vivo. Alternatively, ribozyme molecules may be designed to cleave and destroy the PDE10A mRNAs in vivo. In another alternative, oligonucleotides designed to hybridize to the 5' region of the PDE10A gene (including the region upstream of the coding sequence) and form triple helix structures may be used to block or reduce transcription of the PDE10A gene. In yet another alternative, nucleic acid encoding the full length wild-type PDE10A message may be introduced in vivo into cells which otherwise would be unable to produce the wild-type PDE10A gene product in sufficient quantities or at all.

In a preferred embodiment, the antisense, ribozyme and triple helix nucleotides are designed to inhibit the translation or transcription of PDE10A. To accomplish this, the oligonucleotides used should be designed on the basis of relevant sequences unique to PDE10A.

For example, and not by way of limitation, the oligonucleotides should not fall within those region where the nucleotide sequence of PDE10A is most homologous to that of other PDEs, such as PDE2 PDE5 and PDE6, herein referred to as “unique regions”.

In the case of antisense molecules, it is preferred that the sequence be chosen from the unique regions. It is also preferred that the sequence be at least 18 nucleotides in length in order to

achieve sufficiently strong annealing to the target mRNA sequence to prevent translation of the sequence. Izant and Weintraub, 1984, Cell, 36:1007-1015; Rosenberg et al., 1985, Nature, 313:703-706.

In the case of the "hammerhead" type of ribozymes, it is also preferred that the target sequences of the ribozymes be chosen from the unique regions. Ribozymes are RNA molecules which possess highly specific endoribonuclease activity. Hammerhead ribozymes comprise a hybridizing region which is complementary in nucleotide sequence to at least part of the target RNA, and a catalytic region which is adapted to cleave the target RNA. The hybridizing region contains nine (9) or more nucleotides. Therefore, the hammerhead ribozymes of the present invention have a hybridizing region which is complementary to the sequences listed above and is at least nine nucleotides in length. The construction and production of such ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, 1988, Nature, 334:585-591.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in Tetrahymena Thermophila (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al., 1984, Science, 224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug, et al., 1986, Nature, 324:429-433; published International patent application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, Cell, 47:207-216). The Cech endoribonucleases have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences

that are present in PDE10A but not other PDEs.

The foregoing compounds can be administered by a variety of methods which are known in the art including, but not limited to the use of liposomes as a delivery vehicle. Naked DNA or RNA molecules may also be used where they are in a form which is resistant to degradation such as by modification of the ends, by the formation of circular molecules, or by the use of alternate bonds including phosphothionate and thiophosphoryl modified bonds. In addition, the delivery of nucleic acid may be by facilitated transport where the nucleic acid molecules are conjugated to poly-lysine or transferrin. Nucleic acid may also be transported into cells by any of the various viral carriers, including but not limited to, retrovirus, vaccinia, AAV, and adenovirus.

Alternatively, a recombinant nucleic acid molecule which encodes, or is, such antisense, ribozyme, triple helix, or PDE10A molecule can be constructed. This nucleic acid molecule may be either RNA or DNA. If the nucleic acid encodes an RNA, it is preferred that the sequence be operatively attached to a regulatory element so that sufficient copies of the desired RNA product are produced. The regulatory element may permit either constitutive or regulated transcription of the sequence. In vivo, that is, within the cells or cells of an organism, a transfer vector such as a bacterial plasmid or viral RNA or DNA, encoding one or more of the RNAs, may be transfected into cells e.g. (Llewellyn et al., 1987, *J. Mol. Biol.*, 195:115-123; Hanahan et al. 1983, *J. Mol. Biol.*, 166:557-580). Once inside the cell, the transfer vector may replicate, and be transcribed by cellular polymerases to produce the RNA or it may be integrated into the genome of the host cell. Alternatively, a transfer vector containing sequences encoding one or more of the RNAs may be transfected into cells or

introduced into cells by way of micromanipulation techniques such as microinjection, such that the transfer vector or a part thereof becomes integrated into the genome of the host cell.

Composition, Formulation, and Administration of Pharmaceutical Compositions

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules,

liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In

addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds

may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer,

and an aqueous phase. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding

free base forms.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, transdermal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into an affected area, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with an antibody specific for affected cells. The liposomes will be targeted to and taken up selectively by the cells.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific indication or indications. It is appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms associated with such disorders. Techniques for formulation and administration of the compounds of the instant

application may be found in "*Remington's Pharmaceutical Sciences*," Mack Publishing Co., Easton, Pa., latest edition. For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.001 mg/kg to 10 mg/kg, typically around 0.01 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The invention further provides diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

EXAMPLES

The present invention is further described by the following examples. These examples, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

EXAMPLE 1 - Isolation of PDE10A

Wild-type (B6CBAF1) and HD transgenic [B6CBA-TgN(Hd exon1)^{62Gpb}] mice (Jackson Laboratories) and adult Sprague-Dawley rats (250-300 g; Charles River Laboratories) and were used in this study. The genotype of the mice was determined by PCR amplification of a 100 bp region of the integrated human HD exon 1 transgene using primers corresponding to nts 3340-3459 (5'-AGG GCT GTC AAT CAT GCT GG-3') and nts 3836-3855 (5'-AAA CTC ACG GTC GGT GCA GC-3') of clone E4.1 of the human HD gene (Accession number L34020). PCR conditions used are described in Mangiarini et al.(1996). DNA was extracted from a tail clip and an ear punch from each mouse used in this study. Both samples were subjected to PCR genotype analysis. For *in situ* hybridization analysis, the animals were anesthetized with >100 mg/kg sodium pentobarbital, decapitated, the brains removed and stored at -70°C prior to sectioning. For RNA isolation, animals were anesthetized, decapitated and the striatum and cortex were excised and stored in liquid nitrogen prior to RNA extraction. Animal care was given according to protocols approved by Dalhousie University and the Canadian Council of Animal Care.

Differential display was used to identify novel mRNA or previously described mRNA whose relative expression levels are altered as a result of the presence of the transgene. Using differential display, the mRNA populations derived from the striatum of 10 week old wild type were compared with age-matched R6/2 transgenic mice. Differential display has been used extensively (> 750 references) since its development (Liang and Pardee, 1992) to identify changes in gene expression in cells and in tissues including brain (Douglass et al., 1995; Babity et al., 1997a; Livesey et al., 1997; Berke et al., 1998). Perhaps the most

important finding was the demonstration by Qu et al., (1996) that differential display can be used to isolate genes differentially expressed in inbred strains of mice. The power of differential display is that the sequence information obtained can be directly related to the experimental paradigm. Moreover, such sequence information includes sufficient information to identify transcripts and can then lead to experiments that reveal function of the cognate protein in the experimental model.

DNA sequence information of potentially differentially expressed cDNA can be used to generate oligonucleotide probes for in situ hybridization to define the anatomical and temporal patterns of expression of specific transcripts (see Babity et al., 1997a). This technique is especially useful to study changes in steady-state levels of mRNA in heterogeneous tissue such as brain. Brain tissue can be micro-dissected (Babity et al., 1997b). This enabled the present inventors to reduce the requirement for tissue, and hence compare the mRNA populations derived from individual animals for each experimental group.

Thus RT-PCR (Denovan-Wright et al., 1999) was used to identify differences in the patterns of gene expression between the striatum of wild-type and transgenic mice that were hemizygous for the 5' UTR, exon 1 and part of intron 1 of the human Huntingon's Disease gene. Total cellular RNA was isolated from the striatum and cortex of three 10 week-old wild-type and three 10 week-old R6/2 HD mice (Mangiarini et al., 1996) and used as the template to generate single-stranded cDNA. Total cellular RNA from each animal and tissue was purified using Trizol™ reagent (Gibco BRL) and the manufacture's protocol. 10 µg aliquots of total RNA were treated with RQ1 DNase-free DNase (Promega) in the presence

of DNAsin™ (Promega) DNase inhibitor to remove trace genomic DNA and then converted to single-stranded cDNA. The primers and conditions for PCR amplification follow those of the Delta™ RNA fingerprinting manual (Clontech).

The cDNA was then used as the substrate for PCR reactions using 57 differential display primer combinations. The radio-labelled PCR products were fractionated on a denaturing acrylamide sequencing gels using a Genomyx LR™ sequencing apparatus, transferred to 3MM filter paper and dried. The dried acrylamide gels were exposed to autoradiography film (BioMax MR™) overnight. After fractionating the radio-labelled PCR products on denaturing acrylamide gels, it was found that the overwhelming majority of the approximately 18,000 PCR products screened were common to both the wild-type and HD mice (data not shown). One PCR product, amplified using the primers P7 (5'-ATT AAC CCT CAC TAA ATG CTG TAT G- 3') and T6 (5'- CAT TAT GCT GAG TGA TAT CTT TTT TTT TCG- 3') of approximately 500 bp, was observed in each of three samples derived from the striatum of wild-type mice (FIG. 1). This 500 bp band was absent from the samples derived from the striatum of the HD mice (FIG. 1) and was absent from each of the samples derived from the cortical tissue (data not shown).

FIG. 1 shows the Down-regulated in Huntington's Disease (PDE10A) transcript, identified by differential display RT PCR. A band of approximately 500 bp (arrow) was amplified from cDNA made from 10 week-old wild-type but not 10 week-old HD striatal tissue. Total RNA from individual animals (numbered 1-6) was used as the substrate for the generation of single-stranded cDNA. Animals 1, 2 and 3 were transgenic HD mice. Animals 4, 5 and 6 were wild-type mice.

EXAMPLE 2 - Cloning of PDE10A

The 500 bp band, designate PDE10A_{pcr}, was excised from the dried gel and rehydrated in 40 µl of H₂O for 10 min at room temperature. The eluted DNA was subjected to PCR re-amplification using the P7 and T6 primers, rTaq polymerase (Pharmacia) and the following conditions: 60'' @ 94°C, 19 x (30'' @ 94°C, 30'' @ 58°C, 120'' @ 68°C + 4'' per cycle), 7' @ 68°C. The PCR reaction was subjected to agarose gel electrophoresis and the 500 bp band was removed from the gel, extracted from the agarose using the Qiagen gel extraction protocol and cloned into the vector, pGem-T using standard methods. Plasmid DNA was isolated from selected transformants using Qiagen spin columns. The resultant clone was named pPDE10A.

EXAMPLE 3 - Identification of PDE10A

The cloned insert of pPDE10A was radio-labelled and used as a hybridization probe in northern blot analysis (FIG. 2). Northern blots of total RNA were prepared using the method described in Denovan-Wright et al. (1998). The 500 bp cloned insert of PDE10A was radio-labelled with [α -32P]dCTP (3000 Ci/mmol) using the Ready-to-Go dCTP beads (Pharmacia). Northern blot hybridization, brain tissue preparation and *in situ* hybridization are described in Denovan-Wright et al. (1998). The 500 bp cloned insert of pPDE10A annealed to a transcript of approximately 9.5 kb in total RNA isolated from the striatum of ten week-old wild-type mice.

FIG. 2 demonstrates that PDE10A is expressed in the striatum but not the cortex of wild-type mice and the steady-state levels of PDE10A are reduced in 10 week old transgenic HD mice. The differential expression of PDE10A in HD mice was confirmed by northern blot analysis. The cloned insert of pPDE10A was radio-labelled and used as a hybridization probe in northern blot analysis. The northern blot was prepared by size-fractionating total RNA from the striatum and cortex of three individual 10 week-old HD (1, 2 and 3) and wild-type (4, 5 and 6) mice. Following the hybridization of pPDE10A, the radio-label was removed and the blot was subsequently allowed to hybridize with a probe that detects constitutively expressed cyclophilin. The hybridization pattern of the cyclophilin probe is aligned below the northern blot demonstrating that equivalent amount of RNA were present in each lane. The relative mobility of RNA molecular weight standards (RNA ladder, Gibco BRL) are shown on the left of the northern blot.

The hybridization signal of pPDE10A was significantly lower in the RNA samples derived from the striatum of 10 week-old HD mice. No expression of the PDE10A mRNA was detected in the cortical RNA samples derived from either the wild-type or HD mice.

EXAMPLE 4 - Sequencing PDE10A

The sequence of the cloned differential display band, pPDE10A, was determined using M13 universal forward and reverse sequencing primers and the T7 sequencing kit (Pharmacia). The 484 bp cDNA fragment did not have sequence similarity to any Genbank entries.

FIG. 3 shows the nucleotide sequence of the cloned PDE10A differential display product,

pPDE10A. The position of the primers used to amplify the fragment are underlined and labelled. The nucleotide sequence and position of oligonucleotide probes 1 and 2 within the pPDE10A sequence are shown.

EXAMPLE 5 - Isolation and Characterization of cDNA PDE10A

In order to isolate PDE10A cDNA clones, oligonucleotide probes 1 and 2 were used in 5' and 3' Rapid Amplification of cDNA Ends (RACE) reactions using commercially prepared RACE-ready mouse striatal cDNA (Clontech). Several independent clones were isolated and those that contained the sequence of pPDE10A were selected for further analysis. Each of the 5' RACE clones was identical in sequence over the length that the clones could be aligned. The difference in length between these clones is a result of termination of the original reverse-transcriptase reaction at different positions along the mRNA. No difference in size or sequence was detected between several 3' RACE clones. The longest 5' RACE clone and one 3' RACE clone were completely sequenced using internal primers. The present inventors were able to isolate a very short clone that extended the 5' RACE clone using an internal primer (probe 3, 5'- CTA TTT CAC AAG AGA CTG ACC AGC CAA TAA ATC TC- 3'). The compiled sequence of the first PDE10A cDNA clone, named cPDE10A-1 is presented in FIG. 10. cPDE10A-1 is 3235 bp in length. The restriction map of cPDE10A-1 is shown in FIG. 11.

The mRNA that hybridized with pPDE10A was approximately 9.5 kilobases in length. In order to obtain PDE10A cDNA clone that was larger than cPDE10-1, the present inventors screened a mouse brain cDNA library. Several clones were identified that hybridized with

the pPDE10 probe. The sequence of the largest of these cDNA clones, cPDE10-2, was determined. The sequence (FIG. 12) was 5753 base pairs in length. The restriction map of cPDE10-2 is shown in FIG. 13.

cPDE10-1 and cPDE10-2 share sequence identity over 2095 bp. However, the 5' 1142 bp of cPDE10-1 and the 5' 1689 bp of cPDE10-2 are unique to each clone. Clone cPDE10-2 extends 1969 bp in the 3' direction compared to cPDE10-1. A schematic showing the regions of sequence identity and the unique sequences of cPDE10-1 and -2 are shown in FIG. 14

The compiled sequence of the mouse PDE10 cDNA clone, named cPDE10A, is presented in FIG. 15 with RACEs. A further sequence, without RACEs, is shown in FIG. 19. The coding sequence and restriction map of cPDE10A is shown in FIG. 16. and updated at FIG. 17. FIG. 18 is a restriction map of PDE10A. The coding region has a met initiator commencing at nucleotide 257, with a stop codon ending at nucleotide 2596.

PDE10A was found to have extremely high homology with human PDE10s identified by Loughney et al., WO99/42596, the contents of which are incorporated herein by reference.

EXAMPLE 6 - Localization of PDE10A in the Brain

In order to identify the coding strand and to localize the transcript in the wild-type mouse brain, two oligonucleotide probes were designed (probe 1, 5' - GAA CAT GTA GCA TAT ACT CCA GAC AAC AGA TCA TAT GG - 3'; probe 2, 5' - CAG CTT CTC CAC AGG AAC ACA GTA ACA AAG AG - 3') that were complementary to different regions and

strands of the 484 bp pPDE10A clone. These oligonucleotides were used for *in situ* hybridization analysis. Using high stringency post *in situ* hybridization washes (2 x 30' in 1X SSC @ 58°C, 4 x 15' in 1X SSC @ 58°C, 4 x 15' in 0.5X SSC @ 58°C, 4 x 15' in 0.25X SSC @ 58°C), it was found that oligonucleotide probe 1 annealed with mRNA in the striatum, nucleus accumbens and olfactory tubercle of ten week-old wild-type mice (FIG. 4). The hybridization signal was significantly reduced in the striatum, nucleus accumbens and olfactory tubercle of the 10 week-old HD mice (FIG. 4).

FIG. 5 shows *in situ* hybridization of probe 1 to coronal (top three sections) and sagittal (bottom section) 10 week-old wild-type (WT) and HD mouse brain sections. Specific hybridization of the probe was observed in the striatum, nucleus accumbens and olfactory tubercle of wild-type mice. The top three sections represent the distribution of PDE10A throughout the rostral-caudal axis of the striatum.

The *in situ* hybridization results confirmed the northern blot analysis demonstrating, 1) that the expression of PDE10A mRNA was restricted to the striatum, nucleus accumbens and olfactory tubercle and 2) that the levels of PDE10A mRNA were decreased in HD mice compared to the wild-type. The probe did not anneal with mRNA in any other brain nuclei. No hybridization of oligonucleotide probe 2 was observed in any region of the brain in wild-type or HD mice (Fig. 3). Based on this hybridization, the coding strand, complementary to probe 1, of pPDE10A was defined.

EXAMPLE 7 - Characterization of PDE10

The *in situ* hybridization using oligonucleotide probe 1 demonstrated that PDE10A mRNA levels in the striatum, nucleus accumbens and olfactory tubercle were decreased in ten week- old HD mice. By ten weeks of age, the HD mice all showed motor symptoms including resting tremor and stereotypic involuntary movements. Moreover, these mice immediately clasped their feet together and curled into a tight ball when picked up by their tails.

As the phenotypic signs are progressive over a number of weeks, the present inventors examined whether the PDE10A transcript was ever expressed in the striatum of the HD mice or whether the steady-state levels of the transcript diminished in the striatum in a course that paralleled the development of the motor disorders. Wild-type and HD mice were sacrificed at 5, 7 and 8 weeks of age and their brains were prepared for *in situ* hybridization analysis using probe 1 (FIG. 5).

FIG. 5 shows the levels of PDE10A mRNA decrease in HD mice over the period of time that the HD mice develop abnormal movements and postures. *In situ* hybridization analysis of coronal and sagittal sections of wild-type and HD mouse brain using oligonucleotide probe 1 which is complementary to the coding strand of PDE10A. At 5 weeks of age, before the development of motor symptoms, the HD mice express the PDE10A transcript in the same brain nuclei and at the same relative levels as wild-type mice. The steady-state level PDE10A decreases in the striatum, nucleus accumbens and olfactory tubercle from 5 to 10 weeks in the HD but not wild-type mice. By 9 weeks of age, the HD mice have abnormal

movement and posture. The numbers refer to the age in weeks of the wild-type (WT) and Huntington's (HD) transgenic mice.

None of the mice at these ages had overt motor symptoms. Sections taken throughout the rostral-caudal axis of the striatum showed that PDE10A was expressed in the 5 week-old wild-type and HD mice. The relative hybridization of probe 1 did not change in 5, 7, 8 and 10 week-old wild-type mice. The intensity of the hybridization signal appeared to decrease in the striatum, nucleus accumbens and olfactory tubercle of HD mice from 5 to 10 weeks compared to their wild-type litter mates (FIG. 5).

The levels of PDE10A were significantly reduced by 8 weeks of age in the HD mice, using two *in situ* oligonucleotide probes, one complementary to the 3' UTR, the second complementary to an internal portion of the coding region. The hybridization pattern observed in the wild-type and HD mice was the same for both the probes employed. This analysis demonstrated that there is a reduction in the complete PDE10A mRNA levels during the development of the HD phenotype and not that there was a differential reduction in the PDE10A coding region as compared to the extensive 3' UTR. Moreover, *in situ* hybridization using the PDE10A-specific probe against neurologically normal and HD human brain tissue demonstrated that there was a decrease in PDE10A levels in human HD patients.

One day old wild-type and HD mice were frozen, sectioned on a cryostat and whole mouse sections were prepared for *in situ* hybridization using probe 1. The same high stringency post-hybridization washing conditions were employed for the one day-old mouse body sections as were used for the adult mouse brain sections. Parallel *in situ* hybridization

experiments using the probe 2 were performed in order to determine the level of non-specific signal in the mouse sections. Probe 1 specifically annealed to the developing striatum (FIG. 6).

FIG. 6 demonstrates that PDE10A is expressed in the developing striatum of one day-old wild-type and HD mice. The sections on the left were subjected to *in situ* hybridization using probe 1. Following hybridization, the sections were counter-stained with cresyl violet to visualize the mouse organs. The signal outside the brain was non-specific as probe 2 and other unrelated control oligonucleotide probes all labelled these tissues.

There was no difference in the pattern of hybridization between the one day-old wild-type and HD mice demonstrating that PDE10A was expressed in the developing brain of both wild-type and HD mice.

Following *in situ* hybridization, the sections were covered in autoradiographic emulsion, left in the dark to expose for 4 weeks and then developed and viewed under dark-field microscopy or, after counter-staining the sections with cresyl violet to visualize neuronal cell bodies, under bright-field microscopy. Silver grains were observed to be concentrated in the striatum of the wild-type mice. FIG. 7 shows emulsion autoradiography of mouse brain sections following *in situ* hybridization of probe 1 demonstrated that the PDE10A transcript is expressed in neurons. PDE10A is not homogeneously distributed throughout the mouse striatum. Dark field illumination of the sections after emulsion autoradiography showed that the silver grains were clustered in specific regions of the 10 week old wild-type mouse striatum (A and C). Sections from 10 week old HD mice subjected to identical *in situ* and

emulsion autoradiographic conditions are shown in B and D. The photomicrographs shown in A and B were viewed using the 10X objective (bar represents 100 μm). The micrographs shown in C and D, were viewed under the 20X objective (bar represents 25 μm). The insert in panel C is a portion of the section in A and C counter-stained with cresyl violet to visualize the neurons, viewed using the 40X objective under bright field illumination. Note the distribution of the silver grains over some, but not all, of the striatal neurons as well as being concentrated around clusters of neurons. It appeared that the silver grains were absent from fibre tracks within the striatum. It appeared that PDE10A mRNA was not confined to regions close to the nucleus but was dispersed in cellular processes.

Huntingtin with an expanded polyglutamine tract (htt-HD) is expressed in neurons of the brain and body throughout development and during the lifetime of HD patients (The Huntington's Disease Research Collaborative, 1993; Ross, 1995). Transgenic HD mice express a portion of htt-HD and develop a phenotype with many of the symptoms of HD after a period of normal development and growth (Carter et al., 1999; Cha et al., 1998; Mangiarini et al., 1996). Using differential display RT PCR, northern blot and *in situ* hybridization, we have demonstrated that PDE10A mRNA levels decline in the striatum of HD mice. This specific member of the PDE multigene family is highly expressed in the striatum and olfactory tubercle of mice (Soderling et al., 1999) and rats (Fujishige et al., 1999) and in the caudate and putamen of humans (Fujishige et al., 1999; Loughney et al., 1999). The levels of PDE10A were the same in 5 week old wild-type and HD mice. PDE10A mRNA levels then began to decline and were almost undetectable in the striatum and olfactory tubercle by the time the mice reached 8 weeks of age. This time coincides with the onset of overt motor symptoms in the HD mice indicating that the loss of PDE10A in striatal neurons leads to

dysfunction of the nuclei that control movement. The R6/2 mice develop the HD phenotype in the absence of cell death. The decrease in PDE10A mRNA, therefore, is not due to the loss of PDE10A-expressing cells but rather a change in steady-state RNA levels that occurs due to the expression of mutant huntingtin.

The particular isoform that decreases in HD is PDE10A. PDE10A has been cloned from human lung and fetal brain cDNA libraries (Fujishige et al., 1999; Loughney et al., 1999). It appears that the presence of the expanded polyglutamine tract in huntingtin alters gene expression in the striatum, and that this is the mechanism by which only a small group of neurons in the striatum and cortex are rendered vulnerable to this ubiquitously expressed mutant protein.

EXAMPLE 8 - PDE10A is Highly Conserved Among Mammalian Species

The oligonucleotide (probe 1) complementary to the coding strand of the PDE10A transcript, was also used as an *in situ* hybridization probe against coronal brain sections derived from adult rats. FIG. 8 shows *in situ* hybridization analysis of adult rat brain sections using oligonucleotide probe 1 complementary to the coding-strand of PDE10A revealed that the pattern of expression of PDE10A is the same in rats and mice. The hybridization conditions used to detect the rat homologue of PDE10A in rat brain tissue differed from those used to detect the transcript in mice only in that the stringency of the post-hybridization washes were reduced.

No hybridization was observed in the rat striatum using the post-hybridization washes

employed following the *in situ* hybridization of mouse brain sections. However, when the stringency of the post-hybridization washes was lowered (2 x 60' in 1X SSC @ 42°C, 2 x 60' in 0.5X SSC @ 42°C, 2 x 60' in 0.25X SSC @ room temperature), the PDE10A oligonucleotide probe specifically labelled the adult rat striatum, nucleus accumbens and olfactory tubercle in a pattern indistinguishable from that observed in mouse brain sections. It appears, therefore, that a transcript which shares nucleotide sequence and expression pattern is present in both mice and rats. The evolutionary conservation of PDE10A suggests that it is important for normal function of the basal ganglia.

By northern blot, Fujishige et al. (1999) demonstrated that PDE10A is expressed in human fetal brain. The homology between mouse and human PDE10A is extremely high (data not shown).

EXAMPLE 9 - Analysis of PDE10A in Genomic DNA

Because the transgenic mice employed in this study have a copy of the human HD 5' UTR, exon 1 with expanded CAG repeat and 262 bp of the intron 1 that has been integrated into an undefined locus of the mouse genome, it was possible that the integration event disrupted the PDE10A gene preventing its expression in the HD mouse striatum. Genomic DNA was isolated from wild-type and HD mice and subjected to Southern blot analysis.

Genomic DNA was isolated from wild-type and HD mice and subjected to Southern blot analysis using pPDE10A as a hybridization probe. The size of the *Bam*HI and *Eco*RI fragments that are present in the transgenic R6/2 line that correspond to the insertion of the

human exon 1 gene fragment are 1.9 and 0.8 (*Bam*HI) and 1.9 (*Eco*RI) kb. Analysis of the size of the fragments that hybridized with pPDE10A demonstrated that there was no difference in the size of the hybridizing fragments between the wild-type and HD mice. FIG. 9 shows the genomic DNA restriction fragments that hybridized with pPDE10A were the same in wild-type and HD mice. The size of the hybridizing *Bam*HI and *Eco*RI fragments in each genomic DNA sample is approximately 8 kb and 3 kb, respectively. If the 1.9 kb *Sac*I-*Eco*RI HD gene fragment integrated into the genome within the *Bam*HI and *Eco*RI fragments that hybridized with the DHDM cDNA cloned insert, the sizes of the HD hybridizing bands would have been distinct from those of the wild-type. This Southern blot analysis indicates that the gene encoding PDE10A is present as a single-copy in the mouse genome. The numbers at the left of the blot are the relative mobility of molecular weight markers (1 kb ladder, BioRad).

The PDE10A cDNA has since been cloned using a bioinformatics search strategy involving screening of the expressed sequence tag (EST) database for novel PDE cDNA clones. Independently, the mouse PDE10A cDNA was identified after an EST search for novel PDEs with conserved cGMP binding domains (Soderling et al., 1999). The rat isoforms of PDE10A and splice variants have also been described (Fujishige et al., 1999). Human, mouse and rat PDE10A splice variants differ in their 5' untranslated and part of the 5' coding region but are identical in the coding region when the various splice variants are compared within each species. The human, mouse and rat PDE10A coding regions contain 779, 779 and 794 amino acids, respectively, encoding a protein of approximately 88.5 kDa.

EXAMPLE 10 - Distribution of PDE10A

In mouse, PDE10A mRNA was detected in testis and to a much lesser extent in brain but not in heart, spleen, lung, liver, skeletal muscle, kidney, ovary, pancreas, smooth muscle, eye or in total RNA isolated from 7, 11, 15 or 17 day old embryo (Soderling et al., 1999). This data agrees with the PDE10A mRNA pattern of distribution that we observed in wild-type and pre-symptomatic HD mice. In mice, two different size transcripts are detected in northern blots using the coding region as a probe. In mouse testis, the most abundant transcript is approximately 4 kb. A 9.5 kb transcript was also detected in mouse testis. It appears that the most abundant transcript in mouse brain is 9.5 k. Similarly, two sized PDE10A transcripts were observed in rats, however, it appears that, in rat, the 4 kb mRNA is expressed exclusively in testis while the 9.5 kb mRNA is expressed exclusively in brain (Fujishige et al., 1999). Within the brain, the rat PDE10A mRNA was expressed in striatum and olfactory tubercle and not cortex, cerebellum, hippocampus, midbrain or brainstem. In humans, PDE10A is expressed in the caudate, putamen and testis. As was observed in rodents, mRNAs of approximately 4 and 10 kb hybridized with the PDE10A probe. Again, it appears that, although both sized transcripts are present in brain and testis, the larger mRNA is predominant in the caudate and putamen and the smaller sized transcript is present in the testis. Each of the mouse, rat and human PDE10A sequences are not longer than 4 kb and span the coding region and parts of the 3' UTR. The difference in abundance of the short and long transcript in the testis and brain, respectively, in all three species suggest that the 3' UTR functions to provide transcript stability in the brain. As such, we present the complete sequence of the brain-specific transcript of PDE10A derived from mouse.

EXAMPLE 11 - Modulating Activity of PDE10A Using cGMP-PDE Activity

Cyclic nucleotides are the predominant second messengers that activate cellular signaling pathways (Beavo, 1995; Conti and Jin, 1999). The concentration of intracellular cyclic nucleotides is dependent on their rate of synthesis by adenylyl and guanylyl synthase, the rate of efflux from the cell, and the rate of degradation. PDEs hydrolyze cAMP and cGMP limiting both the duration and amplitude of the cyclic nucleotide signal (Beavo, 1995; Conti and Jin, 1999). In mammals, PDEs are encoded by a large multigene family. The various PDE family members have tissue-specific patterns of expression (Conti and Jin, 1999). PDEs have also been described in *Caenorhabditis*, *Drosophila*, *Dictyostelium*, *Saccharomyces*, *Candida* and *Vibrio* species demonstrating that this enzyme has been conserved throughout evolution. In mammals, PDEs are encoded by at least 10 gene families, each composed of one or more genes. In addition, numerous splice variants of individual gene family members have been described. These splice variants alter the 5' domain of the protein but share identical nucleotide binding and catalytic domains. The catalytic domain, found in the carboxy-terminus of the enzyme, is ~ 275 amino acids and highly conserved in amino acid sequence in all PDEs. In total, it appears that there are ~50 PDEs expressed within the mammalian body. Some PDEs are expressed in multiple tissues while others have a very limited tissue-specific distribution (Conti and Jin, 1999).

PDE gene families differ with respect to their affinity for cAMP and cGMP and their dependence on calcium and calmodulin (Beavo, 1995). Moreover, some PDEs are inhibited or activated by binding cyclic nucleotides to a non-hydrolytic site. For example, PDE2A has a lower K_m for cGMP than cAMP although it hydrolysed both nucleotides. The binding of

cGMP to an allosteric activator site within PDE2 enhances the rate of catalysis of cAMP. PDE2 is, therefore, a cGMP-stimulated cGMP and cAMP phosphodiesterase (Beavo, 1995). Conversely, the affinity of PDE4 for cAMP is much greater than for cGMP and PDE4 activity is not affected by cGMP or calmodulin (Beavo, 1995). The differences in substrate preference, modulation of activity and tissue-specific patterns of expression suggest that subtle alterations in the relative levels of cAMP and cGMP mediated through the action of various PDEs lead to a wide range of responses to extracellular signals.

cGMP-PDE activity of compounds is measured using a one-step assay adapted from Wells et al. (Wells, J. N., Baird, C. E., Wu, Y. J. and Hardman, J. G., *Biochim. Biophys. Acta* 384:430 (1975)) and adopted by Beavo et al, U.S. Patent No. 6,037,119. The reaction medium contains 50 mM Tris-HCl, pH 7.5, 5 mM Mg-acetate, 250 ug/ml 5'-Nucleotidase, 1 mM EGTA and 0.15 uM 8-[H³]-cGMP. The enzyme used is a human recombinant PDE V (ICOS, Seattle U.S.A.).

Compounds of interest are dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

The IC₅₀ values for the compounds examined are determined from concentration-response curves using typically concentrations ranging from 10 nM to 10 uM. Tests against other PDE enzymes using standard methodology also show compounds highly selective for the cGMP specific PDE enzyme.

Rat aortic smooth muscle cells (RSMC) are prepared according to Chamley et al. in *Cell Tissue Res.* 177:503-522 (1977) and used between the 10th and 25th passage at confluence in 24-well culture dishes. Culture media is aspirated and replaced with PBS (0.5 ml) containing the compound tested at the appropriate concentration. After 30 minutes at 37° C, particulates guanylate cyclase are stimulated by addition of ANF (100 nM) for 10 minutes. At the end of incubation, the medium is withdrawn and two extractions were performed by addition of 65% ethanol (0.25 ml). The two ethanolic extracts are pooled and evaporated until dryness, using a Speed-vat system. c-GMP was measured after acetylation by scintillation proximity immunoassay (AMERSHAM). The EC₅₀ values are expressed as the dose giving half of the stimulation at saturating concentrations.

EXAMPLE 12 - Selected Modulators of PDE10A Activity

The catalytic domain of PDE10A is most similar in amino acid sequence to PDE5A, PDE2A, PDE6B and PDE6A. These members of the PDE family each contain a cGMP binding sequence that is not observed in other PDE family members. The non-catalytic cGMP binding sites (GAF) domains found in PDE2, 5 and 6 are also found in PDE10. At least for PDE2, this site acts as an allosteric activator for cAMP hydrolytic activity. The GAF domain of PDE10A binds other small molecules that act as allosteric activators. PDE10A is a cAMP and cAMP-inhibited cGMP PDE (Fujishige et al., 1999; Fujishige et al., 1999; Loughney et al., 1999; Soderling et al., 1999).

Attenuation of the production of cAMP, may ameliorate the symptoms of HD and positively affect gene expression. Pharmaceutically acceptable modulators of cAMP include quinpirole,

alloxan, miconazole nitrate, MDL-12330A, and tetracycline derivatives such as demeclocycline and minocycline.

Compounds which are potent and selective modulators of cGMP-specific PDE, and are useful in a variety of therapeutic areas are taught by Daugan et al, U.S. patent No. 5,981,527, PCT publication No. WO 00/15639 to Icos Corporation and PCT publication No. WO 00/15228 to Icos Corporation, which are incorporated herein by reference. Such compounds include, for example:

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione.

PDE1B1 is expressed throughout the brain and is most abundant in the striatum, nucleus accumbens and olfactory tubercle (Polli and Kincaid, 1994; Yan et al., 1994). PDE1B is a cGMP, Ca/calmodulin-dependent PDE. Therefore, PDE1B and 10A are both expressed in the majority, but not all, striatal neurons and, it is likely that both genes are co-expressed in a subset of striatal projection neurons. Selective inhibitors for PDE1 include KS-505, IC224,

and SCH 51866. Of these inhibitors, it appears that SCH 51866 has a ten-fold higher K_m for PDE1 than PDE10 (Soderling et al., 1999). The non-specific PDE inhibitor IBMX is a potent inhibitor of PDE10A. Dipyridamole and SCH51866 had the highest potency of inhibitors tested on PDE10A activity. Dipyridamole was considered to be a PDE5- and PDE6-specific inhibitor, however, the K_m for dipyridamole is 10 times higher for PDE10A than the other PDEs (Soderling et al., 1999). Selective inhibitors of PDE5, 2, 3 and 4 had much greater IC_{50} for PDE10 (Soderling et al., 1999).

EXAMPLE 13 - Clinical use of PDE10A Modulator

A 38 year-old female was admitted to hospital from a long-term care facility due to progressive deterioration of her physical and mental symptoms caused by Huntington's disease. The patient had been diagnosed with Huntington's disease at age 26. Prior to admission to the hospital, she had become increasingly aggressive and uncooperative. Moreover, there appeared to be an increase in the number of psychotic episodes. SPECT showed no abnormality of brain blood flow but MRI showed bilateral caudate atrophy as well as global atrophy of the cerebrum and corpus callosum.

The patient had been stable for a number of years on the antipsychotic haloperidol (3 mg/day). For the last two years, the haloperidol had been replaced by olanzapine (2.5-7.5 mg/day).

Minocycline, a tetracycline derivative, was administered at 50 mg twice daily for 7 days, followed by 100 mg twice daily for 7 days and finally 200 mg twice daily for 5 weeks. After 5 weeks of 200 mg twice daily minocycline administration, there was a mild improvement

compared to the baseline clinical global assessment made at the time of admission. The minocycline treatment was suspended for 7 days. Due to a significant increase in the number of aggressive incidence and decrease in cooperativity, minocycline (200 mg twice daily) treatment was resumed. The patient responded within 3 days to the resumed minocycline-treatment with a return to mild-improvement compared to the baseline clinical global assessment made at the time of admission. Minocycline (200 mg twice daily) treatment will continue indefinitely. The improvement in behaviour and decrease in apparent psychosis has allowed for the transfer of the patient from the acute care facility back to long-term care.

While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art.

Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

Non-patent Literature Cited

- Atschul, S. F. et al.(1990), *J. Molec. Biol.* 215: 403.
- Babity, J.M., Armstrong, J.N., Plumier, J.-C., Currie, R. W., and Robertson, H.A. (1997a) A novel seizure-induced synaptotagmin gene identified by differential display. *Proc. Nat. Acad. Sci. U.S.A.* 94: 2638-2641.
- Babity, J.M., Newton, R.N., Guido, M.E. and Robertson, H.A. (1997b) The Application Of Differential Display To The Brain: Adaptations For The Study Of Heterogeneous Tissue. *Methods Mol Biol*, 85 (1997) 285-95.
- Barney (1991) in *PCR Methods and Applications*, Aug., Vol. 1(1), page 5.
- Beavo, J. (1995). Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. *Physiol. Rev.* 75, 725-748
- Beretta, S., Robertson, H. and Graybiel, A. (1992) Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. *J. Neurophysiol.* 68, 767-777
- Bennett, D. et al.,(1995) *Journal of Molecular Recognition*, Vol. 8 52-58.
- Berke, J.D., Paletzki, R.F., Aronson, G.J., Hyman, S.E. and Gerfen, C.R. (1998) A Complex Program of Striatal Gene Expression Induced by Dopaminergic Stimulation. *J. Neurosci.* 18: 5301-5310.
- Caine E.D., Hunt R.D., Weingartner H., Ebert M.H. (1978) Huntington's dementia. Clinical and neuropsychological features. *Arch-Gen-Psychiatry.* 35, 377-84.
- Carillo, H., and Lipman, D.(1988), *SIAM J. Applied Math.*, 48: 1073.
- Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnet, S. B., and Morton, A. J. (Apr. 1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. *J Neurosci* 19, 3248-57

- Cha, J.-H. J., Kosinski, C.M., Kerner, J.A., Alsdorf, S.A., Mangiarini, L., Davies, S.W., Penny, John B., Bates, G.P., Young, A.B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. *Proc. Natl. Acad. Sci. USA* 95: 6480-6485.
- Conolly, B. A. (1987) *Nucleic Acids Res.* 15:15(7): 3131.
- Conti, M., and Jin, S. L. (1999). The molecular biology of cyclic nucleotide phosphodiesterases. *Prog Nucleic Acid Res Mol Biol* 63, 1-38
- Crino, P., Khodakhah, K., Becker, K., Ginsberg, S., Hemby, S. and Eberwine, J. (1998) Presence and phosphorylation of transcription factors in developing dendrites. *Proc. Natl. Acad. Sci. USA* 95: 2313-2318
- Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 90, 537-548.
- Davis et al., (1986) *Basic Methods in Molecular Biology*.
- Denovan-Wright, E.M., Newton, R.A., Armstrong, J.N., Babity, J.M., Robertson, H.A. (1998) Acute administration of cocaine, but not amphetamine, increases the level of synaptotagmin IV mRNA in the dorsal striatum of rat. *Mol. Brain Res.* 55, 350-354.
- Denovan-Wright, E.M., Gilby, K.L., Howlett, S.E. and Robertson, H.A. (1999) Cloning of differentially expressed brain cDNA. In *Differential Display - A Practical Approach*, H.A. Robertson and R.A. Leslie, Eds. Oxford University Press (in press).
- Devereux, J., et al.(1984), *Nucleic Acids Research* 12(1): 387.
- Douglass, J., McKinzie, A.A. and Couceyro, P. (1995) PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine. *J.*

Neurosci. 15, 2471-2481.

Douglas, J. and Daoud, S. (1996) Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript. *Gene* 169, 241-245

Eberwine, J. (1996) Amplification of mRNA populations using aRNA generated from immobilized oligo(dt)-T7 primed cDNA. *Biotechniques* 20: 584-589

Eberwine, J., Yeh, H., Miyashiro, K., Cao, Y., Nair, S., Finnell, R., Zettel, M., Coleman, P., (1992) Analysis of gene expression in single live neurons. *Proc. Natl. Acad. Sci. USA* 89: 3010-3014

Fujishige, K., Kotera, J., Michibata, H., Yuasa, K., Takebayashi, S., Okumura, K., and Omori, K. (June 25, 1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). *J Biol Chem* 274, 18438-45

Glass, M., Faull, R.L.M. and Dragunow, M. (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. *Neuroscience* 56: 523-527

Good et al (1977), *Nucl. Acid Res* 4:2157.

Gribskov, M. and Devereux, J., eds., *Sequence Analysis Primer*, M Stockton Press, New York, 1991.

Griffin, A. M., and Griffin, H. G., eds., *Computer Analysis of Sequence Data, Part I*, Humana Press, New Jersey, 1994.

Group THDCR (1993) A novel gene containing a trinucleotide repeat that is extended and unstable on Huntington's disease chromosomes. *Cell* 72: 971-983.

Hardy, J. and Gwinn-Hardy, K. (1998) Genetic classification of primary neurodegenerative disease. *Science* 282: 1075-1079

Hinnen et al., (1978) *PNAS USA* 75:1929-1933.

Houbenweyl, (1987) *Methods of Organic Chemistry*, ed. E. Wansch, Vol. 15 I and II,
Thieme, Stuttgart.

Innis, M. A. and D. H. Gelfand (1989), *PCR Protocols, A guide to Methods and Applications*,
M. A. Innis, D. H. Gelfand, J. J. Shinsky and T. J. White eds, pp 3-12, Academic Press.

Johanson, K. et al.(1995), *The Journal of Biological Chemistry*, Vol. 270, No. 16, pp 9459-
9471.

Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y.
and Orr, H.T. (1998) Ataxin-1 nuclear localization and aggregation: role in
polyglutamine-induced disease in *SCA1* transgenic mice. *Cell* 95: 41-53.

Lesk, A. M., ed., *Computational Molecular Biology*, Oxford University Press, New York,
1988.

Liang, P. and Pardee, A.B. (1992) Differential display of eukaryotic messenger RNA by
means of the polymerase chain reaction. *Science* 257: 967-971.

Livesey, F.J., O'Brien, J.A., Li, M., Smith, A.G., Murphy, L.J. and Hunt, S.P. (1997) A
Schwann cell mitogen accompanying regeneration of motor neurons. *Nature* 390: 614-
618.

Livesey, F.J. and Hunt, S.P. (1996) Identifying changes in gene expression in the nervous
system: mRNA differential display. *Trends Neurosci.* 19: 84-88

Loughney, K., Snyder, P. B., Uher, L., Rosman, G. J., Ferguson, K., and Florio, V. A. (June
1999). Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide
phosphodiesterase. *Gene* 234, 109-17

Ludlow, C.L., Connor, N.P., Bassich, C.J. (1987) Speech timing in Parkinson's and
Huntington's disease. *Brain-Lang*, 32, 195-214.

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B. ,Harper, A., Hetherington, C. Lawton,

- M., Trottier, Y., Lehrach, H., Davies, S. W. and Bates, G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 87: 493-506.
- Merrifield, (1964), *J. Am. Chem. Assoc.* 85:2149-2154.
- Okano, J., (1988) *Neurochem.* 56: 560.
- Pardee, A.B. (1997) Complete genome expression monitoring: the human race. *Nat. Biotechnol.* 15: 1343-1344
- Polli, J.W., and Kincaid, R. L. (1994). Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. *J. Neurosci.* 14, 1251-1261
- Qu,-D., Ludwig,-D.S., Gammeltoft, S., Piper, M., Pelleymounter, M.A., Cullen, M.J. Mathes, W.F., Przypek, R., Kanarek, R. and Maratos-Flier, E. (1996) A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* 380: 243-247.
- Richfield, E.K. and Herkenham, M. (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. *Ann. Neurol.* 36: 577-584.
- Ross, C.A., (1997) Intracellular neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? *Neuron* 19: 1147-1150.
- Saiki et al., (1986) *Nature*, 324: 163-166.
- Sambrook, et al, (1989), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear

inclusions. *Cell* 95: 55-66.

Sisodia, S.S., (1998) Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental or beneficial? *Cell* 95: 1-4.

Smith, D. W., ed., *Biocomputing: Informatics and Genome Projects*, Academic Press, New York, 1993.

Soderling, S. H., Bayuga, S. J., and Beavo. J. A. (June 1999). Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. *Proc Natl Acad Sci U S A* 96, 7071-6

von Heinje, G., *Sequence Analysis in Molecular Biology*, Academic Press, 1987.

Yan, C., Bentley, J. K. Sonnenburg, W. K., and Beavo, J. A. (1994). Differential expression of the 61 kDa a 63 kDa calmodulin-dependent phosphodiesterase in the mouse brain. *J. Neurosci.* 14, 973-984

Young, A.B., Penney, J.B., Starosta-Rubinstein, S., Markel, D.S., Berent, S., Giordani, B., Ehrenkaufer, R., Jewett, D., Hichwa, R. (1986) PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. *Ann-Neurol.* 20, 296-303.

Gene Necessary for Striatal Function, Uses Thereof, and
Compounds for Modulating Same

Abstract

PDE10A, a gene that is normally highly expressed in mammalian striatum and elsewhere, has been found to decrease in expression during the development of CAG repeat disorders such as Huntington's disease. The invention teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder. Compounds which modulate CAG repeat disorders and their uses are taught. Methods for screening for further compounds to modulate CAG repeat disorders are also taught.

005001-00000000

HD WT

1 2 3 4 5 6




Figure 1



Figure 3

5' 11 21 31 41
 1 TGTATGGGAATAGTGTTCATATGATCTGTTGTCTGGAGTATATGCTAC
 ACATACCCTTATCACAAA GGTATACTAGACAACAGACCTCATATACGATG probe 1

5' 61 71 81 91
 51 ATGTTTCAATTTACTGTACAAAAACCCAGTGCAGCTGATGATGCAAAGCAGT
TACAAGTAAATGACATGTTTTTGGGTACGTCGACTACTACGTTTCGTCA

5' 11 21 31 41
 101 CTCTCTCTGTGTACAGTGCCCCACCTATTTAAAAATCACGTACTTGCCCA
 GAGAGAGACACATGTCACGGGGTGGATAAA TTTT TAGTGCATGAACGGGT

5' 61 71 81 91
 151 GAACACTGTGAAACACTTAA CATAAGAACAACGCAGCGTCTGGATTCTT
 CTTGTGACACTTTGTGAATTGTATTCTTGT TTGCGTCGCAGACCTAAGAA

5' 11 probe 2 21 31 41
 201 TCCAAGGAGAG CAGCTTTCTCCACAGGAACACAGTAACAAAAGAGSTCCG
 AGGTTCCCTCTCGTCGAAAGAGGTGTCCTTG TGT CATTGTTTCTCCAGGC

5' 61 71 81 91
 251 CCGCCATCCACACCCAGCCAAGACACCTCAGAGGCCATAGGGACAACCTC
 GGCGGTAGGTGTGGGTCTGTGGAGTCTCCGGTATCCTGTGTTGGAG

5' 11 21 31 41
 301 CTTGCTGGCCAACACCTGCTGGAGCAGGGG CACAGGTCCCAGCAACTGAT
 GAACGACCGGTTGTGGACGACCTCGTCCCCGTGTCCAGGGTCGTTGACTA

5' 61 71 81 91
 351 CCTCAGTGGATGGGTCTGCAGCCAAAGCCTTAATGGGCTCTCTTTTGAAG
 GGAGTCACCTACCCAGACGT CGGTTTCGGAATTACCCGAGAGAAAACCTC

5' 11 21 31 41
 401 GGGAAAGAAAGAATTTCAAG CTTATGATATCCAATATTATATAGTTGAT
 CCCTTTCTTTCTTAAAGTTC GAATACTATAGGTTATAATAATATCAACTA

5' 61 71 81 91
 451 GAGTTAGTAAATTCCAAAAA
 CTCAATCATTTAAGGTTTTTTTTT



Figure 4




Figure 5



Figure 6




Figure 7

—



Figure 8

00900T-80205500




Figure 9

Figure 10

5' 11 21 31 41
1 CACTGAAGCTGGTCCACGTC TATAAACAGGTGACACTGGC TGCAGCAAAA
GTGACTTCGA CCAGGTGCAGATATTTGTCCACTGTGACCGACGTCGTTTT

5' 61 71 81 91
51 AGCCATTTCGATCCACACAAA TTGATCTTCTATCATCTTGGAATCTGAATT
TCGGTAAGCTAGGTGTGTTTAACTAGAAGATAGTAGAACCTTAGACTTAA

5' 11 21 31 41
101 GCAGGGAGGAGCAGTATGTAAGACGACCGTTTAATTCAGG CATTCCGAAG
CGTCCCTCCTCGTCATACAT TCTGCTGGCAAATTAAGTCCGTAAAGGCTTC

5' 61 71 81 91
151 GCATGAGCGCATGGATTCTGT CACCAAGCGTATAAAAGGACCCTGGCATT
CGTACTCGCGTACCTAAGACAGTGGTTCGCATATTTTCCTGGGACCGTAA

5' 11 21 31 41
201 GGGAAACCTATGACGGACTGTTTTTGCTGTAGAAGTAGGGATTTTACAGA
CCCTTTGGATACTGCCTGACAAAAACGACATCTTCATCCC TAAAATGTCT

5' 61 71 81 91
251 AGTCTCCTTGAATTTGCCCTGCCTGGGGCAGTTTTGCAGAGGAACCTGCC
TCAGAGGAAC TTAAACGGGACGGACCCCGT CAAAACGTCTCCTTGGACGG

5' 11 21 31 41
301 AGAGATTTAT TGGCTGGTCA GTCTCTTGTGAAATAGTATCATGTGAGAAA
TCTCTAAATAACCGACCA GT CAGAGAACAC TTTATCATAGTACACTCTTT

5' 61 71 81 91
351 CAGTTTGTAGAAAAAACTA TACCTGGGAAGACCTTTGCAACATTGTTCC
GTCAAACATCTTTTTTTTGATATGGACCCCTCTGGAAACGTTGTAACAAGG

5' 11 21 31 41
401 TTCCATGGGCAAGACTCAGTTAGGAGGCA TAAATCTGCC CGGAATAAAC
AAGGTACCCGTTCTGAGTCAATCCTCCGTATTTAGACGGGCCTTATTTG

5' 61 71 81 91
451 TAGGCCAGGATACAGCCATGTTTAGTTAATAATTTGGTTTTAGAAATTCAC
ATCCGGTCCTATGTCCGTACAAATCAATTA TTAAACCAAAATCTTAAGTG

5' 11 21 31 41
501 ACAGGCAGGAT TGGTTTTTTTGTGTCTTGG CAAGTGGAGCATATTTAACA
TGTCCGTCCTAACCACAAAAACACAGAACC GTTCACCTCGTATAAATTGT

5' 61 71 81 91
551 TACAGGCATGGGAATCCTGCTCTTAGCTT TTCCCACCCTCTTGTCTCAC
ATGTCCGTAC CTTAGGACG GAGAATCGAAAGGGTGGGAGAACAGAGTG

5' 11 21 31 41
601 CAAGTTTTTTCTCTCCAAAGGTTTCCAGGAATTTCTCATTAAATGGCTGAT
GTTCAAAAAAGAGAGGTTTC CAAAGGTCCTTAAAGAGTAA TTACCGACTA

Figure 10 continued

5' 61 71 81 91
651 GCAAACCTTAGTGAATAATAATGAATATAAA CAATGCTCAC CTCACCAAAA
CGTTTGAATCACTTATTATTACTTATATTT GTTACGAGTGGAGTGGTTT

5' 11 21 31 41
701 TTATATTATT TGCAGTCATT TGTGATAACA CAAATTTTAT CGCAATGGTT
AATATAATAAACGTCAGTAAACACTATTGT GTTTAAAATAGCGTTACCAA

5' 61 71 81 91
751 ATTATTTAAT TTGTGGCCACACACTGTGGTTATCTTTTGTTGTGGTTGTT
TAATAAATTAACACCGGTGTGTGACACCAATAGAAAACAACACCAACAA

5' 11 21 31 41
801 TCTGAGAAAA TGTTCCTTGGATATGTAAGTG CCAATACCAGTGTGAAGTAT
AGACTCTTTTACAAGAACCTATACATTACGGTTATGGTCACACTTCATA

5' 61 71 81 91
851 TGATCCCGGG CAGCAAAATA CAGCCTAAGG TTTGTAAACATCAATTCTAT
ACTAGGGCCC GTCGTTTTATGTCGGATTCCAAACATTTGTAGTTAAGATA

5' 11 21 31 41
901 CTCAGTTCAT CAGAGGGCCTGAGAAGCTGCGGGGCAGTGTAAAGTAAAGT
GAGTCAAGTAGTCTCCCGGA CTCTTCGACG CCCCCTCACA TTTCATTTC

5' 61 71 81 91
951 ATGCTGGGCT GGTGGTGGTCAGCCTCCCGCCTGAAGAGTGACCAAGTGCTG
TACGACCCGA CCACCACCAG TCGGAGGGCG GACTTCTCAC TGGTCACGAC

5' 11 21 31 41
1001 GCCCGACGGATCGCTGAGATATTCTCCATAATGGCAAAAAAATAGGCAG
CGGGCTGCCTAGCGACTCTA TAAGAGGGTATTACCGTTTTTTTATCCGTC

5' 61 71 81 91
1051 TTTGATGTGACCTGTTTGTAGTGTGGCTCTCCTCTTTTGAGCATGTGTTAGC
AAACTACACTGGACAAATCA CACCGAGAGGAGAAAACCTCGTACACAATCG

5' 11 21 31 41
1101 ATTTTTATTTTATACTCATC CAGTGAACCTCTGCTCTTCCAAGTGTGTTCA
TAAAAATAAAATATGAGTAGGTCACTTGAGACGAGAAGGT TCACACAAGT

5' 61 71 81 91
1151 TGTATGTGCTAGATATATTAGCACAGCCTGCCTTCTGCTGCACAACGCCT
ACATACACGATCTATATAATCGTGTGCGGACGGAAGACGACGTGTTGCGGA

5' 11 21 31 41
1201 TAGAGACCCGGCCTTTCAATGAGCTTAGCTTGTGCTCTGTTTCTGCTCTC
ATCTCTGGGCGGAAAGTTA CTCGAATCGAACACGAGACAAAGACGAGAG

5' 61 71 81 91
1251 TTAGGTCTAAACTATGGTGT CAGTTTTAATAGAACAAAAGTATGCATCTT
AATCCAGATTGATACCACAGTCAAAATTATCTTGTTTTTCATACGTAGAA

Figure 10 continued

```

5'          11          21          31          41
1301 GCCTTGGCTT GAGCCTTTTCGTTTTC AATGCTGACTTCTCCCTTCTCT
      CGGAACCGAA CTCGGAAAAG CAAAAGTTAC GACTGAAGAG GGGAGAGAGA

5'          61          71          81          91
1351 CCTGTGCTCA CTTACCTTT CCAGAGTGTAAGGGACA ACTTTTAAGGAGG
      GGACACGAGT GGAATGGAAA GGTCTCACAT TCCCTGTTGAAAATTCCTCC

5'          11          21          31          41
1401 CGTGTCCCTG GTAGGGGCAT CCCTGTT CAC CAGGTGCCTGTCATCACCCC
      GCACAGGGAC CATCCCCGTAGGGACAAGTG GTCCACGGACAGTAGTGGGG

5'          61          71          81          91
1451 ACTTGACTGA CATCTACCCT GGTGACTATGGGTTCTCTT GTTTGTAGGG
      TGAAC T GACTGTAGATGGGA CCACTGATAC CCAAGGAGAA CAAACATCCC

5'          11          21          31          41
1501 AACGGTGGCT CCAGGTGGAGGCATCAATCTGTTGGGTTCTGGTTCCCGGC
      TTGCCACCGAGGTCCACCTC CGTAGTTAGA CAACCCAAGA CCAAGGGCCG

5'          61          71          81          91
1551 TGCCTTTGGT TTTGAAAGTC TCTTCTCTGTATATTCCTAC CTTGCATT TG
      ACGGAAACCAAACTTTCAGAGAAGAGACATATAAGGATGGGACGTAAAC

5'          11          21          31          41
1601 CTTTGTGTGG TGCTGATGCTGTGCGCAGTAGGATTCTTG GATGACTCTCC
      GAAACACACCACGACTACGACACGCGTCAT CCTAAGAACC TACTGAGAGG

5'          61          71          81          91
1651 ATCAGTCACAGACTCCCCCTGTTGCAAAGTGTCAGGCTGACTCGACAGTC
      TAGTCAGTGTCTGAGGGGGGCAACGTTTCA CAGTCCGACTGAGCTGT CAG

5'          11          21          31          41
1701 ACCGTAAAAT CTGAGTCAGT CACACACAGGCTGTCAGCCACGGCTTCCAC
      TGGCATTTT TACTCAGTCAGTGTGTGTCCGACAGTCGGTGCCGAAGGTG

5'          61          71          81          91
1751 TTGCATGGCTATTCTATTTT CACACGTGAGTTTCTGTTGCTGGCTGGCTG
      AACGTACCGATAAGATAAAAGTGTGCACTCAAAGACAACGACCGACCGAC

5'          11          21          31          41
1801 ACTGGCATTATCTATGCTAAGTTGAAATCAGGAGTGCCCAGCAGAGCCCA
      TGACCGTAATAGATACGATT CAACTTTAGT CCTCACGGGT CGTCTCGGGT

5'          61          71          81          91
1851 TCATTCTCACTGTCTTTGAAACAAAGCTGTACGGTTTGATCGATGAACGT
      AGTAAGAGTGACAGAACTT TGTTCGACATGCCAAACTAGCTACTTGCA

5'          11          21          31          41
1901 ATTTAAAGCA TTTTCATGCAA TGACAAAGTG CTCAGTAGTGGAAGGCAGGC
      TAAATTT CGTAAAGTACGTT ACTGTTTCACGAGTCATCACCTTCGGTCCG
  
```


Figure 10 continued

5' 61 71 81 91
1951 TGTGACCAGTCTGCCTGCTCCTTACTATAATTGTGAGGATTTGTTACTGG
ACACTGGTCAGACGGACGAGGAATGATATTAACTCCTAAACAATGACC

5' 11 21 31 41
2001 AACAGTACATGGAGGCCTGACCTTGTGGGGGCACAGGGTGAACCTTAGC
TTGTCATGTACCTCCGACTGGAACACCCCGTGTCCACCTTGAATCG

5' 61 71 81 91
2051 TGAATATAGTGTGTGTCTCAAGAGGAAGTCAGGGTACTAGCTCAGTGCTC
ACTTATATCACACAGAGTTCTCCTTCAGTCCCATGATCAGATCACGAG

5' 11 21 31 41
2101 AATCTCCAGGTACTATATATACATTTGCCC GTTTTATCTCTAATGTGAAA
TTAGAGGTCCATGATATATATGTAAACGGGCAAAATAGAGATTACACTTT

5' 61 71 81 91
2151 TAAATCCCCAAACACTTGTTTATCGTGTAGCGTACCTAAAAGACTATTCT
ATTTAGGGGT TTGTGAACAAATAGCACATCGCATGGATTTTCTGATAAGA

5' 11 21 31 41
2201 ATTATGGGTGTCCCCACTTTCTTGGTTTGGTCACCCCGATCCCCGGTCT
TAATACCCACAGGGGTGAAAGAACCACAGTGGGGCTAGGGGGCCAGA

5' 61 71 81 91
2251 TCTGCTGTATCTAGAACAGTGACTATAAATGATGTATGGGAATAGTGTTT
AGACGACATAGATCTTGTCACTGATATTTACTACATACCTTATCACAAA

5' 11 21 31 41
2301 CCATATGATCTGTTGTCTGGAGTATATGCTACATGTTCAATTACTGTACA
GGTATACTAGACAACAGACCTCATATACGATGTACAAGTTAATGACATGT

5' 61 71 81 91
2351 AAAACCCAGTGCAGCTGATGATGCAAAGCAGTCTCTCTCTGTGTACAGTG
TTTTGGGTCACTGCTGACTACTACGTTTCGT CAGAGAGAGACACATGTCAC

5' 11 21 31 41
2401 CCCACCTATTTAAAAATCA CGTACAASCC CAGAACACTGTGAAACACTT
GGGGTGGATAAATTTT TAGTGCATGTTSGGGTCTTGTGACACTTTGTGAA

5' 61 71 81 91
2451 AACATAAGAA CAAACGCAGCGTCTGGATTCTTTCCAAGGAGAGCAGCTTT
TTGTATTCTTGTGCGTCG CAGACCTAAGAAAGGTTCTCTCGTCGAAA

5' 11 21 31 41
2501 CTCCACAGGAACACAGTAACAAAAGAGGTC CGCCGCCATC CACACCCAGC
GAGGTGTCCTTGTGTCAATGTTTTCTCCAGGCGGCGGTAGGTGTGGGTG

5' 61 71 81 91
2551 CAAGACACCTCAGAGGCCATAGGGACAACCTCCTTGCTGGCCAACACCTG
GTTCTGTGGAGTCTCCGGTATCCCTGTTGGAGGAACGACCGGTTGTGGAC

Figure 10 continued

5' 11 21 31 41
2601 CTGGAGCAGGGGCACAGGTC CCAGCAACTGATCCTCAGTGGATGGGTCCG
GACCTCGTCCCGGTGTCCAGGGTCGTTGACTAGGAGTCACCTACCCAGGC

5' 61 71 81 91
2651 CAGTCAAAGCCTTAATGGGCTCTCTTTTGAAGGGGAAAGAAAGAATTTCA
GTCAGTTTCGGAATTACCCGAGAGAAAACCTCCCCTTTCTTTCTTAAAGT

5' 11 21 31 41
2701 AGCTTATGATATCCAACATTATTATAGTTGATGAGTTAGTAAATTCCAAA
TCGAATACTATAGGTTGTAATAATATCAACTACTCAATCATTTAAGGTTT

5' 61 71 81 91
2751 AAAAAAAGATGATTTTATATGTATGACATAAAAAAATCTTTGTAAAGTG
TTTTTTTCTACTAAATATACATACTGTATTTTTTTTAGAAACATTTTCCAC

5' 11 21 31 41
2801 CGCAAGTGCAATAATTTAAAGAGGTCTTATCTTTGCATTTATAAATTATA
GCGTTCACGTTATTAAATTTCTCCAGAATAGAAACGTAAATATTTAATAT

5' 61 71 81 91
2851 AATATTGTACATGTGTGTAAATTTTTCATGTATTCATTTGCAGTCTTTGTA
TTATAACATGTACACACATTAAAAAGTACATAAGTAAACGTCAGAAACAT

5' 11 21 31 41
2901 TTTAAAAAACTTTACTGTTATGTTTGTATAATAGAACATTAATCATTTA
AAATTTTTTTTGAATGACAAACAAACATATTATCTTGTAATTAGTAAAT

5' 61 71 81 91
2951 TTATAACTCAGACAAGGTGTAAATAAATTCATAATTCAAAACAGCCAGTAT
AATATTGAGTCTGTTCCACATTTATTTAAGTATTAAGTTTGTGCGTCATA

5' 11 21 31 41
3001 ATATGCATATATGGGTGTTA CATTGCAAAAATCTCTATCTTTGTTCTATT
TATACGTATATACCCACAATGTAACGTTTTTAGAGATAGAAACAAGATAA

5' 61 71 81 91
3051 CACATGCTTAAAGAAGTAAGAAATCTTTTGTGGATATGTAATTATACATA
GTGTACGAATTTCTTCATTCTTTAGAAAACACCTATACATTAATATGTAT

5' 11 21 31 41
3101 TAAAGTATATATATATGTATGATACATGAAATATATTTAGAAATGTTTCAT
ATTTTCATATATATATACATACTATGTACTTTATATAAATCTTTACAAGTA

5' 61 71 81 91
3151 AATTTTAATGGATATTCTTTGGTGTGAATAATTGAATACAACATTTTTAA
TTAAAATTACCTATAAGAAACACACTTATTAACCTATGTTGTAAAAATT

5' 11 21 31 41
3201 AATGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
TTACTTT




Figure 11
3236 bp

Figure 12

```

5'          11          21          31          41
1  AAGTGTAATAAAATAAACATCTAATAAAAAAATTACATACCATAGAGG
   TTCACATTTATTTTATTTGTAGATTATTTT TTTTAATGTATGGTATCTCC

5'          61          71          81          91
51 AACAAGATAA TTTCTGCCCAACTTCATACC CTCCAGCGTATAGTGTGAG
   TTGTTCTATTAAAGACGGGT TGAAGTATGGGAGGTCGCATATCACAAC TC

5'          11          21          31          41
101 GTTTGGTCTGTTGCTGTGTATTGTAATGTAATGTTAAATT CTCTACCTGA
   CAAACCAGACAACGACACATAACATTACATTACAATTTAAGAGATGGACT

5'          61          71          81          91
151 AGGTCTAGGC CTACAAGTGAATTCTCATGTTTATAGAGTT TTGTTGTGCA
   TCCAGATCCG GATGTTCACTTAAGAGTACAAATATCTCAAACAACACGT

5'          11          21          31          41
201 AACCTTGTTCTTTAATTTAAACTATGGTTAAAAAACAAAACAAAAC TGG
   TTGGAACAAGGAATTAAATTTTGATACCAATTTTTTTGTTTGTGTTTGACC

5'          61          71          81          91
251 CTACAGCCAA TAACTGAAGGGGGTTACCTTGTTGAAGGGG TGGAAAAGAG
   GATGTCGGTTATTGACTTCC CCCAATGGAA CAACTTCCCCACCTTTTCTC

5'          11          21          31          41
301 AGAGGAGGAAGAAGGGAGTTCAAGAGAAGGAGAAGAACAAGAGGAGAGGA
   TCTCCTCCTTCTTCCCTCAAGTTCTCTTCC TCTTCTTGTTCTCCTCTCCT

5'          61          71          81          91
351 GGAAGCTGCCACGAGGGGAGATGGGCCATGAGA ACTTGGC CAGGAGAAAT
   CCTTCGACGGTGCTCCCTCTACCCGGTACTCTTGAACCGGTCTCTTTA

5'          11          21          31          41
401 AGCCAGTATCTGGAGTACACCACTGAGGAGGTAGCCAGGC TAGCAGTTAG
   TCGGTCATAGACCTCATGTGGTGACTCCTC CATCGGTCCGATCGTCAATC

5'          61          71          81          91
451 AAGAGTAGATTAGGGGTTATTTTTCCCCCACTCCACATAGTTATCAAAGC
   TTCTCATCTAATCCCCAATAAAAAGGGGGTGAGGTGTATCAATAGTTTCG

5'          11          21          31          41
501 CAAATAAAATAACCATAGTCTGAGTCTCATCTATTTGTAAAGCTAGTTGGG
   GTTTATTTTATTTGGTATCAGACTCAGAGTAGATAAACATT CGATCAACCC

5'          61          71          81          91
551 TATAAGATTAATTTGGCTGTACTACAGTTTAGATTTCTAA CATAGGAACT
   ATATTCTAATTAAACCGACATGATGTCAAATCTAAAGATTGTATCCTTGA

5'          11          21          31          41
601 ATCAAAAACCTTGCTCAAACAAGAACATGCTGACAATATTT TAAAATGATT
   TAGTTTTTGAACGAGTTTGTCTTGTACGACTGTTATAAAATTTTACTAA

```

Figure 12 continued

5' 61 71 81 91
651 ATTTATATTGTTTGCACCTTCTAAAGTTTCTTCTAAATGTTCCATGGTCA
TAAATATAACAAACGTGAAAGATTTCAAAGAAGATTTACAAGGTACCAGT

5' 11 21 31 41
701 AATTAAAAAATATACATATTGGCTATTAAATTCGTCTAAGTGGGGCTGGA
TTAATTTTTTATATGTATAACCGATAATTTAAGCAGATTCACCCCGACCT

5' 61 71 81 91
751 GAGATAGCTCAGAGGTTAAGAGCACTGACTGCTCTTCCAGAGGTCCTGAG
CTCTATCGAGTCTCCAATTCCTGTGACTGACGAGAAGGTCCTCAGGACTC

5' 11 21 31 41
801 TTCAATTCCCAGCGACCACATGGTGGCTCACAGCCATCTGTAATAGATAG
AAGTTAAGGGTCGCTGGTGTACCACCGAGTGTCTGGTAGACATTATCTATC

5' 61 71 81 91
851 GATCTGACGCCTCTTCTGGAGTGTCTGAAGACAGCTACAATGTACTCAT
CTAGACTGCGGGAGAAGACCTCACAGACTTCTGTCTGATGTACATGAGTA

5' 11 21 31 41
901 ATATATTAAATAAATAATATTAGAAAATTCCTTCTAAGTGTATCATTTATA
TATATAATTTATTTATTATAATCTTTTAAGAAGATTCACATAGTAAATAT

5' 61 71 81 91
951 GAATATTTAATATATAAAGTAAATGCCTCAGGAAATATAAACTTGGAATT
CTTATAAATTATATATTTCAATTTACGGAGTCTTTTATATTTGAACCTTAA

5' 11 21 31 41
1001 AAATCAAAGAACTTCATGAGTAGTGGGCCACAAAAATGTGTACCAGGGG
TTTAGTTTCTTGAAGTACTCATCACCCGGTGTTTTTTACATGGTCCCC

5' 61 71 81 91
1051 AAGACCGGAGGGAGGGGAGAAGGAAGGGATGGAGATAGAAATTTGCCTCT
TTCTGGCCTCCTCCCTCTTCCTTCCCTACCTCTATCTTAAAACGGAGA

5' 11 21 31 41
1101 GCATTCCTTGGGCTGGCACAGGTATAATGCTGTGGGAATTGGGAACTAC
CGTAAGGAACCGACCGTGTCCATATTACGACACCTTAAACCTTTGATG

5' 61 71 81 91
1151 AAGGAAGCTGCAAAGCTGGGCGGAACCTCGTTTCCGCAAGCTGGGCTCATC
TTCCTTCGACGTTTCGACCCGCCTTGAGCAAAGGCGTTCGACCCGAGTAG

5' 11 21 31 41
1201 TAAGTGTCCATGCATGGCTGCCACACTGCAGTGAACCTTAAAACATTTGT
ATTCACAGGTACGTACCGACGGTGTGACGTCACTTGAAATTTTGTAACA

5' 61 71 81 91
1251 GTTCCAGAGATGTAGAGATGCTCACAATAGTACAAAGGCGGGAGGGAGGT
CAAGGTCTCTACATCTCTACGAGTGTTATCATGTTTCCGCCTCCCTCCA

[illegible][illegible]

Figure 12 continued

```

5'          61          71          81          91
1951 GTCCCTGGTAGGGGCATCCC TGTTCACCAGGTGCCTGTCA TCACCCCACT
    CAGGGACCATCCCCGTAGGG ACAAGTGGTC CACGGACAGTAGTGGGGTGA

5'          11          21          31          41
2001 TGA CTGACATCTACCCTGGT GACTATGGGT TCCTCTTGTTTGTAGGGAAC
    ACTGACTGTAGATGGGACCA CTGATACCCAAGGAGAACAAACATCCCTTG

5'          61          71          81          91
2051 GGTGGCTCCAGGTGGAGGCA TCAATCTGTTGGGTTCCTGGT TCCCGGCTGC
    CCACCGAGGTCCACCTCCGTAGTTAGACAA CCAAGACCAAGGGCCGACG

5'          11          21          31          41
2101 CTTTGGTTTTTGAAAGTCTCT TCTCTGTATA TTCCTACCCTGCATTTGCTT
    GAAACCAAAACTTTTCAGAGA AGAGACATATAAGGATGGGACGTAAACGAA

5'          61          71          81          91
2151 TGTGTGGTGC TGATGCTGTG CGCAGCAGGATTCTTGGATGACTCTCCATC
    ACACACCACGACTACGACAC GCGTCGTCCTAAGAACCTACTGAGAGGTAG

5'          11          21          31          41
2201 AGTCACAGACTCCCCCTGTTGCAAAGTGTCAGGCTGACTCGACAGTCACC
    TCAGTGTCTGAGGGGGACAA CGTTTCACAGTCCGACTGAGCTGTCACTGG

5'          61          71          81          91
2251 GTAAAATCTGAGTCAGTCACACACAGGCTGTCAGCCACGGCTTCCACTTG
    CATTTTAGACTCAGTCAGTGTGTGTCCGACAGTCCGGTGCCGAAGGTGAAC

5'          11          21          31          41
2301 CATGGCTATTCTATTTTCACACGTGAGTTTCTGTTGCTGGCTGGCTGACT
    GTACCGATAAGATAAAAGTGTGCACTCAAAGACAACGACCGACCGACTGA

5'          61          71          81          91
2351 GGCATTATCTATGCTAAGTTGAAATCAGGGGTGCCCAGCAGAGCCCATCA
    CCGTAATAGATACGATTCAA CTTTAGTCCC CACGGGTTCGTCTCGGGTAGT

5'          11          21          31          41
2401 TTCTCACTGTCTTTGAAACAAAGCTGTACGGTTTGATCGATGAACGTATT
    AAGAGTGACAGAAACTTTGT TTCGACATGCCAAACTAGCTACTTGCATAA

5'          61          71          81          91
2451 TAAAGCATTTT CATGCAATGACAAAGTGCTCAGTAGTGGAAGGCAGGCTGT
    ATTTTCGTAAAGTACGTTACTGTTTCACGAGTCATCACCTTCCGTCCGACA

5'          11          21          31          41
2501 GACCAGTCTGCCTGCTCCTTACTATAATTGTGAGGATTTGTTACTGGAAC
    CTGGTCAGACGGACGAGGAA TGATATTAAC ACTCCTAAACAATGACCTTG

5'          61          71          81          91
2551 AGTACATGGAGGCCTGACCTTGTGGGGGCA CAGGGTGGAACCTTAGCTGA
    TCATGTACCTCCGACTGGAACACCCCCGTGTCCACCTTGGAATCGACT

```

Figure 12 continued

5' 11 21 31 41
2601 ATATAGTGTGTGTCTCAAGAGGAAGTCAGG GTACTAGCTCAGTGCTCAAT
TATATCACACACAGAGTTCTCCTTCAGTCC CATGATCGAGTCACGAGTTA

5' 61 71 81 91
2651 CTCCAGGTACTATATATACATTTGCCCGTTT TATCTCTAA TGTGAAATAA
GAGGTCCATGATATATATGTAAACGGGCAA AATAGAGATTACACTTTATT

5' 11 21 31 41
2701 ATCCCCAAACACTTGTTTATCGTGTAGCGTACCTAAAAGACTATTCTATT
TAGGGGTTTG TGAACAAATAGCACATCGCATGGATTTTCTGATAAGATAA

5' 61 71 81 91
2751 ATGGGTGTCC CCACTTTCTTGGTTTGGTCA CCCC GATCCC CCGGTCTTCT
TACCCACAGGGGTGAAAGAA CCAAACCAGTGGGGCTAGGGGGCCAGAAGA

5' 11 21 31 41
2801 GCTGTATCTAGAACAGTGACTATAAATGATGTATGGGAATAGTGTTTCCA
CGACATAGATCTTGTCACTGATATTTACTA CATAACCCTTATCACAAAGGT

5' 61 71 81 91
2851 TATGATCTGTTGTCTGGAGTATATGCTACATGTTTCA TTTA CTGTACAAAA
ATACTAGACAACAGACCTCATATACGATGTACAAGTAAATGACATGTTTT

5' 11 21 31 41
2901 ACCCAGTGCGAGCTGATGATGCAAAGCAGTCTCTCTGTGTACAGTGCCC
TGGGTCACGTGACTACTACGTTTCGTCAGAGAGAGACACATGTCACGGG

5' 61 71 81 91
2951 CACCTATTTAAAAATCACGTACTTGCCCAGAACACTGTGAAACACTTAAAC
GTGGATAAATTTTTAGTGCA TGAACGGGTC TTGTGACACT TTGTGAATTG

5' 11 21 31 41
3001 ATAAGAACAACGCAGCGTC TGGATTCTTTCCAAGGAGAGCAGCTTTCTC
TATTCTTGTTT TCGTCGCAGACCTAAGAAAGGTTCTCTC GTCGAAAGAG

5' 61 71 81 91
3051 CACAGGAACA CAGTAACAAAAGAGGTCCGCGCCATCCACACCCAGCCAA
GTGTCCTTGTTGTCATTGTTTTCTCCAGGCGGCGGTAGGTGTGGGTCTGGTT

5' 11 21 31 41
3101 GACACCTCAGAGGCCATAGGGACAACCTCCTTGCTGGCCAACACCTGCTG
CTGTGGAGTCTCCGGTATCCCTGTTGGAGGAACGACCGGT TGTGGACGAC

5' 61 71 81 91
3151 GAGCAGGGGCACAGGTCCCAAGCAACTGATCCTCAGTGGATGGGTCTGCAG
CTCGTCCCCGTGTCCAGGGTCGTTGACTAGGAGTCACCTA CCCAGACGTC

5' 11 21 31 41
3201 CCAAAGCCTTAATGGGCTCTCTTTTGAAGGGGAAAGAAAG AATTTCAAGC
GGTTTCGGAATTACCCGAGAGAAAACCTCCCTTTCTTTC TTAAAGTTTCG

Figure 12 continued

```

5'          61          71          81          91
3251 TTATGATATCCAATATTATTATAGTTGATGAGTTAGTAAATTCCAAAAAA
    AATACTATAGGTTATAATAATATCAACTACTCAATCATTTAAGGTTTTTT

5'          11          21          31          41
3301 AAAAGATGATTTTATATGTATGACATAAAAAAATCTTTGTAAAGTGCGC
    TTTTCTACTAAATATACATACTGTATTTTTTTTAGAAACATTTACGCG

5'          61          71          81          91
3351 AAGTGCAATAATTTAAAGAGGTCTTATCTTTGCATTTATAAATTATAAAT
    TTCACGTTATTAAATTTCTCAGAAATAGAAACGTAAATATTTAATATTTA

5'          11          21          31          41
3401 ATTGTACATGTGTGTAATTTTTCATGTATTCATTTGCAGTCTTTGTATTT
    TAACATGTACACACATTAAAAAGTACATAAGTAAACGTCAGAAACATAAA

5'          61          71          81          91
3451 AAAAAAATCTTTACTGTTATGTTTGTATAATAGAACATTAATCATTTATTA
    TTTTTTTGAAATGACAATACAAACATATTATCTTGTAATTAGTAAATAAT

5'          11          21          31          41
3501 TAACTCAGACAAGGTGTAAATAAATTCATAATTCAAACAGCCAGTATATA
    ATTGAGTCTGTTCCACATTTATTTAAGTATTAAGTTTGTCTGGTCATATAT

5'          61          71          81          91
3551 TGCATATATGGGTGTTACATTGCAAAAATCTCTATCTTTGTTCTATTCAC
    ACGTATATACCCACAATGTAACGTTTTTAGAGATAGAAACAAGATAAGTG

5'          11          21          31          41
3601 ATGCTTAAAGAAGTAAGAAATCTTTTGTGGATATGTAATTATACATATAA
    TACGAATTTCTTCATTCTTTAGAAAACACCTATACATTAAATATGTATATT

5'          61          71          81          91
3651 AGTATATATA TATGTATGATACATGAAATA TATTTAGAAATGTTTCATAAT
    TCATATATATATACATACTA TGTACTTTATATAAATCTTTACAAGTATTA

5'          11          21          31          41
3701 TTTAATGGATATTCTTTGGTGTGAATAATTGAATACAACATTTTTTAAAT
    AAATTACCTATAAGAAACCA CACTTATTAACTTATGTTGTAAAAATTTTA

5'          61          71          81          91
3751 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTTTTTTTTTTTTTTT
    TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAAAAAAAAAAAAAAAAAA

5'          11          21          31          41
3801 TTATTCCAGAGATTAAAGACACTAGATCTTTAACCTTGAAGGGCAGGCAA
    AATAAGGTCTCTAATTTCTG TGATCTAGAAATTGGAACCTTCCCGTCCGTT

5'          61          71          81          91
3851 GAGGTCGGCAATGCTGTCAA CATAGAAGTCAGGGACCATTTTCTTCTTGA
    CTCCAGCCGTTACGACAGTTGTATCTTCAGTCCCTGGTAAAGAAGAAGT

```

Figure 12 continued

```

5'          11          21          31          41
3901 ACATGCAGTCACTTTTCCTGATTGCTCTTCACATCCTCAAGGCTCCGGAAT
    TGTACGTCAGTGAAAGGACTAACGAGAAGTGTAGGAGTTCGAGGCCTTA

5'          61          71          81          91
3951 TCCGGGGGGTG TGGTGGGCTTTGATCTCAGGACTCTGGAGGCAGAAGCAGG
    AGGCCCCCACACCACCCGAACTAGAGTCC TGAGACCTCCGTCTTCGTCC

5'          11          21          31          41
4001 CAGATCTCTGTGAATATGAGGCCAGCCTGCACTACACAGAGCTCCAGACC
    GTCTAGAGACACTTATACTCCGGTCGGACGTGATGTGTCTCGAGGTCTGG

5'          61          71          81          91
4051 AGTCATGGCTACATCATGAAACCCTGTCTCAAAAAGAAAA TAAAACTGT
    TCAGTACCGATGTAGTACTTTGGGACAGAGTTTTTCTTTTATTTTGTACA

5'          11          21          31          41
4101 TGTGTTTTCTACCATAGTGTTAAACTCAGAGTCTGAGTAATGTCGGGCTGA
    ACACAAAGATGGTATCACAA TTTGAGTCTCAGACTCATTACAGCCCGACT

5'          61          71          81          91
4151 CATGCTCGGGTGTTTAACATACCTTCAGCTTTGACGAGGCGCTGAACAGT
    GTACGAGCCCACAAATTGTATGGAAGTCGAAACTGCTCCGCGACTTGTCAT

5'          11          21          31          41
4201 CAAAGTCTGGCCTTGGGGAGCGGTGGCTGTGTTTGTGCTCAAGTCCACCG
    GTTTCAGACCGGAACCCCTCGCCACCGACA CAAACACGAGTTCAGGTGGC

5'          61          71          81          91
4251 TGAAATCCTGATTGTGAATTTGGACAACCGTGTCCTTCTTCTTGGCCTTC
    ACTTTAGGACTAACACTTAAACCTGTTGGCACAGGAAGAA GAACCGGAAG

5'          11          21          31          41
4301 CATGCAACCTCAAACCTTCATGTTGGTCATTTTGTCAAAACACTGTGTGAT
    GTACGTTGGAGGTTGAAGTACAACCAGTAAACAGTTTTGTGACACACTA

5'          61          71          81          91
4351 GTTTTTATCAATATACTGCCATTCCACATATG TAGAGATGTAGTCTGCCT
    CAAAAATAGTTATATGACGGTAAGGTGTATACATCTCTACATCAGACGGA

5'          11          21          31          41
4401 GGCTTTCCTTTTCTTTAGCCAATCGAATGCTCTTGATCATGCCCTCAATC
    CCGAAAGGAAAAGAAATCGGTTAGCTTACGAGAACTAGTACGGGAGTTAG

5'          61          71          81          91
4451 TCATCTCTAGCTTTTATCACGTCTCTGCTAATTCCTGAAACTTGAATCGA
    AGTAGAGATCGAAAATAGTGCAGAGACGATTAAGGACTTTGAACTTAGCT

5'          11          21          31          41
4501 AGTTTTCTTCTGGTTCATCTCAATGGTGATGTTCAAGTTCC TTCTGAATCT
    TCAAAAGAAGACCAAGTAGAGTTACCACTA CAAGTCAAGGAAGACTTAGA

```

Figure 12 continued

5' 61 71 81 91
4551 CATTTCAGTTTCTCGTACTCC TCCATGTCAAAGTCACTGACACACTCATCG
GTAAGTCAAAGAGCATGAGGAGGTACAGTTTCAGTGACTGTGTGAGTAGC

5' 11 21 31 41
4601 TCATTGGTGTAGGAAAGCTGCTCTTTGGTAATCAGTTCCTTTAGCCAGGA
AGTAACCACATCCTTTTCGACGAGAAACCATTAGTCAAGGAAATCGGTCCT

5' 61 71 81 91
4651 GATTGTTTTGTTCACACTGTCTACCCCTGAACACATACC TGGAAAAC TG
CTAACAAAACAAGTGTGACAGATGGGGACTTGGTGTATGGACCTTTTGAC

5' 11 21 31 41
4701 TGTGCTCTATTTTCTTTTCCAAAACCAGGGTGTCTTTT TGGGGAAGCT
ACACGAGATAAAAGAAAAGGTTTTGGTCCCACAAGAAAAA CCCCCTTCGA

5' 61 71 81 91
4751 TGCTTGGGAAAGCCAAGAAAAGGCTAAAGAGAAAATGGAAATTAATGTTTC
ACGAACCCTTTCGGTCTTTCCGATTTCTCTTTTACCTTTAATTACAAAG

5' 11 21 31 41
4801 TTTTACTCCCTTCAACATCAAGGTTAGGAA TATGTATTTTCATAAAAGCTA
AAAATGAGGGAAGTTGTAGTTCCAATCCTTATACATAAAGTATTTTCGAT

5' 61 71 81 91
4851 ACAACTCACAGGCAATCTTAGACATCACTGACTGCTTGGCAGGCGACTGC
TGTTGAGTGTCCGTTAGAATCTGTAGTGACTGACGAACCGTCCGCTGACG

5' 11 21 31 41
4901 TTGGGGGGGAGCTGGAGAGCC TTCTCTTTCTTTCATGTTGT CGTAAAAAA
AACCCCCCTCGACCTCTCGGAAGAGAAAGAAAGTACAACAGCATTTTTTTT

5' 61 71 81 91
4951 TTGCAGAATATGGGGCTGGAAGATAACAAC TTTAACTCTCTTCACAGCCT
AACGTCTTATACCCCGACCTTCTATTGTTGAAATTGAGAGAAGTGTCCGA

5' 11 21 31 41
5001 GCACTGATTTTTTCTGGACAAATTCTTCAA TGGCATCTATTATCGCTTTT
CGTGACTAAAAAGACCTGTTTAAGAAGTTACCGTAGATAATAGCGAAAA

5' 61 71 81 91
5051 GCTACTACGTTTGGGTCCTGTTGAGCATTT CCTTCAAAAA CAAAAAAGC
CGATGATGCAAACCCAGGACAAC TCGTAAAGGAAGTTTTTGTTTTTTTCG

5' 11 21 31 41
5101 ACATTTTTTAAAAAGTCAAGGTTAAGATCCACCTGCAAAAAAAGCTGCAA
TGTA AAAATTTTTTCAGTTCCAATTCTAGGTGGACGTTTTTTTTCGACGTT

5' 61 71 81 91
5151 TATAAGCGAGGAATTCTAGTTGTCACAGGAAATAAAAATGTCTGTTCCTCA
ATATTCGCTCCTTAAGATCAACAGTGTCTTTTATTTTTTACAGACAAGGGT

Figure 12 continued

```

5'          11          21          31          41
5201 CTATAATCAA TGTAGACTGA TAATATTATGCCAGCAAATAGTTTTGAAGT
    GATATTAGTTACATCTGACTATTATAATACGGTCGTTTATCAAACCTTCA

5'          61          71          81          91
5251 CCTAGGCACAGTGGGAGGAGGTTTTGTTCCACGCTGTTCA TAAGCCAATA
    GGATCCGTGT CACCCTCCTC CAAAACAAGGTGCGACAAGTATTCGGTTAT

5'          11          21          31          41
5301 CCCCAGCAAAAGACCTTAAAGGACAACCTTGTAATTTGGGCAATTACATC
    GGGGTCGTTT TCTGGAATTTCTGTTGAACATTAAACCCTGTAAGTGTAG

5'          61          71          81          91
5351 TGCCTCTTCATCTGATCTGCTCCCAGTGTCACCTCTCTAACACGGTCCT
    ACAGGAGAAGTAGACTAGAC CGAGGGTCACAGTGAGAGATTGTGCCAGGA

5'          11          21          31          41
5401 TAGAGGGACAATTTATCCCTGCCTCTGCTTGATCTTATGCATGTATCTGT
    ATCTCCCTGTTAAATAGGGACGAGAGACGAACTAGAATACGTACATAGACA

5'          61          71          81          91
5451 ATTCTTCCAGCCATCCCTGGCGACCTGATTTTCTAAGGCACCCAAAAC
    TAAGAAGGTCGGTAGGGACC GCTGGACTAAAAGATTCCGTGGGTTTTGA

5'          11          21          31          41
5501 GTAAGCTACTTCTTATAATCTATAATTCTGAGCATATTAGTTAGCCTGAG
    CATTCGATGAAGAATATTAGATATTAAGACTCGTATAATCAATCGGACTC

5'          61          71          81          91
5551 CCTCCAGGATATCTTTCTTC CCTATACTCAGTCCAGTTTTAGCTGCCAG
    GGAGGTCCTA TAGAAAGAAGGGATATGAGT CAGGTCAAAATCGACGGGTC

5'          11          21          31          41
5601 AAGGATTCAAAGCTGATCTACGAGTAGATCACTCCTGTCTACAGCTTGTT
    TTCCTAAGTTTCGACTAGATGCTCATCTAGTGAGGACAGATGTCGAACAA

5'          61          71          81          91
5651 CCAGATCTTGTTTCTCAAGC CCTGGAAGCCATCAGCCAGGTAAGATTGTA
    GGTCTAGAACAAAGAGTTCG GGACCTTCGGTAGTCGGTCCATTCTAACAT

5'          11          21          31          41
5701 AAACAATCCCTTTCTAATCA TGGGTGTGGC CCAAAGTGAA TGGCCGGAAT
    TTTGTTAGGGAAAGATTAGTACCCACACCGGTTTCACTTACCGGCCTTA

5'          61          71          81          91
5751 TC
    AG

```




Figure 13

5752 bp




Figure 14

Figure 15

PDE10a and RACEs compiled

1	CGCCCGGGCA	GGTCTGTTGG	AGGGCAGTTG	GTCAACCTGA	CCAGAGAGAG	CTGAGCTGGA
	GCGGGCCCCGT	CCAGACAACC	TCCCGTCAAC	CAGTTGGACT	GGTCTCTCTC	GA CTGACCT
61	AGACCCCACT	GATGGTGTGC	TGCCTTTTCAG	TCCAGGAAGA	AAGAAAGGAA	GGATTCTGAG
	TCTGGGGTGA	CTACCACACG	ACGGAAAGTC	AGGTCCTTCT	TTCTTTTCCTT	CCTAAGACTC
121	GATTTGGGCA	AAGCCACATT	CCTGGAGAAG	TCTGTATACT	GATGCCAAAC	CCAAGAGCTG
	CTAAACCCGT	TTCGGTGTA	GGACCTCTTC	AGACATATGA	CTACGGTTTG	GGTTCTCGAC
181	AGCTGCTGAT	GAGGCCCAGG	GAGTAGCCCA	CGCGCCCTGA	GCTGTTGGCT	AGCAAGGCCT
	TCGACGACTA	CTCCGGGTCC	CTCATCGGGT	GCGCGGGACT	CGACAACCGA	TCGTTCCGGA
241	TCCTGCTCCA	TGTGGCATGG	AAAAATTATA	TGGTTTGACG	GATGAAAAGG	TGAAGGCCTA
	AGGACGAGGT	ACACCGTACC	TTTTTAATAT	ACCAAAGTGC	CTACTTTTCC	ACTTCCGGAT
301	TCTTTCTCTC	CATCCCCAGG	TATTAGATGA	ATTTGTTTCT	GAAAGTGTTA	GTGCAGAGAC
	AGAAAGAGAG	GTAGGGGTCC	ATAATCTACT	TAAACAAAGA	CTTTCACAAT	CACGTCTCTG
361	TGTGGAAAAG	TGGCTGAAGA	GGAAAAACAA	CAAAGCAAAA	GATGAACCAT	CTCCAAGGA
	ACACCTTTTC	ACCGACTTCT	CCTTTTGGTT	GTTTCGTTTT	CTACTTGGTA	GAGGGTTTCT
421	AGTCAGCAGG	TACCAGGATA	CGAATATGCA	GGGAGTCGTG	TACGAGCTGA	ACAGCTACAT
	TCAGTCGTCC	ATGGTCCTAT	GCTTATACGT	CCCTCAGCAC	ATGCTCGACT	TGTCGATGTA
481	AGAGCAGCGC	CTGGACACGG	GCGGGGACAA	CCACCTGCTC	CTCTATGAGC	TCAGCAGCAT
	TCTCGTCGCG	GACCTGTGCC	CGCCCTGTT	GGTGGACGAG	GAGATACTCG	AGTCGTCGTA
541	CATCAGGATA	GCCACAAAAG	CCGACGGATT	TGCACTGTAC	TTCCTTGGAG	AGTGAATAA
	GTAGTCCTAT	CGGTGTTTTT	GGCTGCCTAA	ACGTGACATG	AAGGAACCTC	TCACGTTATT
601	TAGCCTGTGT	GTGTTTCATC	CACCCGGGAT	GAAGGAAGGC	CAACCCCGGC	TCATCCCTGC
	ATCGGACACA	CACAAGTATG	GTGGGCCCTA	CTTCCTTCCG	GTTGGGGCCG	AGTAGGGACG
661	AGGGCCCATC	ACCCAGGGTA	CCACCATCTC	TGCCTACGTG	GCCAAGTCTA	GGAAGACGTT
	TCCCGGGTAG	TGGGTCCCAT	GGTGGTAGAG	ACGGATGCAC	CGGTTTCAGAT	CCTTCTGCAA
		EcoRV		XhoI		
721	GTTGGTAGAG	GATATCCTTG	GGGATGAGCG	ATTTCTCTGA	GGTACTGGCC	TGGAATCAGG
	CAACCATCTC	CTATAGGAAC	CCCTACTCGC	TAAAGGAGCT	CCATGACCGG	ACCTTAGTCC
781	AAACCCGCATC	CAGTCTGTTC	TTTGCTTGCC	CATTGTCACT	GCCATTGGAG	ACTTGATTGG
	TTGGGCGTAG	GTCAGACAAG	AAACGAACGG	GTAACAGTGA	CGGTAACCTC	TGAAC TAACC
841	CATCCTTGAA	CTGTACAGGC	ACTGGGGCAA	AGAGGCCTTC	TGCCTCAGCC	ATCAGGAGGT
	GTAGGAACCTT	GACATGTCCG	TGACCCCGTT	TCTCCGGAAG	ACGGAGTCGG	TAGTCTCCCA
901	TGCAACAGCC	AATCTTGCTT	GGGCTTCCGT	AGCAATACAC	CAGGTGCAGG	TGTGTAGAGG
	ACGTTGTCCG	TTAGAACGAA	CCCGAAGGCA	TCGTTATGTG	GTCCACGTCC	ACACATCTCC
961	TCTCGCCAAA	CAGACCGAAC	TGAATGACTT	CCTACTCGAC	GTATCAAAGA	CATACTTTGA
	AGAGCGGTTT	GTCTGGCTTG	ACTTACTGAA	GGATGAGCTG	CATAGTTTCT	GTATGAAACT
1021	TAACATAGTT	GCCATAGACT	CTCTACTTGA	ACACATCATG	ATATATGCAA	AAAATCTAGT
	ATTGTATCAA	CGGTATCTGA	GAGATGAACT	TGTGTAGTAC	TATATACGTT	TTTTAGATCA
1081	GAACGCCGAC	CGCTGCGCGC	TCTTCCAGGT	GGACCACAAG	AACAAGGAGC	TGTA CTGGA
	CTTGCGGCTG	GCGACGCGCG	AGAAGGTCCA	CCTGGTGTTT	TTGTTTCTCG	ACATGAGCCT
1141	CCTGTTTGAC	ATTGGGGAGG	AGAAGGAGGG	GAAGCCCATC	TTCAAGAAGA	CCAAGGAGAT
	GGACAAACTG	TAACCCCTCC	TCTTCTCTCC	CTTCGGGTAG	AAGTTCTTCT	GGTTCTCTTA
1201	CAGATTTTCC	ATTGAGAAAG	GGATTGCTGG	TCAAGTGGCA	AGAACAGGCG	AAGTCTTGAA
	GTCTAAAAGG	TAACCTTTTC	CCTAACGACC	AGTTCACCGT	TCTTGTCCGC	TTCAGAACTT
1261	CATTCCCAGT	GCCTACGCGG	ACCCTCGCTT	TAACAGGGAG	GTGGACCTGT	ACACAGGCTA
	GTAAGGGCTA	CGGATGCGCC	TGGGAGCGAA	ATTGTCCCTC	CACCTGGACA	TGTGTCCGAT
1321	CACCACGAGG	AACATTCTGT	GTATGCCCAT	AGTGAGCCGA	GGCAGCGTGA	TTGGCGTGGT
	GTGGTGCTCC	TTGTAAGACA	CATACGGGTA	TCACTCGGCT	CCGTCGCACT	AACCGCACCA

Figure 15 (con't)

PDE10a and RACEs compiled

1381	GCAGATGGTG	AACAAGATCA	GCGGTAGCGC	CTTCTCCAAG	ACAGACGAGA	ACAACTTCAA
	CGTCTACAC	TTGTTCTAGT	CGCCATCGCG	GAAGAGGTTC	TGTCTGCTCT	TGTTGAAGTT
						BamHI
1441	GATGTTTGCT	GTCTTCTGCG	CACTGGCCTT	GCACTGTGCT	AACATGTACC	ACAGGATCCG
	CTACAAACGA	CAGAAGACGC	GTGACCGGAA	CGTGACACGA	TTGTACATGG	TGTCCTAGGC
				HindIII		
1501	CCACTCAGAA	TGCATCTACA	GGGTTACCAT	GGAGAAGCTT	TCCTACCACA	GCATCTGCAC
	GGTGAGTCTT	ACGTAGATGT	CCCAATGGTA	CCTCTTCGAA	AGGATGGTGT	CGTAGACGTG
1561	CTCCGAGGAG	TGGCAAGGCC	TCATGCGCTT	CAACCTACCA	GCACGCATCT	GCCGGGACAT
	GAGGCTCCTC	ACCGTTCCGG	AGTACGCGAA	GTTGGATGGT	CGTGCGTAGA	CGGCCCTGTA
1621	CGAGCTATTC	CACTTTGACA	TTGGTCCTTT	CGAGAACATG	TGGCCTGGGA	TCTTTGTCTA
	GCTCGATAAG	GTGAAACTGT	AACCAGGAAA	GCTCTTGTAC	ACCGGACCCT	AGAAACAGAT
1681	CATGATCCAT	CGGTCTTG TG	GGACATCCTG	TTTTGAAC TT	GAAAAATTGT	GCCGTTTTAT
	GTACTAGGTA	GCCAGAACAC	CCTGTAGGAC	AAAAC TTGAA	CTTTTTAACA	CGGCAAAATA
1741	CATGTCTGTG	AAGAAGAACT	ATCGGCGGGT	TCCTTACCAC	AACTGGAAGC	ATGCAGTCAC
	GTACAGACAC	TTCTTCTTGA	TAGCCGCCCA	AGGAATGGTG	TTGACCTTCG	TACGTCAGTG
						XhoI
1801	GGTGGCACAC	TGCATGTATG	CCATACTTCA	AAACAACAAT	GGCCTCTTCA	CAGACCTCGA
	CCACCGTGTG	ACGTACATAC	GGTATGAAGT	TTTGTTGTTA	CCGGAGAAGT	GTCTGGAGCT
	XhoI					
1861	GCGCAAAGGC	CTGCTAATTG	CGTGTCTGTG	CCATGACCTG	GACCACAGGG	GCTTCAGTAA
	CGCGTTTTCG	GACGATTAAC	GCACAGACAC	GGTACTGGAC	CTGGTGTCCC	CGAAGTCATT
1921	CAGCTACCTG	CAGAAGTTTC	ACCACCCCTT	GGCGGCGCTG	TACTCCACCT	CCACCATGGA
	GTCGATGGAC	GTCTTCAAGC	TGGTGGGGGA	CCGCCGCGAC	ATGAGGTGGA	GGTGGTACCT
1981	GCAACACCAC	TTCTCCCAGA	CGGTGTCCAT	CCTTCAGCTG	GAAGGGCACA	ATATCTTCTC
	CGTTGTGGTG	AAGAGGGTCT	GCCACAGGTA	GGAAGTCGAC	CTTCCCGTGT	TATAGAAGAG
2041	CACCCTGAGC	TCCAGCGAGT	ACGAGCAGGT	GCTGGAGATC	ATCCGCAAAG	CCATCATCGC
	GTGGGACTCG	AGGTCGCTCA	TGCTCGTCCA	CGACCTCTAG	TAGGCGTTTC	GGTAGTAGCG
2101	CACCGACCTC	GCCCTATACT	TTGGGAACAG	GAAGCAGTTG	GAGGAGATGT	ACCAGACAGG
	GTGGCTGGAG	CGGGATATGA	AACCTTTGTC	CTTCGTCAAC	CTCCTCTACA	TGGTCTGTCC
2161	GTCGCTGAAC	CTCCACAACC	AGTCCCATCG	AGACCGTGTC	ATCGGCTTGA	TGATGACTGC
	CAGCGACTTG	GAGGTGTTGG	TCAGGGTAGC	TCTGGCACAG	TAGCCGAAC T	ACTACTGACG
2221	CTGTGATCTT	TGCTCTGTGA	CCAACTATG	GCCAGTTACA	AAATTGACAG	CGAATGATAT
	GACACTAGAA	ACGAGACACT	GGTTTGATAC	CGGTCAATGT	TTTAACTGTC	GCTTACTATA
		EcoRI				
2281	ATATGCAGAA	TTCTGGGCTG	AGGGTGATGA	GATGAAGAAG	CTGGGCATAC	AGCCCATTC
	TATACGTCTT	AAGACCCGAC	TCCCACTACT	CTACTTCTTC	GACCCGTATG	TGGGGTAAGG
2341	TATGATGGAC	AGAGACAAGC	GAGATGAAGT	CCCTCAAGGG	CAGCTCGGAT	TCTACAATGC
	ATACTACCTG	TCTCTGTTTC	CTCTACTTCA	GGGAGTTCCC	GTCGAGCCTA	AGATGTTACG
2401	TGTGGCCATT	CCCTGCTATA	CCACCTTGAC	GCAGATCCTC	CCACCCACAG	AGCCTCTGCT
	ACACCGGTAA	GGGACGATAT	GGTGGAACTG	CGTCTAGGAG	GGTGGGTGTC	TGGGAGACGA
2461	GAAGGCCTGC	AGGGATAACC	TCAATCAGTG	GGAGAAGGTA	ATTGCGGGGG	AAGAGACAGC
	CTTCCGGACG	TCCCTATTGG	AGTTAGTCAC	CCTCTTCCAT	TAAGCGCCCC	TTCTCTGTCTG
2521	AATGTGGATT	TCAGGCCAG	GCCCGGCGCC	TAGCAAGAGC	ACACCTGAGA	AGCTGAACGT
	TTACACCTAA	AGTCCGGGTC	CGGGCCGCGG	ATCGTTCTCG	TGTGGACTCT	TGCACTTGCA
2581	GAAGGTTGAA	GACTGATCCT	GAAGTGACGT	CCTGATGTCT	GCCCAGCAAC	CGACTCAACC
	CTTCCAAC TT	CTGACTAGGA	CTTCACTGCA	GGACTACAGA	CGGGTCGTTG	GCTGAGTTGG
2641	TGCTTCTGTG	ACTTCGTTCT	TTTTGTTTTT	AAGGGGTGAA	AACCCCTGT	CAGAAGGTAC
	ACGAAGACAC	TGAAGCAAGA	AAAACAAAAG	TTCCCCACTT	TTGGGGGACA	GTCTTCCATG

Figure 15 (con't)

PDE10a and RACEs compiled

2701	CGTCGCATAT	CCATGTGAAG	CAGACGACTC	CCTGCTTGCC	GCACACACCT	CGGACAGTGA
	GCAGCGTATA	GGTACACTTC	GTCTGCTGAG	GGACGAACGG	CGTGTGTGGA	GCCTGTCACT
2761	GCAACCCAGG	CTCTGCCGTG	TTCAGACGTC	GGCTACTCCG	TGGCTCCACC	TGACCTCCGA
	CGTTGGGTCC	GAGACGGCAC	AAGTCTGCAG	CCGATGAGGC	ACCGAGGTGG	ACTGGAGGCT
2821	ATGCTATTTG	CTCCCAGGCC	AGCACTGCAC	TGTCTGGAGG	GGGCAGAGAC	CACAGGAGAG
	TACGATAAAC	GAGGGTCCGG	TCGTGACGTG	ACAGACCTCC	CCCGTCTCTG	GTGTCTCTCTC
2881	GTTCTTGCCCT	GCATCCTCCC	ATGAGGGTGT	GGCCAGTTCC	CTAGTTCTGT	GCCATGCTGC
	CAAGAACGGA	CGTAGGAGGG	TACTCCCACA	CCGGTCAAGG	GATCAAGACA	CCGTACGACG
2941	TGCTTGGTGG	CATTGGTTAG	GAATGGGACA	CACGCCCTT	GTTGTGAAGT	TTACATGTGA
	ACGAACCACC	GTAACCAATC	CTTACCCTGT	GTGCGGGGAA	CAACACTTCA	AATGTACACT
3001	CCTTCTTATA	GGTTAACTGA	GTTTGTGGCC	TGGACACATG	TAATGAAGGT	CACAGTCCAC
	GGAAGAATAT	CCAATTGACT	CAAACACCGG	ACCTGTGTAC	ATTACTTCCA	GTGTCAGGTG
3061	AGGTGACAGA	GAAATCCAAA	CTGTTGATTA	CAGGTGCACT	ACAGGTATGC	TCTTTCAGTC
	TCCACTGTCT	CTTTAGGTTT	GACAACTAAT	GTCCACGTGA	TGTCCATACG	AGAAAGTCAG
3121	TATCTGGGGG	CACATAGGTG	AGTCTGCTCC	ACTCAGAANN	AAGCATACCT	CTGCCCTCAT
	ATAGACCCCC	GTGTATCCAC	TCAGACGAGG	TGAGTCTTNN	TTCGTATGGA	GACGGGAGTA
3181	CCAGGGGACA	CAGGGTACAT	CCCAGGCATC	GGGGAAGTGA	AGCTCTCACT	TCAAACCATG
	GGTCCCTGT	GTCCCATGTA	GGGTCCGTAG	CCCCTTGACT	TCGAGAGTGA	AGTTTGGTAC
3241	TCAAAGAATT	AAAACACCTC	CCCTCCCCCT	CACTGTAGCC	TTCGACAACT	GCGCCAATCC
	AGTTTCTTAA	TTTTGTGGAG	GGGAGGGGGA	GTGACATCGG	AAGCTGTTGA	CGCGGTTAGG
3301	CTTTATACAA	AGAAAATAAA	AGTAAGGCAT	ATAAATTTCC	TCCAGCAAGC	AAATCTTGTC
	GAAATATGTT	TCTTTTATTT	TCATTCCGTA	TATTTAAAGG	AGGTCGTTCC	TTTAGAACAC
3361	GGTAAAAAAA	AAGCATGTGA	ATNNTAACAA	CNTCTANANT	NTCNCNGNAT	GTTATGGCAG
	CCATTTTTTTT	TTCGTACACT	TANNATTGTT	GNAGATNTNA	NAGNGNCNTA	CAATACCGTC
3421	AATTTTAGTC	ACGTCCAAAA	CAAAAAGATT	ATTCCAGAAG	ATACCTCATC	CTATGCCTGA
	TTAAAATCAG	TGCAGGTTTT	GTTTTTCTAA	TAAGGTCTTC	TATGGAGTAG	GATACGGACT
3481	AAGGCTCCAC	AGCATGGCGT	CCGTCTCCCA	GGGTCTTGAT	CCGTCTCCTC	ACGGTGCAAT
	TTCCGAGGTG	TCGTACCGCA	GGCAGAGGGT	CCCAAGACTA	GGCAGAGGAG	TGCCACGTTA
3541	CAGGCAGGAC	AGAGAGGAGG	GCTGCAGGGC	TACCACATTG	ACCCAGAAGG	TATCTCCTCT
	GTCCGTCTCTG	TCTCTCCTCC	CGACGTCCCG	ATGGTGTAAC	TGGGTCTTCC	ATAGAGGAGA
3601	CACCATTCAG	ACATCCATAA	GGAATGCCAA	ATGCTGTATT	GAATAGTTCT	CTGTGTGACT
	GTGGTAAGTC	TGTAGGTATT	CCTTACGGTT	TACGACATAA	CTTATCAAGA	GACACACTGA
	XbaI					
3661	TTCTAGAGAA	GCCAGGACAC	CCTGAGCCTT	TCCNNGGGAA	CTCTAAGGAG	TCACAGGTTC
	AAGATCTCTT	CGGTCCCTGTG	GGACTCGGAA	AGGNCCCCTT	GAGATTCCCTC	AGTGTCCAAG
3721	ACACCGTGGG	GATTTTCAGG	ATAGCATGGA	GACAGAGATC	CGGTGCTTGT	TCTCACTCGT
	TGTGGCACCC	CTAAAAGTCC	TATCGTACCT	CTGTCTCTAG	GCCAGCAACA	AGAGTGAGCA
3781	GAGCCTTGAG	AAGGAGAGAC	TGACCAGAAA	CACTCACTCA	GCACTCTGCA	GGAGCAGGAG
	CTCGGAAGTC	TTCTCTCTCTG	ACTGGTCTTT	GTGAGTGAGT	CGTGAGACGT	CCTCGTCCCTC
3841	AAGATACTTT	AAGATGAATC	TTGGATAGAT	TTTGATACAC	CCAATACCAT	ACACACAGGA
	TTCTATGAAA	TTCTACTTAG	AACCTATCTA	AAACTATGTG	GGTTATGGTA	TGTGTGTCTT
3901	GCTTGGCATT	TGCAAAGTCT	ATTCAAGTTT	CTTCCGCGCT	CTGACCCACG	GTTGTAGCGG
	CGAACCCTAA	ACGTTTCAGA	TAAGTCAAAG	GAAGGCGCGA	GACTGGGTGC	CAACATCGCC
3961	AGTGGGCTGA	ACACTGTAAC	ACTGTACATG	CGATTTCCCC	ATGGGCTTCT	AAAATGTCAC
	TCACCCGACT	TGTGACATTG	TGACATGTAC	GCTAAAGGGG	TACCCGAAGA	TTTTACAGTG
4021	CATCTCCTCC	CCTGCTGTGT	CCTACTCCAT	TTACTGGTTA	CAAGGTGATG	TCAACAAGAG
	GTAGAGGAGG	GGACGACACA	GGATGAGGTA	AATGACCAAT	GTTCCACTAC	AGTTGTTCTC

Figure 15 (con't)

PDE10a and RACEs compiled

4081	AAGCTATCAC	AACACCAGGG	CTGTGCACAC	GTGCACACAC	ATGTATGCAC	AAGCACACAG
	TTCGATAGTG	TTGTGGTCCC	GACACGTGTG	CACGTGTGTG	TACATACGTG	TTCGTGTGTC
4141	ATGTATGTAC	AGCACACACA	CACACACACA	CCCCAAAAGG	AGAGAAAAGG	AAGAAAACAT
	TACATACATG	TCGTGTGTGT	GTGTGTGTGT	GGGGTTTTTC	TCTCTTTTCC	TTCTTTTGTA
4201	TTATAAAAAG	CGACAGCTAC	CCCATATCAA	AATAGTCTTT	CCTGTAGGAA	ACAGGAGCTC
	AATATTTTTT	GCTGTGCGAT	GGGTATAGTT	TTATCAGAAA	GGACATCCTT	TGTCCTCGAG
4261	TCCATAAGGA	ATTATCATGA	GTGTGTTCTC	CCATCAGTGC	ACTCTCCCAG	GGGTGCTCAC
	AGGTATTCCT	TAATAGTACT	CACACAAGAG	GGTAGTCACG	TGAGAGGGTC	CCCACGAGTG
4321	TGAAGCTGGT	CCACRTCTAT	AAACAGGTGA	CACTGGCTGC	AGCAAAAAGC	CATTTCGATCC
	ACTTCGACCA	GGTGRAGATA	TTTGTCCACT	GTGACCGACG	TCGTTTTTCG	GTAAGCTAGG
4381	ACACAAATTG	ATCTTCTATC	ATCTTGGAAT	CTGAATTGCA	GGGAGGAGCA	GYATGTAAGA
	TGTGTTTAAC	TAGAAGATAG	TAGAACCTTA	GACTTAACGT	CCCTCCTCGT	CYTACATTCT
4441	CGACCGTTTA	ATTCAGGCAT	TCCGAAGGCA	TGAGCGCATG	GATTCTRICA	CCAAGCGTAT
	GCTGGCAAAT	TAAGTCCGTA	AGGCTTCCGT	ACTCGCGTAC	CTAAGARAGT	GGTTCGCATA
4501	AAAAGGACCC	TGGCATTGGG	AAACCTATGA	CGGACTGTTT	TTGCTGTAGA	AGTAGGGATT
	TTTTCTGGG	ACCGTAACCC	TTTGGTACT	GCCTGACAAA	AACGACATCT	TCATCCCTAA
4561	TTACAGAAGT	CTCCTTGRAT	TTGCCCTGCC	TGGGGCAGTT	TTGCAGAGGA	ACCTGCCAGA
	AATGTCTTCA	GAGGAACRTA	AACGGGACGG	ACCCCGTCAA	AACGTCTCCT	TGGACGGTCT
4621	GATTTATTGG	CTGGTCAGTC	TCTTGTGAAA	TAGTATCATG	TGAGAAACAG	TTTGTAGAAA
	CTAAATAACC	GACCAGTCAG	AGAACACTTT	ATCATAGTAC	ACTCTTTGTC	AAACATCTTT
4681	AAAACATATC	CTGGGAAGAC	CTTTGCAACA	TTGTTCCCTC	CATGGGCCAA	GACTCAGTTA
	TTTTGATATG	GACCCTTCTG	GAAACGTTGT	AACAAGGAAG	GTACCCGGTT	CTGAGTCAAT
4741	GGAGGCATAA	ATCTGCCCCG	AATAAACTAG	GCCAGGATAC	AGCCATGTTT	AGTTAATAAT
	CCTCCGTATT	TAGACGGGCC	TTATTTGATC	CGGTCCATG	TCGGTACAAA	TCAATTATTA
		EcoRI				
4801	TTGGTTTTAG	AATTCACACA	GGCAGGATTG	GTTTTTTTGT	GTCTTGCCAA	GTGGAGCATA
	AACCAAAATC	TTAAGTGTGT	CCGTCCCTAAC	CAAAAAACA	CAGAACCGTT	CACCTCGTAT
4861	TTTAACATAC	AGGCATGGGA	ATCCTGCCTC	TTAGCTTTTC	CCACCCTCTT	GTCTACCCAA
	AAATTGTATG	TCCGTACCCT	TAGGACGGAG	AATCGAAAAG	GGTGGGAGAA	CAGAGTGGTT
4921	GTTTTTTCTC	TCCAAAGGTT	TCCAGGAATT	TCTCATTAAT	GGCTGATGCA	AACTTAGTGA
	CAAAAAAGAG	AGGTTTCCAA	AGGTCCTTAA	AGAGTAATTA	CCGACTACGT	TTGAATCACT
4981	ATAATAATGA	ATATAAACAA	TGCTCACCTC	ACCAAAATTA	TATTATTTGC	AGTCATTTGT
	TATTATTACT	TATATTTGTT	ACGAGTGGAG	TGGTTTTAAT	ATAATAAACG	TCAGTAAACA
5041	GATAACACAA	ATTTTATCGC	AATGGTTATT	ATTTAATTTG	TGGCCACACA	CTGTGGTTAT
	CTATTGTGTT	TAAAATAGCG	TTACCAATAA	TAAATTAAAC	ACCGGTGTGT	GACACCAATA
5101	CTTTTGTTGT	GGTTGTTTCT	GAGAAAATGT	TCTTGATAT	GTAAGTGCCA	ATACCAGTGT
	GAAAACAACA	CCAACAAGA	CTCTTTTACA	AGAACCTATA	CATTACGGT	TATGGTCACA
5161	GAAGTATTGA	TCCCGGGCAG	CAAAATACAG	CCTAAGGTTT	GTAAACATCA	ATTCTATCTC
	CTTCATAACT	AGGGCCCGTC	GTTTTATGTC	GGATTCCAAA	CATTTGTAGT	TAAGATAGAG
5221	AGTTCATCAG	AGGGCCTGAG	AAGCTGCGGG	GCAGTGTAAG	GTAAAGTATG	CTGGGCTGGT
	TCAAGTAGTC	TCCCGGACTC	TTGACGCCC	CGTCACATTT	CATTTTCATC	GACCCGACCA
5281	GGTGGTCAGC	CTCCCTTTCG	CAAGAAGAGA	GCAATTGAAT	CCTGTCCCCA	GCTCCCTCCA
	CCACCAGTCG	GAGGGGAACG	GTTCTTCTCT	CGTTAACTTA	GGACAGGGGT	CGAGGGAGGT
5341	CGCCTGAAGA	GTGACCACTG	CTGGCCCGAC	GGATCGCTGA	GATATTCTCC	CATAATGGCA
	GCGGACTTCT	CACCTGGTCAC	GACCGGGCTG	CCTAGCGACT	CTATAAGAGG	GTATTACCGT
5401	AAAAAATAGG	CAGTTTGATG	TGACCTGTTT	AGTGTGGCTC	TCCTCTTTTG	AGCATGTGTT
	TTTTTTATCC	GTCAAACCTAC	ACTGGACAAA	TCACACCGAG	AGGAGAAAAC	TCGTACACAA

Figure 15 (con't)

PDE10a and RACEs compiled

5461	AGCATTTTTA	TTTTATACTC	ATCCAGTGAA	CTCTGCTCTT	CCAAGTGTGT	TCATGTATGT
	TCGTAAAAAT	AAAATATGAG	TAGGTCACCT	GAGACGAGAA	GGTTCACACA	AGTACATACA
5521	GCTAGATATA	TTAGCACAGC	CTGCCTTCTG	CTGCACAACG	CCTTAGAGAC	CCGGCCTTTC
	CGATCTATAT	AATCGTGTCG	GACGGAAGAC	GACGTGTTGC	GGAATCTCTG	GGCCGGAAG
5581	AATGAGCTTA	GCTTGTGCTC	TGTTTCTGCT	CTCTTAGGTC	TAAACTATGG	TGTCAGTTTT
	TTACTCGAAT	CGAACACGAG	ACAAAGACGA	GAGAATCCAG	ATTTGATACC	ACAGTCAAAA
5641	AATAGAACAA	AAGTATGCAT	CTTGCCTTGG	CTTGAGCCTT	TTCGTTTTCA	ATGCTGACTT
	TTATCTTGTT	TTCATACGTA	GAACGGAACC	GAAGTCGGAA	AAGCAAAAGT	TACGACTGAA
5701	CTCCCTTTTC	TCTCCTGTGC	TCACCTTACC	TTTCCAGAGT	GTAAGGGACA	ACTTTTAAGG
	GAGGGGAAAG	AGAGGACACG	AGTGGGAATGG	AAAGGTCTCA	CATTCCCTGT	TGAAAATTCC
5761	AGGCGTGTCC	CTGGTAGGGG	CATCCCTGTT	CACCAGGTGC	CTGTCATCAC	CCCACTTGAC
	TCCGCACAGG	GACCATCCCC	GTAGGGACAA	GTGGTCCACG	GACAGTAGTG	GGGTGAAGTG
5821	TGACATCTAC	CCTGGTGACT	ATGGGTTTCT	CTTGTTTGTA	GGGAACGGTG	GCTCCAGGTG
	ACTGTAGATG	GGACCACTGA	TACCCAAGGA	GAACAAACAT	CCCTTGCCAC	CGAGGTCCAC
5881	GAGGCATCAA	TCTGTTGGGT	TCTGGTTCCC	GGCTGCCTTT	GGTTTTGAAA	GTCTCTTCTC
	CTCCGTAGTT	AGACAACCCA	AGACCAAGGG	CCGACGGAAA	CCAAAACTTT	CAGAGAAGAG
5941	TGTATATTCC	TACCCTGCAT	TTGCTTTGTG	TGGTGCTGAT	GCTGTGGCAG	TAGGATCTTG
	ACATATAAGG	ATGGGACGTA	AACGAAACAC	ACCACGACTA	CGACACCGTC	ATCCTAGAAC
6001	GATGACTCTC	CATCAGTCAC	AGACTCCCCC	TGTTGCAAAG	TGTCAGGCTG	ACTCGACAGT
	CTACTGAGAG	GTAGTCAGTG	TCTGAGGGGG	ACAACGTTTC	ACAGTCCGAC	TGAGCTGTCA
6061	CACCGTAAAA	TCTGAGTCAG	TCACACACAG	GCTGTACGCC	ACGGCTTCCA	CTTGCATGGC
	GTGGCATTTC	AGACTCAGTC	AGTGTGTGTC	CGACAGTCGG	TGCCGAAGGT	GAACGTACCG
6121	TATTCTATTT	TCACACGTGA	GTTTCTGTTG	CTGGCTGGCT	GACTGGCATT	ATCTATGCTA
	ATAAGATAAA	AGTGTGCACT	CAAAGACAAC	GACCGACCGA	CTGACCGTAA	TAGATACGAT
6181	AGTTGAAATC	AGGAGTGTGC	CCAGCAGAGC	CCATCATTCT	CACTGTCTTT	GAAACAAAGC
	TCAACTTTAG	TCCTCACACG	GGTCGTCTCG	GGTAGTAAGA	GTGACAGAAA	CTTTGTTTCG
6241	TGTACGGTTT	GATCGATGAA	CGTATTTAAA	GCATTTTCATG	CAATGACAAA	GTGCTCAGTA
	ACATGCCAAA	CTAGCTACTT	GCATAAATTT	CGTAAAGTAC	GTTACTGTTT	CACGAGTCAT
6301	GTGGAAGGCA	GGCTGTGACC	AGTCTGCCTG	CTCCTTACTA	TAATTGTGAG	GATTTGTTAC
	CACCTTCCGT	CCGACACTGG	TCAGACGGAC	GAGGAATGAT	ATTAACACTC	CTAAACAATG
6361	TGGAACAGTA	CATGGAGGCC	TGACCTTGTG	GGGGCACAGG	GTGGAACCTT	AGCTGAATAT
	ACCTTGTCAT	GTACCTCCGG	ACTGGAACAC	CCCCGTGTCC	CACCTTGGA	TCGACTTATA
6421	AGTGTGTGTC	TCAAGAGGAA	GTCAGGGTAC	TAGCTCAGTG	CTCAATCTCC	AGGTACTATA
	TCACACACAG	AGTTCTCCTT	CAGTCCCATG	ATCGAGTCAC	GAGTTAGAGG	TCCATGATAT
6481	TATACATTTG	CCCGTTTTAT	CTCTAATGTG	AAATAAATCC	CCAAACACTT	GTTTATCGTG
	ATATGTAAAC	GGGCAAAATA	GAGATTACAC	TTTATTTAGG	GGTTTGTGAA	CAAATAGCAC
6541	TAGCGTACCT	AAAAGACTAT	TCTATTATGG	GTGTCCCCAC	TTTCTTGGTT	TGGTCACCCC
	ATCGCATGGA	TTTTCTGATA	AGATAATACC	CACAGGGGTG	AAAGAACCAA	ACCAGTGGGG
			XbaI			
6601	GATCCCCCGG	TCTTCTGCTG	TATCTAGAAC	AGTGACTATA	AATGATGTAT	GGGAATAGTG
	CTAGGGGGCC	AGAAGACGAC	ATAGATCTTG	TAAGTATGAT	TTACTACATA	CCCTTATCAC
6661	TTTCCATATG	ATCTGTTGTC	TGGAGTATAT	GCTACATGTT	CATTTACTGT	ACAAAAACCC
	AAAGGTATAC	TAGACAACAG	ACCTCATATA	CGATGTACAA	GTAAATGACA	TGTTTTTGGG
6721	AGTGCAGCTG	ATGATGCAAA	GCAGTCTCTC	TCTGTGTACA	GTGCCCCACC	TATTTAAAAA
	TCACGTCGAC	TACTACGTTT	CGTCAGAGAG	AGACACATGT	CACGGGGTGG	ATAAATTTTT
6781	TCACGTACAA	NCCCAGAACA	CTGTGAAACA	CTTAACATAA	GAAACAAACG	CAGCGTCTGG
	AGTGCATGTT	NGGGTCTTGT	GACACTTTGT	GAATTGTATT	CTTTGTTTGC	GTGCGAGACC

Figure 15 (con't)

PDE10a and RACEs compiled

6841	ATTCTTTCCA	AGGAGAGCAG	CTTTCTCCAC	AGGAACACAG	TAACAAAAGA	GGTCCGCCGC
	TAAGAAAGGT	TCCTCTCGTC	GAAAGAGGTG	TCCTTGTTGTC	ATTGTTTTCT	CCAGGCGGCG
6901	CATCCACACC	CAGCCAAGAC	ACCTCAGAGG	CCATAGGGAC	AACCTCCTTG	CTGGCCAACA
	GTAGGTGTGG	GTCGGTCTG	TGGAGTCTCC	GGTATCCCTG	TTGGAGGAAC	GACCGTTGT
6961	CCTGCTGGAG	CAGGGCACAG	GTCCAGCAA	CTGATCCTCA	GTGGATGGGT	CCGAGTCAA
	GGACGACCTC	GTCCCGTGTC	CAGGGTCGTT	GACTAGGAGT	CACCTACCCA	GGCGTCAGTT
					HindIII	EcoRV
7021	AGCCTTAATG	GGCTCTCTTT	TGAAGGGGAA	AGAAANNNTT	CAAGCTTATG	ATATCCAACA
	TCGGAATTAC	CCGAGAGAAA	ACTTCCCCTT	TCCTTNNAAA	GTTCTGAATAC	TATAGGTTGT
7081	TTATTATAGT	TGATGAGTTA	GTAAATTCCG	AAAAAAAAAG	ATGATTTTAT	ATGTATGACA
	AATAATATCA	ACTACTCAAT	CATTTAAGGC	TTTTTTTTTC	TACTAAAATA	TACATACTGT
7141	TAAAAAAAT	CTTTGTAAAG	TGCGCAAGTG	CAATAATTTA	AAGAGGTCTT	ATCTTTGCAT
	ATTTTTTTTA	GAAACATTTT	ACGCGTTCAC	GTTATTAAAT	TTCTCCAGAA	TAGAAACGTA
7201	TTATAAATTA	TAAATATTGT	ACATGTGTGT	AATTTTTCAT	GTATTCATTT	GCAGTCTTTG
	AATATTTAAT	ATTTATAACA	TGTACACACA	TTAAAAAGTA	CATAAGTAAA	CGTCAGAAAC
7261	TATTTAAAAA	AACTTTACTG	TTATGTTTGT	ATAATAGAAC	ATTAATCATT	TATTATAACT
	ATAAATTTTT	TTGAAATGAC	AATACAAACA	TATTATCTTG	TAATTAGTAA	ATAATATTGA
7321	CAGACAAGGT	GTAAATAAAT	TCATAATTCA	AACAGCCAGT	ATATATGCAT	ATATGGGTGT
	GTCTGTTCCA	CATTTATTTA	AGTATTAAAT	TTGTCGGTCA	TATATACGTA	TATACCCACA
7381	TACATTGCAA	AAATCTCTAT	CTTTGTTCTA	TTCACATGCT	TAAAGAAGTA	AGAAATCTTT
	ATGTAACGTT	TTTAGAGATA	GAAACAAGAT	AAGTGTACGA	ATTTCTTCAT	TCTTTAGAAA
7441	TGTGGATATG	TAATTATACA	TATAAAGTAT	ATATATATGT	ATGATACATG	AAATATATTT
	ACACCTATAC	ATTAATATGT	ATATTTTATA	TATATATACA	TACTATGTAC	TTTATATAAA
7501	AGAAATGTTT	ATAATTTTAA	TGGATATTCT	TTGGTGTGAA	TAATTGAATA	CAACATTTTT
	TCTTTACAAG	TATTAAAATT	ACCTATAAGA	AACCACACTT	ATTAACCTAT	GTTGTAAAAA
7561	AAAATGAAAA	AAAAAAAAAA	C			
	TTTTACTTTT	TTTTTTTTTT	G			

Figure 16





Figure 17

PDE10A compiled - coding sequence and features




PDE10A compiled

7618 bp

Figure 18

PDE10A compiled - restriction sites



PDE10A compiled

7618 bp

Figure 19

PDE10A compiled

1	CGCCCGGGCA	GGTCTGTTGG	AGGGCAGTTG	GTCAACCTGA	CCAGAGAGAG	CTGAGCTGGA
	GCGGGCCCGT	CCAGACAACC	TCCCGTCAAC	CAGTTGGACT	GGTCTCTCTC	GA CTGACCT
61	AGACCCCACT	GATGGTGTGC	TGCCTTTCAG	TCCAGGAAGA	AAGAAAGGAA	GGATTCTGAG
	TCTGGGGTGA	CTACCACACG	ACGGAAAGTC	AGGTCCCTTCT	TTCTTTCCTT	CCTAAGACTC
121	GATTTGGGCA	AAGCCACATT	CCTGGAGAAG	TCTGTATACT	GATGCCAAAC	CCAAGAGCTG
	CTAAACCCGT	TTCGGTGTA	GGACCTCTTC	AGACATATGA	CTACGGTTTG	GGTTCTCGAC
181	AGCTGCTGAT	GAGGCCCAGG	GAGTAGCCCA	CGCGCCCTGA	GCTGTTGGCT	AGCAAGGCCT
	TCGACGACTA	CTCCGGGTCC	CTCATCGGGT	GCGCGGGACT	CGACAACCGA	TCGTTCCGGA
241	TCCTGCTCCA	TGTGGCATGG	AAAAATTATA	TGGTTTGACG	GATGAAAAGG	TGAAGGCCTA
	AGGACGAGGT	ACACCGTACC	TTTTTAATAT	ACCAAACCTGC	CTACTTTTCC	ACTTCCGGAT
301	TCTTCTCTCT	CATCCCCAGG	TATTAGATGA	ATTTGTTTCT	GAAAGTGTTA	GTGCAGAGAC
	AGAAAGAGAG	GTAGGGGTCC	ATAATCTACT	TAAACAAAGA	CTTTCACAAT	CACGTCTCTG
361	TGTGGAAAAG	TGGCTGAAGA	GGAAAACCAA	CAAAGCAAAA	GATGAACCAT	CTCCCAAGGA
	ACACCTTTTC	ACCGACTTCT	CCTTTTGGTT	GTTTCGTTTT	CTACTTGGTA	GAGGGTTTCT
421	AGTCAGCAGG	TACCAGGATA	CGAATATGCA	GGGAGTCGTG	TACGAGCTGA	ACAGCTACAT
	TCAGTCGTCC	ATGGTCCTAT	GCTTATACGT	CCCTCAGCAC	ATGCTCGACT	TGTCGATGTA
481	AGAGCAGCGC	CTGGACACGG	GCGGGGACAA	CCACCTGCTC	CTCTATGAGC	TCAGCAGCAT
	TCTCGTCGCG	GACCTGTGCC	CGCCCCTGTT	GGTGGACGAG	GAGATACTCG	AGTCGTCGTA
541	CATCAGGATA	GCCACAAAAG	CCGACGGATT	TGCACTGTAC	TTCTTGGAG	AGTGCAATAA
	GTAGTCCTAT	CGGTGTTTTT	GGCTGCCTAA	ACGTGACATG	AAGGAACCTC	TCACGTTATT
601	TAGCCTGTGT	GTGTTTCATC	CACCCGGGAT	GAAGGAAGGC	CAACCCCGGC	TCATCCCTGC
	ATCGGACACA	CACAAGTATG	GTGGGCCCTA	CTTCCTTCCG	GTTGGGGCCG	AGTAGGGACG
661	AGGGCCCATC	ACCCAGGGTA	CCACCATCTC	TGCCTACGTG	GCCAAGTCTA	GGAAGACGTT
	TCCCGGGTAG	TGGGTCCCAT	GGTGGTAGAG	ACGGATGCAC	CGGTTCAGAT	CCTTCTGCAA
721	GTTGGTAGAG	GATATCCTTG	GGGATGAGCG	ATTTCTCTGA	GGTACTGGCC	TGGAATCAGG
	CAACCATCTC	CTATAGGAAC	CCCTACTCGC	TAAAGGAGCT	CCATGACCGG	ACCTTAGTCC
781	AACCCGCATC	CAGTCTGTTC	TTTGCTTGCC	CATTGTCACT	GCCATTGGAG	ACTTGATTGG
	TTGGGCGTAG	GTCAGACAAG	AAACGAACGG	GTAACAGTGA	CGGTAACCTC	TGAACTAACC
841	CATCCTTGAA	CTGTACAGGC	ACTGGGGCAA	AGAGGCCTTC	TGCCTCAGCC	ATCAGGAGGT
	GTAGGAACTT	GACATGTCCG	TGACCCCGTT	TCTCCGGAAG	ACGGAGTCGG	TAGTCTCCA
901	TGCAACAGCC	AATCTTGCTT	GGGCTTCCGT	AGCAATACAC	CAGGTGCAGG	TGTGTAGAGG
	ACGTTGTCCG	TTAGAACGAA	CCCGAAGGCA	TCGTTATGTG	GTCCACGTCC	ACACATCTCC
961	TCTCGCCAAA	CAGACCGAAC	TGAATGACTT	CCTACTCGAC	GTATCAAAGA	CATACTTTGA
	AGAGCGGTTT	GTCTGGCTTG	ACTTACTGAA	GGATGAGCTG	CATAGTTTCT	GTATGAAACT
1021	TAACATAGTT	GCCATAGACT	CTCTACTTGA	ACACATCATG	ATATATGCAA	AAAATCTAGT
	ATTGTATCAA	CGGTATCTGA	GAGATGAACT	TGTGTAGTAC	TATATACGTT	TTTTAGATCA
1081	GAACGCCGAC	CGCTGCGCGC	TCTTCCAGGT	GGACCACAAG	AACAAGGAGC	TGTACTCGGA
	CTTGCGGCTG	GCGACGCGCG	AGAAGGTCCA	CCTGGTGTTT	TTGTTCTCTG	ACATGAGCCT
1141	CCTGTTTGAC	ATTGGGGAGG	AGAAGGAGGG	GAAGCCCATC	TTCAAGAAGA	CCAAGGAGAT
	GGACAAACTG	TAACCCCTCC	TCTTCCTCCC	CTTCGGGTAG	AAGTTCTTCT	GGTTCTCTA
1201	CAGATTTTCC	ATTGAGAAAAG	GGATTGCTGG	TCAAGTGGCA	AGAACAGGCG	AAGTCTTGAA
	GTCTAAAAGG	TAACCTTTTC	CCTAACGACC	AGTTCACCGT	TCTTGTCGCG	TTCAGAACTT
1261	CATTCCCGAT	GCCTACGCGG	ACCCTCGCTT	TAACAGGGAG	GTGGACCTGT	ACACAGGCTA
	GTAAGGGCTA	CGGATGCGCC	TGGGAGCGAA	ATTGTCCCTC	CACCTGGACA	TGTGTCCGAT
1321	CACCACGAGG	AACATTCTGT	GTATGCCCAT	AGTGAGCCGA	GGCAGCGTGA	TTGGCGTGGT
	GTGGTGCTCC	TTGTAAGACA	CATACGGGTA	TCACTCGGCT	CCGTGCGACT	AACCGCACCA

Figure 19 (con't)

PDE10A compiled

1381	GCAGATGGTG	AACAAGATCA	GCGGTAGCGC	CTTCTCCAAG	ACAGACGAGA	ACAACTTCAA
	CGTCTACCAC	TTGTTCTAGT	CGCCATCGCG	GAAGAGGTTT	TGTCTGCTCT	TGTTGAAGTT
1441	GATGTTTGCT	GTCTTCTGCG	CACTGGCCTT	GCACTGTGCT	AACATGTACC	ACAGGATCCG
	CTACAAACGA	CAGAAGACGC	GTGACCGGAA	CGTGACACGA	TTGTACATGG	TGTCCTAGGC
1501	CCACTCAGAA	TGCATCTACA	GGGTTACCAT	GGAGAAGCTT	TCCTACCACA	GCATCTGCAC
	GGTGAGTCTT	ACGTAGATGT	CCCAATGGTA	CCTCTTCGAA	AGGATGGTGT	CGTAGACGTG
1561	CTCCGAGGAG	TGGCAAGGCC	TCATGCGCTT	CAACCTACCA	GCACGCATCT	GCCGGGACAT
	GAGGCTCCCT	ACCGTTCGCG	AGTACGCGAA	GTTGGATGGT	CGTGCGTAGA	CGGCCCTGTA
1621	CGAGCTATTC	CACTTTGACA	TTGGTCTTTT	CGAGAACATG	TGGCCTGGGA	TCTTTGTCTA
	GCTCGATAAG	GTGAAACTGT	AACCAGGAAA	GCTCTTGTA	ACCGGACCCT	AGAAACAGAT
1681	CATGATCCAT	CGGTCTTGTT	GGACATCCTG	TTTTGAACTT	GAAAAATTGT	GCCGTTTAT
	GTACTAGGTA	GCCAGAACAC	CCTGTAGGAC	AAAACCTGAA	CTTTTTAACA	CGGCAAAATA
1741	CATGTCTGTG	AAGAAGAACT	ATCGGCGGGT	TCCTTACCAC	AACTGGAAGC	ATGCAGTCAC
	GTACAGACAC	TTCTTCTTGA	TAGCCGCCCA	AGGAATGGTG	TTGACCTTCG	TACGTCAGTG
1801	GGTGGCACAC	TGCATGTATG	CCATACTTCA	AAACAACAAT	GGCCTCTTCA	CAGACCTCGA
	CCACCGTGTG	ACGTACATAC	GGTATGAAGT	TTTGTGTGTA	CCGGAGAAGT	GTCTGGAGCT
1861	GCGCAAAGGC	CTGCTAATTG	CGTGTCTGTG	CCATGACCTG	GACCACAGGG	GCTTCAGTAA
	CGCGTTTCCG	GACGATTAAC	GCACAGACAC	GGTACTGGAC	CTGGTGTCCC	CGAAGTCATT
1921	CAGCTACCTG	CAGAAGTTTG	ACCACCCCTT	GGCGGCGCTG	TACTCCACCT	CCACCATGGA
	GTCGATGGAC	GTCTTCAAGC	TGGTGGGGGA	CCGCCGCGAC	ATGAGGTGGA	GGTGGTACCT
1981	GCAACACCAC	TTCTCCCAGA	CGGTGTCCAT	CCTTCAGCTG	GAAGGGCACA	ATATCTTCTC
	CGTTGTGGTG	AAGAGGGTCT	GCCACAGGTA	GGAAGTCGAC	CTTCCCCTGT	TATAGAAGAG
2041	CACCTGAGC	TCCAGCGAGT	ACGAGCAGGT	GCTGGAGATC	ATCCGCAAAG	CCATCATCGC
	GTGGGACTCG	AGGTCGCTCA	TGCTCGTCCA	CGACCTCTAG	TAGGCGTTTC	GGTAGTAGCG
2101	CACCGACCTC	GCCCTATACT	TTGGGAACAG	GAAGCAGTTG	GAGGAGATGT	ACCAGACAGG
	GTGGCTGGAG	CGGGATATGA	AACCCTTGTC	CTTCGTCAAC	CTCCTCTACA	TGGTCTGTCC
2161	GTCGCTGAAC	CTCCACAACC	AGTCCCATCG	AGACCGTGTC	ATCGGCTTGA	TGATGACTGC
	CAGCGACTTG	GAGGTGTTGG	TCAGGGTAGC	TCTGGCACAG	TAGCCGAAC	ACTACTGACG
2221	CTGTGATCTT	TGCTCTGTGA	CCAAACTATG	GCCAGTTACA	AAATTGACAG	CGAATGATAT
	GACACTAGAA	ACGAGACACT	GGTTTGATAC	CGGTCAATGT	TTTAACTGTC	GCTTACTATA
2281	ATATGCAGAA	TTCTGGGCTG	AGGGTGATGA	GATGAAGAAG	CTGGGCATAC	AGCCCATTC
	TATACGTCTT	AAGACCCGAC	TCCCACACT	CTACTTCTTC	GACCCGTATG	TCGGGTAAGG
2341	TATGATGGAC	AGAGACAAGC	GAGATGAAGT	CCCTCAAGGG	CAGCTCGGAT	TCTACAATGC
	ATACTACCTG	TCTCTGTTCC	CTCTACTTCA	GGGAGTTCCC	GTCGAGCCTA	AGATGTTACG
2401	TGTGGCCATT	CCCTGCTATA	CCACCTTGAC	GCAGATCCTC	CCACCCACAG	AGCCTCTGCT
	ACACCGGTAA	GGGACGATAT	GGTGGAAGTG	CGTCTAGGAG	GGTGGGTGTC	TCGGAGACGA
2461	GAAGGCCTGC	AGGGATAACC	TCAATCAGTG	GGAGAAGGTA	ATTGCGGGGG	AAGAGACAGC
	CTTCCGGACG	TCCCTATTGG	AGTTAGTCAC	CCTCTTCCAT	TAAGCGCCCC	TTCTCTGTCC
2521	AATGTGGATT	TCAGGCCCG	GCCCCGCGCC	TAGCAAGAGC	ACACCTGAGA	AGCTGAACGT
	TTACACCTAA	AGTCCGGGTC	CGGGCCGCGG	ATCGTTCTCG	TGTGGACTCT	TCGACTTGCA
2581	GAAGGTTGAA	GAAGTATCCT	GAAGTGACGT	CCTGATGTCT	GCCCAGCAAC	CGACTCAACC
	CTTCCAACCT	CTGACTAGGA	CTTCACTGCA	GGACTACAGA	CGGGTCGTTG	GCTGAGTTGG
2641	TGCTTCTGTG	ACTTCGTTCT	TTTTGTTTTT	AAGGGGTGAA	AACCCCTGTT	CAGAAGGTAC
	ACGAAGACAC	TGAAGCAAGA	AAAACAAAAG	TTCCCCACTT	TTGGGGGACA	GTCTTCCATG
2701	CGTCGCATAT	CCATGTGAAG	CAGACGACTC	CCTGCTTGCC	GCACACACCT	CGGACAGTGA
	GCAGCGTATA	GGTACACTTC	GTCTGCTGAG	GGACGAACGG	CGTGTGTGGA	GCCTGTCACT

Figure 19 (con't)

PDE10A compiled

2761	GCAACCCAGG	CTCTGCCGTG	TTCAGACGTC	GGCTACTCCG	TGGCTCCACC	TGACCTCCGA
	CGTTGGGTCC	GAGACGGCAC	AAGTCTGCAG	CCGATGAGGC	ACCGAGGTGG	ACTGGAGGCT
2821	ATGCTATTTG	CTCCAGGCC	AGCACTGCAC	TGTCTGGAGG	GGGCAGAGAC	CACAGGAGAG
	TACGATAAAC	GAGGGTCCGG	TCGTGACGTG	ACAGACCTCC	CCCGTCTCTG	GTGTCTCTCTC
2881	GTTCTTGCCCT	GCATCCTCCC	ATGAGGGTGT	GGCCAGTTCC	CTAGTTCTGT	GCCATGCTGC
	CAAGAACGGA	CGTAGGAGGG	TACTCCCACA	CCGGTCAAGG	GATCAAGACA	CGGTACGACG
2941	TGCTTGGTGG	CATTGGTTAG	GAATGGGACA	CACGCCCCTT	GTTGTGAAGT	TTACATGTGA
	ACGAACCACC	GTAACCAATC	CTTACCCTGT	GTGCGGGGAA	CAACACTTCA	AATGTACACT
3001	CCTTCTTATA	GGTAACTGA	GTTTGTGGCC	TGGGACACAT	GTAATGAAGG	TCACAGTCCA
	GGAAGAATAT	CCAATTGACT	CAAACACCGG	ACCCTGTGTA	CATTACTTCC	AGTGTCAAGT
3061	CAGGTGACAG	AGAAATCCAA	ACTGTTGATT	ACAGGTGCAC	TACAGGTATG	CTCTTTCAGT
	GTCCACTGTC	TCTTTAGGTT	TGACAACTAA	TGTCCACGTG	ATGTCCATAC	GAGAAAGTCA
3121	CTATCTGGGG	GCACATAGGT	GAGTCTGCTC	CACTCAGAAG	GAAGCATACC	TCTSCCCTCA
	GATAGACCCC	CGTGTATCCA	CTCAGACGAG	GTGAGTCTTC	CTTCGTATGG	AGASGGGAGT
3181	TCCAGGGGAC	ACAGGGTACA	TCCCAGGCAT	CGGGGAACTG	AAGCTCTCAC	TTCAAACCAT
	AGGTCCCCTG	TGTCCCATGT	AGGGTCCGTA	GCCCCCTTAC	TTGAGAGTGG	AAGTTTGGTA
3241	GTCAAAGAAT	TAAAACACCT	CCCCTCCCCC	TACTGTAGC	CTTCGGCAAC	TGCGCCAATC
	CAGTTTCTTA	ATTTTGTGGA	GGGGAGGGGG	AGTGACATCG	GAAGCCGTTG	ACGCGGTTAG
3301	CCTTTATACA	AAGAAAATAT	AAGTAAGGCA	TATAAATTTT	CTCCAGCAAG	CAAATCTTGT
	GGAAATATGT	TTCTTTTATA	TTCAATCCGT	ATATTTAAAG	GAGGTCGTTT	GTTTAGAACA
3361	GGGTAAAAAA	AAAAAATGTG	AATTTTAACA	ACCTCTATAT	TTTCACTGTA	TGTTATGGCA
	CCCATTTTTT	TTTTTTACAC	TTAAAATTGT	TGGAGATATA	AAAGTGACAT	ACAATACCGT
3421	GAATTTTAGT	CACGTCCAAA	ACAAAAGATT	ATTCCAGAAG	ATACCTCATC	CTATGCCTGA
	CTTAAAATCA	GTGCAGGTTT	TGTTTTCTAA	TAAGGTCTTC	TATGGAGTAG	GATACGGACT
3481	AAGCTCCACA	GCATGGCGTC	CGTCTCCCAG	GGTTCTGATC	CGTCTCCTCA	CGGTGCAATC
	TTGAGGTTGT	CGTACCGCAG	GCAGAGGGTC	CCAAGACTAG	GCAGAGGAGT	GCCACGTTAG
3541	AGGCAGGACA	GGAGGAGGTG	CAGGGCTACC	ACATTGACCC	AGATGGTATC	TCCTCTCACC
	TCCGTCTCTG	CCTCCTCCAC	GTCCCGATGG	TGTAACGGG	TCTACCATAG	AGGAGAGTGG
3601	ATTGAGACAT	CCATAAGGAA	TGCCAAATGC	TGTATTGAAT	AGTTCTCCTG	TGTGACTTTC
	TAAGTCTGTA	GGTATTCCCT	ACGGTTTACG	ACATAACTTA	TCAAGAGGAC	ACACTGAAAG
3661	TAGAGAAGCC	AGGACACCCC	TGAGCCTTTC	CTGGGAACCT	CTAAGGAAGT	CACAGGTTCA
	ATCTCTTTCG	TCCTGTGGGG	ACTCGGAAAG	GACCCCTTGA	GATTCCTTCA	GTGTCCAAGT
3721	CACCGTGGGG	ATTTTCAGGA	TAGCATGGAG	ACCAGAGAAT	CCCGGTTTCG	TTGTTCTCAC
	GTGGCACCCC	TAAAAGTCCT	ATCGTACCTC	TGGTCTCTTA	GGGCCAAGCC	AACAAGAGTG
3781	TCGGTGAGCC	TTGAGAAGGA	AGAGACTGAC	CAGAAACACT	CACTCAGCAC	TCTGGCAGGA
	AGCCACTCGG	AACTCTTCCT	TCTCTGACTG	GTCTTTGTGA	GTGAGTCGTG	AGACCGTCCT
3841	GCAGGAGAAG	ATACTTTAAG	ATGAATCTTT	GGGATAGATT	TTGATACACC	CAATACCATA
	CGTCTCTTTC	TATGAAATTC	TACTTAGAAA	CCCTATCTAA	AACTATGTGG	GTTATGGTAT
3901	CACACAGGAG	CTTGGCATT	GCAAAGTCTA	TTCAGTTTCC	TTCCACACTC	TGACCCACGG
	GTGTGTCTCT	GAACCGTAAA	CGTTTCAGAT	AAGTCAAAGG	AAGGTGTGAG	ACTGGGTGCC
3961	TTGTAGCGGA	GTGGGCTGAA	CACTGTAACA	CTGTACATGC	GATTTCCCCA	TGGGCTTCTA
	AACATCGCCT	CACCCGACTT	GTGACATTGT	GACATGTACG	CTAAAGGGGT	ACCCGAAGAT
4021	AAATGTCACC	ATCTCCTCCC	CTGCTGTGTC	CTACTCCATT	TACTGGTTAC	AAGGTGATGT
	TTTACAGTGG	TAGAGGAGGG	GACGACACAG	GATGAGGTAA	ATGACCAATG	TTCCACTACA
4081	CAACAAGAGA	AGCTATCACA	ACACCAGGGC	TGTGCACACG	TGCACACACA	TGTATGCACA
	GTTGTTCTCT	TCGATAGTGT	TGTGGTCCCG	ACACGTGTGC	ACGTGTGTGT	ACATACGTGT

Figure 19 (con't)

PDE10A compiled

4141	AGCACACAGA	TGTATGTACA	GCACACACAC	ACACACACAC	CCCAAAAGGA	GAGAAAAGGA
	TCGTGTGTCT	ACATACATGT	CGTGTGTGTG	TGTGTGTGTG	GGGTTTTCTT	CTCTTTTCTT
4201	AGAAAACATT	TATAAAAAGC	GACAGCTACC	CCCATATTCA	AAAATAGTTC	TTTTCCCTGT
	TCTTTTGTAA	ATATTTTTCG	CTGTCGATGG	GGGTATAAGT	TTTTATCAAG	AAAAGGGACA
4261	AGGGAAACAG	GTAGCTCTCC	ATAAGGAAAT	TATCATGAGT	GTGTTCTCCC	ATCAGTGCAC
	TCCCTTTGTC	CATCGAGAGG	TATTCTTTTA	ATAGTACTCA	CACAAGAGGG	TAGTCACGTG
4321	TTCTCCCAGG	GGTGCTCACT	GAAGCTGGTC	CACGTCTATA	AACAGGTGAC	ACTGGCTGCA
	AAGAGGGTCC	CCACGAGTGA	CTTCGACCAG	GTGCAGATAT	TTGTCCACTG	TGACCGACGT
4381	GCAAAAAGCC	ATTCGATCCA	CACAAATTGA	TCTTCTATCA	TCTTGGAATC	TGAATTGCAG
	CGTTTTTTCG	TAAGCTAGGT	GTGTTTAACT	AGAAGATAGT	AGAACCTTAG	ACTTAACGTC
4441	GGAGGAGCAG	CATGTAAGAC	GACCGTTTTA	TTCAGGCATT	CCGAAGGCAT	GAGCGCATGG
	CCTCCTCGTC	GTACATTCTG	CTGGCAAATT	AAGTCCGTAA	GGCTTCCGTA	CTCGCGTACC
4501	ATTCTGTCAC	CAAGCGTATA	AAAGGACCCT	GGCATTGGGA	AACCTATGAC	GGACTGTTTT
	TAAGACAGTG	GTTTCGCATAT	TTTTCTGGGA	CCGTAACCCT	TTGGATACTG	CCTGACAAAA
4561	TGCTGTAGAA	GTAGGGATTT	TACAGAAGTC	TCCTTGGATT	TGCCCTGCCT	GGGGCAGTTT
	ACGACATCTT	CATCCCTAAA	ATGTCTTCAG	AGGAACCTAA	ACGGGACGGA	CCCCGTCAAA
4621	TGCAGAGGAA	CCTGCCAGAG	ATTTATTGGC	TGGTCAGTCT	CTTGTGAAAT	AGTATCATGT
	ACGTCTCCTT	GGACGGTCTC	TAAATAACCG	ACCAGTCAGA	GAACACTTTA	TCATAGTACA
4681	GAGAAACAGT	TTGTAGAAAA	AACTATAACC	TGGGAAGACC	TTTGCAACAT	TGTTCTCTCC
	CTCTTTGTCA	AACATCTTTT	TTTGATATGG	ACCCTTCTGG	AAACGTTGTA	ACAAGGAAGG
4741	ATGGGCCAAG	ACTCAGTTAG	GAGGCATAAA	TCTGCCCGGA	ATAAACTAGG	CCAGGATACA
	TACCCGGTTC	TGAGTCAATC	CTCCGTATTT	AGACGGGCCT	TATTTGATCC	GGTCTATGT
4801	GCCATGTTTA	GTTAATAATT	TGGTTTTAGA	ATTCACACAG	GCAGGATTGG	TTTTTTTGTG
	CGGTACAAAT	CAATTATTAA	ACCAAAATCT	TAAGTGTGTC	CGTCCTAACC	AAAAAACAC
4861	TCTTGGCAAG	TGGAGCATAT	TTAACATACA	GGCATGGGAA	TCCTGCCTCT	TAGCTTTTCC
	AGAACCCTTC	ACCTCGTATA	AATTGTATGT	CCGTACCCTT	AGGACGGAGA	ATCGAAAAGG
4921	CACCCTCTTG	TCTCACCAAG	TTTTTTCTCT	CCAAAGGTTT	CCAGGAATTT	CTCATTAATG
	GTGGGAGAAC	AGAGTGGTTC	AAAAAAGAGA	GGTTTCCAAA	GGTCCTTAAA	GAGTAATTAC
4981	GCTGATGCAA	ACTTAGTGAA	TAATAATGAA	TATAAACAAT	GCTCACCTCA	CCAAAATTAT
	CGACTACGTT	TGAATCACTT	ATTATTACTT	ATATTTGTTA	CGAGTGGAGT	GGTTTTAATA
5041	ATTATTTGCA	GTCATTTGTG	ATAACACAAA	TTTTATCGCA	ATGGTTATTA	TTTAATTTGT
	TAATAAACGT	CAGTAAACAC	TATTGTGTTT	AAAATAGCGT	TACCAATAAT	AAATTAAGCA
5101	GGCCACACAC	TGTGGTTATC	TTTTGTTGTG	GTTGTTTCTG	AGAAAATGTT	CTTGGATATG
	CCGGTGTGTG	ACACCAATAG	AAAACAACAC	CAACAAAGAC	TCTTTTACAA	GAACCTATAC
5161	TAAGTGCCAA	TACCAAGTGT	AAGTATTGAT	CCCGGGCAGC	AAAATACAGC	CTAAGGTTTG
	ATTCACGGTT	ATGGTCACAC	TTCATAACTA	GGGCCCCGTC	TTTTATGTCG	GATTCCAAAC
5221	TAAACATCAA	TTCTATCTCA	GTTTCATCAG	GGGCCTGAGA	AGCTGCGGGG	CAGTGTAAG
	ATTTGTAGTT	AAGATAGAGT	CAAGTAGTCT	CCCGGACTCT	TCGACGCCCC	GTCACATTTT
5281	TAAAGTATGC	TGGGCTGGTG	GTGGTCAGCC	TCCCTTGCC	AAGAAGAGAG	CAATTGAATC
	ATTTCATACG	ACCCGACCAC	CACCAAGTCG	AGGGGAACGG	TTCTTCTCTC	GTTAACTTAG
5341	CTGTCCCCAG	CTCCCTCCAC	GCCTGAAGAG	TGACCAAGTGC	TGGCCCAGCG	GATCGCTGAG
	GACAGGGGTC	GAGGGAGGTG	CGGACTTCTC	ACTGGTCACG	ACCGGGCTGC	CTAGCGACTC
5401	ATATTCTCCC	ATAATGGCAA	AAAAATAGGC	AGTTTGATGT	GACCTGTTTA	GTGTGGCTCT
	TATAAGAGGG	TATTACCGTT	TTTTTATCCG	TCAAATACAC	CTGGACAAAT	CACACCGAGA
5461	CCTCTTTTGA	GCATGTGTTA	GCATTTTTAT	TTTATACTCA	TCCAGTGAAC	TCTGCTCTTC
	GGAGAAAAC	CGTACACAAT	CGTAAAAATA	AAATATGAGT	AGGTCACTTG	AGACGAGAAG

Figure 19 (con't)

PDE10A compiled

5521	CAAGTGTGTT	CATGTATGTG	CTAGATATAT	TAGCACAGCC	TGCCTTCTGC	TGCACAACGC
	GTTCCACACAA	GTACATACAC	GATCTATATA	ATCGTGTCCG	ACGGAAGACG	ACGTGTTGCG
5581	CTTAGAGACC	CGGCCTTTCA	ATGAGCTTAG	CTTGTGCTCT	GTTTCTGCTC	TCTTAGGTCT
	GAATCTCTGG	GCCGGAAAGT	TACTCGAATC	GAACACGAGA	CAAAGACGAG	AGAATCCAGA
5641	AAACTATGGT	GTCAGTTTTA	ATAGAACAAA	AGTATGCATC	TTGCCTTGGC	TTGAGCCTTT
	TTTGATACCA	CAGTCAAAAT	TATCTTGTTT	TCATACGTAG	AACGGAACCG	AACTCGGAAA
5701	TCGTTTTTCAA	TGCTGACTTC	TCCCCTTTCT	CTCCTGTGCT	CACCTTACCT	TTCCAGAGTG
	AGCAAAAGTT	ACGACTGAAG	AGGGGAAAGA	GAGGACACGA	GTGGAATGGA	AAGGTCTCAC
5761	TAAGGGACAA	CTTTTAAGGA	GGCGTGTCCC	TGGTAGGGGC	ATCCCTGTTC	ACCAGGTGCC
	ATTCCCTGTT	GAAAATTCCT	CCGCACAGGG	ACCATCCCCG	TAGGGACAAG	TGGTCCACGG
5821	TGTCATCACC	CCACTTGACT	GACATCTACC	CTGGTGACTA	TGGGTTCCTC	TTGTTTGTAG
	ACAGTAGTGG	GGTGAAGTGA	CTGTAGATGG	GACCACTGAT	ACCCAAGGAG	AACAAACATC
5881	GGAACGGTGG	CTCCAGGTGG	AGGCATCAAT	CTGTTGGGTT	CTGGTTCCCG	GCTGCCTTTG
	CCTTGCCACC	GAGGTCCACC	TCCGTAGTTA	GACAACCCAA	GACCAAGGGC	CGACGGAAAC
5941	GTTTTGAAAG	TCTCTTCTCT	GTATATTCCT	ACCCTGCATT	TGCTTTGTGT	GGTGCTGATG
	CAAACTTTTC	AGAGAAGAGA	CATATAAGGA	TGGGACGTAA	ACGAAACACA	CCACGACTAC
6001	CTGTGGCAGT	AGGATCTTGG	ATGACTCTCC	ATCAGTCACA	GACTCCCCCT	GTTGCAAAGT
	GACACCGTCA	TCCTAGAACC	TACTGAGAGG	TAGTCAGTGT	CTGAGGGGGA	CAACGTTTCA
6061	GTCAGGCTGA	CTCGACAGTC	ACCGTAAAAT	CTGAGTCAGT	CACACACAGG	CTGTCAGCCA
	CAGTCCGACT	GAGCTGTCAG	TGGCATTTTA	GAFTCAGTCA	GTGTGTGTCC	GACAGTCGGT
6121	CGGCTTCCAC	TTGCATGGCT	ATTCTATTTT	CACACGTGAG	TTTCTGTTGC	TGGCTGGCTG
	GCCGAAGGTG	AACGTACCGA	TAAGATAAAA	GTGTGCACTC	AAAGACAACG	ACCGACCGAC
6181	ACTGGCATT	TCTATGCTAA	GTTGAAATCA	GGAGTGTGCC	CAGCAGAGCC	CATCATTCTC
	TGACCGTAAT	AGATACGATT	CAACTTTAGT	CCTCACACGG	GTCGTCTCGG	GTAAGTAAGAG
6241	ACTGTCTTTG	AAACAAAGCT	GTACGGTTTG	ATCGATGAAC	GTATTTAAAG	CATTTTCATGC
	TGACAGAAAC	TTTGTTTCGA	CATGCCAAAC	TAGCTACTTG	CATAAATTTT	GTAAAGTACG
6301	AATGACAAAG	TGCTCAGTAG	TGGAAGGCAG	GCTGTGACCA	GTCTGCCTGC	TCCTTACTAT
	TTACTGTTTC	ACGAGTCATC	ACCTTCCGTC	CGACACTGGT	CAGACGGACG	AGGAATGATA
6361	AATTGTGAGG	ATTTGTTACT	GGAACAGTAC	ATGGAGGCCT	GACCTTGTGG	GGGCACAGGG
	TTAACACTCC	TAAACAATGA	CCTTGTCATG	TACCTCCGGA	CTGGAACACC	CCCGTGTCCC
6421	TGGAACCTTA	GCTGAATATA	GTGTGTGTCT	CAAGAGGAAG	TCAGGGTACT	AGCTCAGTGC
	ACCTTGGAAT	CGACTTATAT	CACACACAGA	GTTCTCCTTC	AGTCCCATGA	TCGAGTCACG
6481	TCAATCTCCA	GGTACTATAT	ATACATTTGC	CCGTTTTATC	TCTAATGTGA	AATAAATCCC
	AGTTAGAGGT	CCATGATATA	TATGTAAACG	GGCAAAATAG	AGATTACACT	TTATTTAGGG
6541	CAAACACTTG	TTTATCGTGT	AGCGTACCTA	AAAGACTATT	CTATTATGGG	TGTCCCCACT
	GTTTGTGAAC	AAATAGCACA	TCGCATGGAT	TTTCTGATAA	GATAAATACC	ACAGGGGTGA
6601	TTCTTGGTTT	GGTCACCCCG	ATCCCCCGGT	CTTCTGCTGT	ATCTAGAACA	GTGACTATAA
	AAGAACCAAA	CCAGTGGGGC	TAGGGGGCCA	GAAGACGACA	TAGATCTTGT	CACTGATATT
6661	ATGATGTATG	GGAATAGTGT	TTCCATATGA	TCTGTTGTCT	GGAGTATATG	CTACATGTTC
	TACTACATAC	CCTTATCACA	AAGGTATACT	AGACAACAGA	CCTCATATAC	GATGTACAAG
6721	ATTTACTGTA	CAAAAACCCA	GTGCAGCTGA	TGATGCAAAG	CAGTCTCTCT	CTGTGTACAG
	TAAATGACAT	GTTTTTGGGT	CACGTGCACT	ACTACGTTTC	GTCAGAGAGA	GACACATGTC
6781	TGCCCCACCT	ATTTAAAAAT	CACGTACAAN	CCCAGAACAC	TGTGAAACAC	TTAACATAAG
	ACGGGGTGGA	TAAATTTTTA	GTGCATGTTN	GGGTCTTGTT	ACACTTTGTG	AATTGTATTTC
6841	AAACAAACGC	AGCGTCTGGA	TTCTTTCCAA	GGAGAGCAGC	TTTCTCCACA	GGAACACAGT
	TTTGTGTTGCG	TCGCAGACCT	AAGAAAGGTT	CCTCTCGTCC	AAAGAGGTGT	CCTTGTGTCA

Figure 19 (con't)

PDE10A compiled

6901	AACAAAAGAG	GTCCGCCGCC	ATCCACACCC	AGCCAAGACA	CCTCAGAGGC	CATAGGGACA
	TTGTTTTCTC	CAGGCGGCGG	TAGGTGTGGG	TCGGTTCTGT	GGAGTCTCCG	GTATCCCTGT
6961	ACCTCCTTGC	TGGCCAACAC	CTGCTGGAGC	AGGGCACAGG	TCCCAGCAAC	TGATCCTCAG
	TGGAGGAACG	ACCGGTTGTG	GACGACCTCG	TCCCGTGTCC	AGGGTCGTTG	ACTAGGAGTC
7021	TGGATGGGTC	CGCAGTCAAA	GCCTTAATGG	GCTCTCTTTT	GAAGGGGAAA	GAAANNNTTC
	ACCTACCCAG	GCGTCAGTTT	CGGAATTACC	CGAGAGAAAA	CTTCCCTTTT	CTTTNNAAAG
7081	AAGCTTATGA	TATCCAACAT	TATTATAGTT	GATGAGTTAG	TAAATTCCGA	AAAAAAAAGA
	TTCGAATACT	ATAGGTTGTA	ATAATATCAA	CTACTCAATC	ATTTAAGGCT	TTTTTTTTCT
7141	TGATTTTATA	TGTATGACAT	AAAAAAAATC	TTTGTAAGT	GCGCAAGTGC	AATAATTTAA
	ACTAAAATAT	ACATACTGTA	TTTTTTTTTAG	AAACATTTCA	CGCGTTCACG	TTATTAAATT
7201	AGAGGTCTTA	TCTTTGCATT	TATAAATTAT	AAATATTGTA	CATGTGTGTA	ATTTTTCATG
	TCTCCAGAAT	AGAAACGTAA	ATATTTAATA	TTTATAACAT	GTACACACAT	TAAAAAGTAC
7261	TATTCATTTG	CAGTCTTTGT	ATTTAAAAAA	ACTTTACTGT	TATGTTTGTA	TAATAGAACA
	ATAAGTAAAC	GTCAGAAACA	TAAATTTTTT	TGAAATGACA	ATACAAACAT	ATTATCTTGT
7321	TTAATCATTT	ATTATAACTC	AGACAAGGTG	TAAATAAATT	CATAATTCAA	ACAGCCAGTA
	AATTAGTAAA	TAATATTGAG	TCTGTTCCAC	ATTTATTTAA	GTATTAAGTT	TGTCGGTCAT
7381	TATATGCATA	TATGGGTGTT	ACATTGCAAA	AATCTCTATC	TTTGTTCTAT	TCACATGCTT
	ATATACGTAT	ATACCCACAA	TGTAACGTTT	TTAGAGATAG	AAACAAGATA	AGTGACGAA
7441	AAAGAAGTAA	GAAATCTTTT	GTGGATATGT	AATTATACAT	ATAAAGTATA	TATATATGTA
	TTTCTTCATT	CTTTAGAAAA	CACCTATACA	TTAATATGTA	TATTTTCATAT	ATATATACAT
7501	TGATACATGA	AATATATTTA	GAAATGTTCA	TAATTTTAAT	GGATATTCTT	TGGTGTGAAT
	ACTATGTACT	TTATATAAAT	CTTTACAAGT	ATTAAAATTA	CCTATAAGAA	ACCACACTTA
7561	AATTGAATAC	AACATTTTTT	AAATGAAAAA	AAAAAAAAAA	AAAAAAAAAA	AAAAAAAA
	TTAACTTATG	TTGTAAAAAT	TTTACTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTT

DECLARATION, POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND COMPOUNDS FOR MODULATING SAME, the specification of which

(Check ☒ is attached hereto.
one)

☐ was filed on _____ as
Application Serial No. _____
and was amended on _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, S.1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, S.119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority
Claimed

(Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
----------	-----------	------------------------	------------------------------	-----------------------------

I hereby claim the benefit under Title 35, United States Code, S. 119(e) of the United States provisional applications listed below.

<u>60/158,043</u>	<u>October 7th, 1999</u>
(Application Number)	(Filing Date)

<u>60/217,765</u>	<u>July 12th, 2000</u>
(Application Number)	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, S.120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, S.112, I acknowledge the duty

to disclose material information as defined in Title 37, Code of Federal Regulations, S.1.56(a) which occurred between the filing date of the prior

[illegible]

application and the national or PCT international filing date of this application:

<u>(Application Serial No.)</u>	<u>(Filing Date)</u>	<u>(Status)</u>
		(Patented, pending, abandoned)

POWER OF ATTORNEY

I hereby appoint P. E. McArdle (Registration No. 26,138), R.A.R. Parsons (Registration No. 28,159), P. K. Holland (Registration No. 28,174), J. R. Lake (Registration No. 31,081), R. S. Mitchell (Registration No. 31,228), W. B. Vass (Registration No. 36,416), R.H. Joachim (Registration No. 40,353), David Heller (Registration No. 43,384) and Ian McMillan (Registration No. 43,390) telephone no. (416) 868-1482, as my attorneys or agents to prosecute this application, to make alterations or amendments therein, to receive the patent and all correspondence relating to this application, and to transact all business in the U.S. Patent and Trademark Office connected therewith, and the said attorneys or agents are hereby given full power of substitution and revocation.

Address all correspondence and telephone calls to:

Mr. David J. Heller
c/o Ridout & Maybee
Suite 2400, One Queen Street East
Toronto, Ontario, Canada, M5C 3B1

Telephone: (416) 868-1482

I hereby declare that all statements made herein of my own know-ledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dr. Harold A. Robertson
Full name of first inventor

H.A. Robertson
Inventor's Signature

4/10/00 Canadian
Date Citizenship

Post Office Address:

2384 Clifton St., Halifax, Nova Scotia, Canada B3K 4V1

Residence Address:

2384 Clifton St., Halifax NS B3K 4V1

Dr. Eileen M. Denovan-Wright

Full name of second inventor

E. Denovan-Wright

Inventor's Signature

October 4, 2000

Date

Canadian

Citizenship

Post Office Address

22 Fleming Dr. Halifax, Nova Scotia, Canada B3P 1A9

Residence Address:

22 Fleming Dr. Halifax, Nova Scotia, Canada B3P 1A9

SEQUENCE LISTING

<110> ROBERTSON, Harold
 DENOVAN-WRIGHT, Eileen
 NOVANEURON, INC.

<120> GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND
 COMPOUNDS FOR MODULATING SAME

<130> 36541-0005

<140>

<141>

<150> US60/158,043

<151> 1999-10-07

<150> US60/217,765

<151> 2000-07-12

<160> 12

<170> PatentIn Ver. 2.0

<210> 1

<211> 3236

<212> DNA

<213> mouse

<400> 1

```
cactgaagct ggtccacgtc tataaacagg tgacactggc tgcagcaaaa agccattcga 60
tccacacaaa ttgatcttct atcatcttgg aatctgaatt gcagggagga gcagtatgta 120
agacgaccgt ttaattcagg cattccgaag gcatgagcgc atggattctg tcaccaagcg 180
tataaaaagga ccctggcatt gggaaaccta tgacggactg tttttgctgt agaagtaggg 240
attttacaga agtctccttg aatttgcctt gcctggggca gttttgcaga ggaacctgcc 300
agagatttat tggctggtca gtctcttgtg aaatagtatc atgtgagaaa cagttttag 360
aaaaaaacta tacctgggaa gacctttgca acattgttcc ttccatgggc caagactcag 420
ttaggaggca taaatctgcc cggaataaac taggccagga tacagccatg tttagttaat 480
```

aatttggttt tagaattcac acaggcagga ttggtttttt tgtgtcttgg caagtggagc 540
atatttaaca tacaggcatg ggaatcctgc ctcttagctt ttcccaccct cttgtctcac 600
caagtttttt ctctccaaag gtttcagga atttctcatt aatggctgat gcaaacttag 660
tgaataataa tgaatataaa caatgctcac ctccacaaaa ttatattatt tgcagtcatt 720
tgtgataaca caaatTTTTat cgcaatgggt attatttaaat ttgtggccac aactgtgggt 780
tatcttttTgt tgtgggtTgt tctgagaaaa tgttcttTga tatgtaagtg ccaataccag 840
tgtgaagtat tgatcccggg cagcaaaata cagcctaagg tttgtaaaca tcaattctat 900
ctcagttcat cagagggcct gagaagctgc ggggcagtgt aaagtaaagt atgctgggct 960
ggTggTggTc agcctcccgc ctgaagagt accagtgtctg gcccgacgga tcgctgagat 1020
attctcccat aatggcaaaa aaataggcag tttgatgtga cctgtttagt gtggctctcc 1080
tcttttgagc atgtgttagc atttttatTT tatactcatc cagtgaactc tgctcttcca 1140
agtgtgttca tgtatgtgct agatatatta gcacagcctg cttctgtctg cacaacgcct 1200
tagagaccgc gcctttcaat gagcttagct tgtgtctctgt ttctgtctct ttaggtctaa 1260
actatggTgt cagttttaat agaacaaaag tatgcatctt gccttggctt gagcctttttc 1320
gttttcaatg ctgaacttct ccctttctct cctgtgtctc ccttaccttt ccagagtgtA 1380
agggacaact tttAaggagg cgtgtccctg gtaggggcat ccctgttcac caggTgcctg 1440
tcatcacccc acttgactga catctaccct ggtgactatg ggTtccctt gtttgtaggg 1500
aacggtggct ccaggTggag gcatcaatct gttgggttct ggTtcccggc TgcctttggT 1560
tttgaaagtC tcttctctgt atattcctac cctgcatttg ctttTgtTgg Tgctgatgct 1620
gtgcgcagta ggattctTgg atgactctcc atcagtcaca gactccccct gttgcaaagt 1680
gtcaggctga ctgcacagtc accgtaaaat ctgagtcagt cacacacagg ctgtcagcca 1740
cggcttccac ttgcatggct attctatTTT cacacgtgag tttctgtTgc Tggctggctg 1800
actggcatta tctatgctaa gttgaaatca ggagtGCCa gcagagccca tcattctcac 1860
tgtctttgaa acaaagctgt acggtttgat cgatgaacgt atttaaagca tttcatgcaa 1920
tgacaaagtg ctcagtagtg gaaggcaggc tgtgaccagt ctgcctgtct ctTactataa 1980
ttgtgaggat ttgttactgg aacagtacat ggaggcctga cttgtgggg gcacagggtg 2040
gaaccttagc tgaatatagt gtgtgtctca agaggaagtc agggTactag ctcagtgtct 2100
aatctccagg tactatatat acatttgccc gttttatctc taatgtgaaa taaatcccca 2160
aacacttgTt tatcgtgtag cgtacctaaa agactattct attatgggtg tccccacttt 2220
cttggtttTg Tcacccegat ccccggtct tctgtgtat ctagaacagt gactataaat 2280
gatgtatggg aatagtgttt ccatatgatc tgttgtctgg agtatatgct acatgttcaa 2340
ttactgtaca aaaaccagT gcagctgatg atgcaaagca gtctctctct gtgtacagtg 2400
ccccacctat ttaaaaatca cgtacaasc cagaacactg tgaaacactt aacataagaa 2460
caaacgcagc gtctggattc tttccaagga gagcagcttt ctccacagga acacagtaac 2520
aaaagaggTc cgccgcctac cacaccagc caagacacct cagaggccat agggacaacc 2580
tccttgtctg ccaacacctg ctggagcagg ggcacaggTc ccagcaactg atcctcagtg 2640
gatgggtccg cagtcaaagc cttaatgggc tctcttttga aggggaaaga aagaatttca 2700
agcttatgat atccaacatt attatagttg atgagttagt aaattccaaa aaaaaaagat 2760
gattttatat gtatgacata aaaaaaatct ttgtaaagtg cgcaagtgca ataatttaaa 2820

gagggtcttat ctttgcattt ataaattata aatattgtac atgtgtgtaa tttttcatgt 2880
 attcatttgc agtctttgta tttaaaaaaaa ctttactggt atgtttgtat aatagaacat 2940
 taatcattta ttataactca gacaagggtg aaataaattc ataattcaaa cagccagtat 3000
 atatgcata atgggtgtta cattgcaaaa atctctatct ttgttctatt cacatgctta 3060
 aagaagtaag aaatcttttg tggatatgta attatacata taaagtatat atatatgtat 3120
 gatacatgaa atatatattag aaatgttcat aattttaatg gatattcttt ggtgtgaata 3180
 attgaataca acatttttaa aatgaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 3236

<210> 2

<211> 5752

<212> DNA

<213> mouse

<400> 2

aagtgtaaat aaaataaaca tctaataaaa aaaattacat accatagagg aacaagataa 60
 tttctgcccc acttcatacc ctccagcgta tagtggtgag gtttggctctg ttgctgtgta 120
 ttgtaatgta atgttaaatt ctctacctga aggtctaggg ctacaagtga attctcatgt 180
 ttatagagtt ttgttgtgca aaccttggtc cttaatttaa aactatgggt aaaaaacaaa 240
 aaaaaactgg ctacagccaa taactgaagg gggttacctt gttgaagggg tggaaaagag 300
 agaggaggaa gaaggaggtt caagagaagg agaagaacaa gaggagagga ggaagctgcc 360
 acgaggggag atggggccatg agaacttggc caggagaaat agccagtatc tggagtacac 420
 cactgaggag gtagccaggc tagcagttag aagagtagat tagggggttat ttttcccca 480
 ctccacatag ttatcaaagc caaataaaat aaccatagtc tgagtctcat ctatttgtaa 540
 gctagttagg tataagatta atttggctgt actacagttt agattttctaa cataggaact 600
 atcaaaaact tgctcaaaca agaacatgct gacaatattt taaaatgatt atttatattg 660
 tttgcacttt ctaaagtttc ttctaaatgt tccatggcca aattaaaaaa tatacatatt 720
 ggctattaaa ttctgtctaag tggggctgga gagatagctc agagggttaag agcactgact 780
 gctcttcag aggtcctgag ttcaattccc agcgaccaca tgggtggctca cagccatctg 840
 taatagatag gatctgacgc cctcttctgg agtgtctgaa gacagctaca atgtactcat 900
 atatattaaa taaataatat tagaaaattc ttctaagtgt atcatttata gaatatttaa 960
 tatataaagt aaatgcctca ggaaatataa acttggaatt aaatcaaaga acttcatgag 1020
 tagtgggcca caaaaaatgt gtaccagggg aagaccggag ggaggggaga aggaagggat 1080
 ggagatagaa ttttgctctc gcattccttg ggctggcaca ggtataatgc tgtgggaatt 1140
 gggaaactac aaggaagctg caaagctggg cggaactcgt ttccgcaagc tgggctcatc 1200
 taagtgtcca tgcattggctg ccacactgca gtgaacttta aaacatttgt gttccagaga 1260
 tgtagagatg ctcaaatag tacaaggcg ggagggaggt atttccagac taagaggaag 1320
 aaaaaccatt gctgattaaa catctgcata tgagcgcccc cacctccata cacacacaca 1380
 cacacacaca cacacacaca caaccaaaaa gaacaaatac acatgcatgt ctacagcctg 1440
 caggaacaaa atgggtatgtc tgtgaggaac caggagatgc acaggtccta acctctgtct 1500

cctacaagcc ctgaagctctg gtcagggtca aatgtacaaa agcaggctaa ggaagctggt 1560
tagtgaaaga ttttttttctt caactctagg aacaacctat ttcctaggat ttggagagtg 1620
ctcaggagga aacattcaga caactgatgc tctctgtgta ccccagattc aggtattggg 1680
gtagttagtt gtgctcatgt atgtgctaga tatattagca cagcctgcct tctgctgcac 1740
aacgccttag agaccgggcc tttcaatgag cttagcttgt gctctgtttc tgctctctta 1800
gggtctaaact atgggtgtcag ttttaataga acaaaagtat gcattcttgc ttggcttgag 1860
ccttttcgtt ttcaatgctg acttctcccc tttctctcct gtgctcacct tacctttcca 1920
gagtgttaagg gacaactttt aaggaggcgt gtccctggta ggggcatccc tgttcaccag 1980
gtgcctgtca tcacccact tgactgacat ctaccctggg gactatgggt tctcttgggt 2040
tgtagggaac ggtggctcca ggtggaggca tcaatctggt gggttctggg tcccggtgc 2100
ctttggtttt gaaagtctct tctctgtata ttccctacct gcatttgctt tgtgtgggtgc 2160
tgatgctgtg cgcagcagga ttcttggatg actctccatc agtcacagac tccccctgtt 2220
gcaaagtgtc aggctgactc gacagtcacc gtaaaatctg agtcagtcac acacaggctg 2280
tcagccacgg cttccacttg catggctatt ctattttcac acgtgagttt ctgttgctgg 2340
ctggctgact ggcattatct atgctaagtt gaaatcaggg gtgccagca gagcccatca 2400
ttctcactgt ctttgaaaca aagctgtacg gtttgatcga tgaacgtatt taaagcattt 2460
catgcaatga caaagtgtc agtagtgga ggcaggctgt gaccagtctg cctgctcctt 2520
actataattg tgaggatttg ttactggaac agtacatgga ggcctgacct tgtgggggca 2580
caggggtgga ccttagctga atatagtgtg tgtctcaaga ggaagtcagg gtactagctc 2640
agtgctcaat ctccaggtag tatatatata tttgcccgtt ttatctctaa tgtgaaataa 2700
atcccaaac acttgtttat cgtgtagcgt acctaaaaga ctattctatt atgggtgtcc 2760
ccactttctt ggtttggtca cccgatccc ccggtcttct gctgtatcta gaacagtgc 2820
tataaatgat gtatgggaat agtgtttcca tatgatctgt tgtctggagt atatgctaca 2880
tgttcattta ctgtacaaaa acccagtgc gctgatgatg caaagcagtc tctctctgtg 2940
tacagtgcc cacctattta aaaatcacgt acttgcccag aacctgtga aaccttaac 3000
ataagaacaa acgcagcgtc tggattcttt ccaaggagag cagctttctc cacaggaaca 3060
cagtaacaaa agaggccgc cgccatccac acccagccaa gacacctcag aggccatagg 3120
gacaacctcc ttgctggcca acacctgctg gagcaggggc acagggtcca gcaactgatc 3180
ctcagtggat ggtctgcag ccaaagcctt aatgggctct cttttgaagg ggaaagaaag 3240
aatttcaagc ttatgatatc caatattatt atagttgatg agttagttaa ttccaaaaaa 3300
aaaagatgat tttatatgta tgacataaaa aaaatctttg taaagtgcgc aagtgaata 3360
atttaaagag gtcttatctt tgcatttata aattataaat attgtacatg tgtgtaattt 3420
ttcatgtatt catttgagcgt ctttgatatt aaaaaactt tactgttatg tttgtataat 3480
agaacattaa tcatttatta taactcagac aagggtgtaa taaattcata attcaaacag 3540
ccagtatata tgcatatatg ggtgttacat tgcaaaaatc tctatctttg ttctattcac 3600
atgcttaaag aagtaagaaa tcttttgtgg atatgtaatt atacatataa agtatatata 3660
tatgtatgat acatgaaata tatttagaaa tgttcataat tttaatggat attctttggg 3720
gtgaataatt gaatacaaca tttttaaaat aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3780
aaaatttttt tttttttttt ttattccaga gattaaagac actagatctt taaccttgaa 3840

```

gggcaggcaa gaggtcggca atgctgtcaa catagaagtc agggaccatt ttcttcttga 3900
acatgcagtc actttcctga ttgctcttca catcctcaag gctccggaat tccgggggtg 3960
tggtgggctt tgatctcagg actctggagg cagaagcagg cagatctctg tgaatatgag 4020
gccagcctgc actacacaga gctccagacc agtcatggct acatcatgaa accctgtctc 4080
aaaaagaaaa taaaaactgt tgtgtttcta ccatagtgtt aaactcagag tctgagtaat 4140
gtcgggctga catgctcggg tgtttaacat accttcagct ttgacgaggc gctgaacagt 4200
caaagtctgg ccttggggag cgggtggctgt gtttgtgctc aagtccaccg tgaaatcctg 4260
attgtgaatt tggacaaccg tgccttctt cttggccttc catgcaacct ccaacttcat 4320
gttggtcatt ttgtcaaac actgtgtgat gtttttatca atatactgcc attccacata 4380
tgtagagatg tagtctgcct ggctttcctt ttcttttagcc aatcgaatgc tcttgatcat 4440
gccctcaatc tcactcttag ctttttatcac gtctctgcta attcctgaaa cttgaatcga 4500
agttttcttc tggttcatct caatggtgat gtccagttcc ttctgaatct cattcagttt 4560
ctcgtactcc tccatgtcaa agtcaactgac acactcatcg tcattgggtgt aggaaagctg 4620
ctctttggta atcagttcct ttagccagga gattgttttg ttcacactgt ctaccctga 4680
accacatacc tggaaaactg tgtgctctat tttcttttcc aaaaccaggg tgttcttttt 4740
gggggaagct tgcttgggaa agccaagaaa ggctaaagag aaaatggaaa ttaatgtttc 4800
ttttactccc ttcaacatca aggttaggaa tatgtatttc ataaaagcta acaactcaca 4860
ggcaatctta gacatcactg actgcttggc aggcgactgc ttggggggag ctggagagcc 4920
ttctctttct ttcattgtgt cgtaaaaaaa ttgcagaata tggggctgga agataacaac 4980
tttaactctc ttcacagcct gcactgattt tttctggaca aattcttcaa tggcatctat 5040
tatcgctttt gctactacgt ttgggtcctg ttgagcattt ccttcaaaaa caaaaaaagc 5100
acatttttaa aaagtcaagg ttaagatcca cctgcaaaaa aaagctgcaa tataagcgag 5160
gaattctagt tgtcacagga aataaaaatg tctgttccca ctataatcaa tgtagactga 5220
taatattatg ccagcaaata gttttgaagt cctaggcaca gtgggaggag gttttgttcc 5280
acgctgttca taagccaata cccagcaaaa agaccttaaa ggacaacttg taatttggga 5340
cattcacatc tgcctcttcc atctgatctg gctcccagtg tcactctcta acacggtcct 5400
tagagggaca atttatccct gcctctgctt gatcttatgc atgtatctgt attcttccag 5460
ccatccctgg cgacctgatt tttctaaggc acccaaaact gtaagctact tcttataatc 5520
tataattctg agcatattag ttagcctgag cctccaggat atctttcttc cctataactca 5580
gtccagtttt agctgccag aaggattcaa agctgatcta cgagtagatc actcctgtct 5640
acagcttggt ccagatcttg tttctcaagc cctggaagcc atcagccagg taagattgta 5700
aaacaatccc tttctaataca tgggtgtggc ccaaagtga tggccggaat tc 5752

```

<210> 3

<211> 475

<212> DNA

<213> mouse

<400> 3

tgtatgggaa tagtgtttcc atatgatctg ttgtctggag tatatgctac atgttcattt 60
 actgtacaaa aaccacagtgc agctgatgat gcaaagcagt ctctctctgt gtacagtgcc 120
 ccacctattht aaaaatcacg tacttgccca gaacactgtg aaacacttaa cataagaaca 180
 aacgcagcgt ctggattctt tccaaggaga gcagctttct ccacaggaac acagtaacaa 240
 aagaggctcg ccgccatcca caccacagcca agacacctca gaggccatag ggacaacctc 300
 cttgctggcc aacacctgct ggagcagggg cacaggctcc agcaactgat cctcagtgga 360
 tgggtctgca gccaaagcct taatgggctc tcttttgaag gggaaagaaa gaatttcaag 420
 cttatgatat ccaatattat tatagttgat gagttagtaa attccaaaaa aaaaa 475

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 4

agggctgtca atcatgctgg 20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 5

aaactcacgg tcggtgcagc 20

<210> 6

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 6

attaaccctc actaaatgct gtat

24

<210> 7

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 7

cattatgctg agtgatatct ttttttttcg

30

<210> 8

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 8

gaacatgtag catatactcc agacaacaga tcatatgg

38

<210> 9

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 9

cagcttctcc acaggaacac agtaacaaag ag

32

<210> 10

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

ctatttcaca agagactgac cagccaataa atctc

35

<210> 11

<211> 7581

<212> DNA

<213> Unknown

<400> 11

cgccccgggca ggtctgttgg agggcagttg gtcaacctga ccagagagag ctgagctgga 60
agacccccact gatggtgtgc tgcctttcag tccaggaaga aagaaaggaa ggattctgag 120
gatttgggca aagccacatt cctggagaag tctgtatact gatgccaaac ccaagagctg 180
agctgctgat gaggcccagg gagtagccca cgcgcctga gctgttggct agcaaggcct 240
tcctgctcca tgtggcatgg aaaaattata tggtttgacg gatgaaaagg tgaaggccta 300
tctttctctc catccccagg tattagatga atttgtttct gaaagtgtta gtgcagagac 360
tgtggaaaag tggctgaaga ggaaaaccaa caaagcaaaa gatgaaccat ctcccaagga 420
agtcagcagg taccaggata cgaatatgca gggagtcgtg tacgagctga acagctacat 480
agagcagcgc ctggacacgg gcgggggacaa ccacctgctc ctctatgagc tcagcagcat 540
catcaggata gccacaaaag ccgacggatt tgcactgtac ttccttggag agtgcaataa 600
tagcctgtgt gtgttcatac cacccgggat gaaggaaggc caaccccggc tcatccctgc 660
agggcccatc acccagggtta ccaccatctc tgcctacgtg gccaaagtcta ggaagacgtt 720
gttggttagag gatatccttg gggatgagcg atttcctcga ggtactggcc tggaatcagg 780
aaccgcgcatc cagtctgttc tttgcttgcc cattgtcact gccattggag acttgattgg 840
catccttgaa ctgtacaggc actggggcaa agaggccttc tgcctcagcc atcaggaggt 900
tgcaacagcc aatcttgctt gggcttccgt agcaatacac caggtgcagg tgtgtagagg 960
tctcgccaaa cagaccgaac tgaatgactt cctactcgac gtatcaaaga catactttga 1020
taacatagtt gccatagact ctctacttga acacatcatg atatatgcaa aaaatctagt 1080
gaacgccgac cgctgcgcgc tcttccaggt ggaccacaag aacaaggagc tgtactcgga 1140
cctgtttgac attggggagg agaaggaggg gaagcccatc ttcaagaaga ccaaggagat 1200
cagattttcc attgagaaag ggattgctgg tcaagtggca agaacaggcg aagtcttgaa 1260
cattcccgat gcctacgcgg accctcgctt taacaggagg gtggacctgt acacaggcta 1320
caccacgagg aacattctgt gtatgcccac agtgagccga ggcagcgtga ttggcgtggt 1380
gcagatggtg aacaagatca gcggtagcgc cttctccaag acagacgaga acaacttcaa 1440
gatgtttgct gtcttctgcg cactggcctt gcactgtgct aacatgtacc acaggatccg 1500

ccactcagaa tgcattctaca ggggttaccat ggagaagctt tcctaccaca gcatctgcac 1560
 ctccgaggag tggcaaggcc tcatgcgctt caacctacca gcacgcatct gccgggacat 1620
 cgagctattc cacttttgaca ttggctcctt cgagaacatg tggcctggga tctttgtcta 1680
 catgatccat cggctcttggt ggacatcctg ttttgaactt gaaaaattgt gccgttttat 1740
 catgtctgtg aagaagaact atcggcggggt tccttaccac aactggaagc atgcagtcac 1800
 ggtggcacac tgcattgtatg ccatacttca aaacaacaat ggctcttca cagacctcga 1860
 gcgcaaaggc ctgctaattg cgtgtctgtg ccatgacctg gaccacaggg gcttcagtaa 1920
 cagctacctg cagaagttcg accacccctt ggcggcgctg tactccacct ccacctgga 1980
 gcaacaccac ttctcccaga cgggtgtccat ccttcagctg gaagggcaca atatcttctc 2040
 caccctgagc tccagcgagt acgagcaggt gctggagatc atccgcaaag ccatcatcgc 2100
 caccgacctc gccctatact ttgggaacag gaagcagttg gaggagatgt accagacagg 2160
 gtcgctgaac ctccacaacc agtcccctcg agaccgtgtc atcggcttga tgatgactgc 2220
 ctgtgatctt tgctctgtga ccaaactatg gccagttaca aaattgacag cgaatgatat 2280
 atatgcagaa ttctgggctg aggggtgatga gatgaagaag ctgggcatac agccatttcc 2340
 tatgatggac agagacaagc gagatgaagt cctcaaggg cagctcggat tctacaatgc 2400
 tgtggccatt ccttgctata ccaccttgac gcagatcctc ccaccacag agcctctgct 2460
 gaaggcctgc agggataacc tcaatcagtg ggagaaggta attcgcgggg aagagacagc 2520
 aatgtggatt tcaggcccag gcccgcgcc tagcaagagc acacctgaga agctgaacgt 2580
 gaaggttgaa gactgatcct gaagtgaagt cctgatgtct gccagcaac cgactcaacc 2640
 tgcttctgtg acttcgttct ttttgttttc aaggggtgaa aacccctgt cagaaggtac 2700
 cgtcgcatat ccatgtgaag cagacgactc cctgcttgcc gcacacacct cggacagtga 2760
 gcaaccagg ctctgccgtg ttcagacgtc ggctactccg tggctccacc tgacctccga 2820
 atgctatttg ctcccaggcc agcaactgcac tgtctggagg gggcagagac cacaggagag 2880
 gttcttgctt gcactcctcc atgaggggtgt ggccagttcc ctagtctctgt gccatgctgc 2940
 tgcttggtgg cattgggttag gaatgggaca cagccccctt gttgtgaagt ttacatgtga 3000
 ccttcttata ggttaactga gtttgtggcc tggacacatg taatgaaggc cacagtccac 3060
 aggtgacaga gaaatccaaa ctgttgatta caggtgcact acaggtatgc tctttcagtc 3120
 tatctggggg cacataggtg agtctgctcc actcagaann aagcatacct ctgccctcat 3180
 ccaggggaca caggttacat ccaggcatc ggggaactga agctctcact tcaaaccatg 3240
 tcaaagaatt aaaacacctc cctccccct cactgtagcc ttcgacaact gcgccaatcc 3300
 ctttatacaa agaaaataaa agtaaggcat ataaatttcc tccagcaagc aaatcttgtg 3360
 ggtaaaaaaa aagcatgtga atnntaaca cntctanant ntncnngnat gttatggcag 3420
 aatttttagtc acgtccaaaa caaaaagatt attccagaag atacctcatc ctatgcctga 3480
 aaggctccac agcatggcgt ccgtctccca gggttctgat ccgtctcctc acggtgcaat 3540
 caggcaggac agagaggagg gctgcagggc taccacattg acccagaagg tatctcctct 3600
 caccattcag acatccataa ggaatgccaa atgctgtatt gaatagttct ctgtgtgact 3660
 ttctagagaa gccaggacac cctgagcctt tcnnggggaa ctctaaggag tcacaggttc 3720
 acaccgtggg gattttcagg atagcatgga gacagagatc cggtcgttgt tctcactcgt 3780
 gagccttgag aaggagagac tgaccagaaa cactcactca gcactctgca ggagcaggag 3840

aagatacttt aagatgaatc ttggatagat tttgatacac ccaataccat acacacagga 3900
gcttggcatt tgcaaagtct attcagtttc cttccgcgct ctgacccacg gttgtagcgg 3960
agtgggctga aactgtaac actgtacatg cgatttcccc atgggcttct aaaatgtcac 4020
catctcctcc cctgctgtgt cctactccat ttactgggta caagggtgatg tcaacaagag 4080
aagctatcac aacaccaggg ctgtgcacac gtgcacacac atgtatgcac aagcacacag 4140
atgtatgtac agcacacaca cacacacaca ccccaaaagg agagaaaagg aagaaaacat 4200
ttataaaaag cgacagctac cccatatcaa aatagtcttt cctgtaggaa acaggagctc 4260
tccataagga attatcatga gtgtgttctc ccatcagtgc actctcccag ggggtgctcac 4320
tgaagctggc ccacrtctat aaacaggtga cactggctgc agcaaaaagc cattcgatcc 4380
acacaaattg atcttctatc atcttggaa ctgaattgca gggaggagca gyatgtaaga 4440
cgaccgttta attcaggcat tccgaaggca tgagcgcgatg gattctrtca ccaagcgtat 4500
aaaaggaccc tggcattggg aaacctatga cggactgttt ttgctgtaga agtagggatt 4560
ttacagaagt ctccctgrat ttgcctgccc tggggcagtt ttgcagagga acctgccaga 4620
gatttattgg ctggtcagtc tcttgtgaaa tagtatcatg tgagaaacag tttgtagaaa 4680
aaaactatac ctgggaagac ctttgcaaca ttgttccttc catgggccaa gactcagtta 4740
ggaggcataa atctgcccg aataaactag gccaggatac agccatgttt agttaataat 4800
ttggtttttag aattcacaca ggcaggattg gtttttttgt gtcttggaac gtggagcata 4860
tttaacatac aggcattggg atcctgcctc ttagcttttc ccacctctt gtctcaccaa 4920
gttttttctc tccaaagggt tccaggaatt tctcattaat ggctgatgca aacttagtga 4980
ataataatga atataaacia tgctcacctc accaaaatta tattatttgc agtcatttgt 5040
gataacacia attttatcgc aatggttatt atttaatttg tggccacaca ctgtggttat 5100
cttttgttgt ggttgtttct gagaaaatgt tcttgatat gtaagtcca ataccagtgt 5160
gaagtattga tccggggcag caaaatacag cctaagggtt gtaaacaatca attctatctc 5220
agttcatcag agggcctgag aagctgcggg gcagtgtaaa gtaaagtatg ctgggctggc 5280
ggtggtcagc ctcccttgc caagaagaga gcaattgaat cctgtcccca gctccctcca 5340
cgctgaaga gtgaccagtg ctggcccgac ggatcgctga gatattctcc cataatggca 5400
aaaaaatagg cagtttgatg tgacctgttt agtgtggctc tctcttttg agcatgtgtt 5460
agcattttta ttttatactc atccagtga ctctgctctt ccaagtgtgt tcatgtatgt 5520
gctagatata ttagcacagc ctgccttctg ctgcacaacg ccttagagac ccggcctttc 5580
aatgagctta gcttgtgctc tgtttctgct ctcttaggtc taaactatgg tgtcagtttt 5640
aatagaacia aagtatgcat cttgccttgg cttgagcctt ttcgttttca atgctgactt 5700
ctccctttc tctcctgtgc tcaccttacc tttccagagt gtaagggaca acttttaagg 5760
aggcgtgtcc ctggtagggg catccctgtt caccaggtgc ctgtcatcac ccacttgac 5820
tgacatctac cctggtgact atgggttctt cttgtttgta gggaacggtg gctccagggtg 5880
gaggcatcaa tctgttgggt tctgggtccc ggctgccttt ggttttgaaa gtctcttctc 5940
tgtatattcc taccctgcat ttgctttgtg tgggtgctgat gctgtggcag taggatcttg 6000
gatgactctc catcagtcac agactcccc tgttgcaaag tgtcaggctg actcgacagt 6060
caccgtaaaa tctgagtcag tcacacacag gctgtcagcc acggcttcca cttgcatggc 6120
tattctattt tcacacgtga gtttctgttg ctggctggct gactggcatt atctatgcta 6180

atgctatattg ctcccaggcc agcactgcac tgtctggagg gggcagagac cacaggagag 2880
 gttcttgcct gcatectccc atgaggggtgt ggccagttcc ctagtctctgt gccatgctgc 2940
 tgcttggtgg cattggtttag gaatgggaca cacgccccctt gttgtgaagt ttacatgtga 3000
 ccttcttata ggtaactga gtttgtggcc tgggacacat gtaatgaagg tcacagtcca 3060
 caggtgacag agaaatccaa actgttgatt acaggtgcac tacaggtatg ctctttcagt 3120
 ctatctgggg gcacataggt gagtctgctc cactcagaag gaagcatacc tctscctca 3180
 tccaggggac acaggggtaca tcccaggcat cggggaactg aagctctcac ttcaaaccat 3240
 gtcaaagaat taaaacacct cccctcccc tctactgtagc cttcggcaac tgcgccaatc 3300
 cctttatata aagaaaatat aagtaaggca tataaatttc ctccagcaag caaatcttgt 3360
 gggtaaaaaa aaaaaatgtg aattttaaca acctctatat ttctactgta tggtatggca 3420
 gaatttttagt cacgtccaaa acaaaagatt attccagaag atacctcatc ctatgcctga 3480
 aagctccaca gcatggcgtc cgtctcccag ggttctgata cgtctcctca cggtgcaatc 3540
 aggcaggaca ggaggaggtg cagggctacc acattgaccc agatggatc tctctcacc 3600
 attcagacat ccataaggaa tgccaaatgc tgtattgaat agttctcctg tgtgactttc 3660
 tagagaagcc aggacacccc tgagcctttc ctgggaactc ctaaggaagt cacaggttca 3720
 caccgtgggg attttcagga tagcatggag accagagaat cccggttcgg ttgttctcac 3780
 tcggtgagcc ttgagaagga agagactgac cagaaacact cactcagcac tctggcagga 3840
 gcaggagaag atactttaag atgaatcttt gggatagatt ttgatacacc caataccata 3900
 cacacaggag cttggcattt gcaaagtcta ttcagtttcc ttccacactc tgaccacagg 3960
 ttgtagcgga gtgggctgaa cactgtaaca ctgtacatgc gatttcccca tgggcttcta 4020
 aaatgtcacc atctctccc ctgctgtgtc ctactccatt tactggttac aagtgatgt 4080
 caacaagaga agctatcaca acaccagggc tgtgcacacg tgcacacaca tgtatgcaca 4140
 agcacacaga tgtatgtaca gcacacacac acacacacac cccaaaagga gagaaaagga 4200
 agaaaacatt tataaaaagc gacagctacc cccatattca aaaatagttc ttttccctgt 4260
 agggaaacag gtagctctcc ataaggaaat tatcatgagt gtgttctccc atcagtgcac 4320
 ttctcccagg ggtgctcact gaagctggtc cacgtctata aacaggtgac actggctgca 4380
 gcaaaaagcc attcgatcca cacaaattga tcttctatca tcttggaatc tgaattgcag 4440
 ggaggagcag catgtaagac gaccgtttaa ttcaggcatt ccgaaggcat gagcgcattg 4500
 attctgtcac caagcgata aaaggacct ggcattggga aacctatgac ggactgtttt 4560
 tgctgtagaa gtagggattt tacagaagtc tccttgatt tgccctgcct ggggcagttt 4620
 tgcagaggaa cctgccagag atttattggc tggtcagtct cttgtgaaat agtatcatgt 4680
 gagaaacagt ttgtagaaaa aaactatacc tgggaagacc tttgcaacat tgttcttcc 4740
 atgggccaag actcagttag gaggcataaa tctgcccga ataaactagg ccaggatata 4800
 gccatgttta gttaataatt tggttttaga attcacacag gcaggattgg tttttttgtg 4860
 tcttggcaag tggagcatat ttaacataca ggcattggga tcctgcctct tagcttttcc 4920
 caccctcttg tctaccaag ttttttctct ccaaaggttt ccaggaattt ctcattaatg 4980
 gctgatgcaa acttagtgaa taataatgaa tataaacaat gctcacctca ccaaaattat 5040
 attatttgca gtcatttgtg ataacacaaa ttttatcgca atggttatta ttttaatttgt 5100
 ggccacacac tgtggttatc ttttgttgtg gttgtttctg agaaaatgtt cttggatatg 5160

taagtgccaa taccagtgtg aagtattgat cccgggcagc aaaatacagc ctaagggttg 5220
 taaacatcaa ttctatctca gttcatcaga gggcctgaga agctgcgggg cagtgtaaag 5280
 taaagtatgc tgggctggtg gtggtcagcc tccccttgcc aagaagagag caattgaatc 5340
 ctgtccccag ctccctccac gcctgaagag tgaccagtgc tggcccgcag gatcgctgag 5400
 atattctccc ataatggcaa aaaaataggg agtttgatgt gacctgttta gtgtggctct 5460
 cctcttttga gcatgtgtta gcatttttat tttatactca tccagtgaac tctgctcttc 5520
 caagtgtgtt catgtatgtg ctagatatat tagcacagcc tgccttctgc tgcacaacgc 5580
 cttagagacc cggcctttca atgagcttag cttgtgctct gtttctgctc tcttaggtct 5640
 aaactatggg gtcagtttta atagaacaaa agtatgcac ttgccttggc ttgagccttt 5700
 tcgttttcaa tgctgacttc tcccctttct ctctgtgct caccctacct ttccagagt 5760
 taagggacaa cttttaagga ggcgtgtccc tggtaggggc atccctgttc accaggtgcc 5820
 tgtcatcacc ccacttgact gacatctacc ctggtgacta tgggttcctc ttgtttgtag 5880
 ggaacggtgg ctccaggtgg aggcacatcaat ctggtgggtt ctggttcccg gctgcctttg 5940
 gttttgaaag tctcttctct gtatatctct accctgcatt tgctttgtgt ggtgctgatg 6000
 ctgtggcagt aggatcttgg atgactctcc atcagtcaca gactccccct gttgcaaagt 6060
 gtcaggctga ctgcacagtc accgtaaaat ctgagtcagt cacacacagg ctgtcagcca 6120
 cggcttccac ttgcatggct attctatttt cacacgtgag tttctgttgc tggctggctg 6180
 actggcatta tctatgctaa gttgaaatca ggagtgtgcc cagcagagcc catcattctc 6240
 actgtctttg aaacaaagct gtacggtttg atcgatgaac gtatttaaag catttcatgc 6300
 aatgacaaag tgctcagtag tggaaggcag gctgtgacca gtctgcctgc tccttactat 6360
 aattgtgagg atttgttact ggaacagtac atggaggcct gacctgtgtg gggcacaggg 6420
 tggaacctta gctgaatata gtgtgtgtct caagaggaag tcagggtact agctcagtgc 6480
 tcaatctcca ggtactatat atacatttgc ccgttttata tctaattgtga aataaatccc 6540
 caaacacttg tttatcgtgt agcgtaccta aaagactatt ctattatggg tgtccccact 6600
 ttcttggttt ggtaaccccg atccccggg cttctgctgt atctagaaca gtgactataa 6660
 atgatgtatg ggaatagtgt ttccatatga tctgttgtct ggagtatatg ctacatgttc 6720
 atttactgta caaaaaacca gtgcagctga tgatgcaaag cagtctctct ctgtgtacag 6780
 tgccccacct atttaaaaat cacgtacaan ccagaaacac tgtgaaacac ttaacataag 6840
 aaacaaacgc agcgtctgga ttctttccaa ggagagcagc tttctccaca ggaacacagt 6900
 aacaaaagag gtccgcgcgc atccacaccc agccaagaca cctcagaggc catagggaca 6960
 acctccttgc tggccaacac ctgctggagc agggcacagg tcccagcaac tgatcctcag 7020
 tggatgggtc cgcagtcaaa gccttaatgg gctctctttt gaaggggaaa gaaanntttc 7080
 aagcttatga tatccaacat tattatagtt gatgagttag taaattccga aaaaaaaga 7140
 tgattttata tgtatgacat aaaaaaatc tttgtaaagt gcgcaagtgc aataatttaa 7200
 agaggtctta tctttgcatt tataaattat aaatattgta catgtgtgta atttttcatg 7260
 tattcatttg cagtctttgt atttaaaaaa actttactgt tatgtttgta taatagaaca 7320
 ttaatcattt attataactc agacaagggt taaataaatt cataattcaa acagccagta 7380
 tatatgcata tatgggtgtt acattgcaaa aatctctatc tttgttctat tcacatgctt 7440
 aaagaagtaa gaaatctttt gtggatatgt aattatacat ataaagtata tatatatgta 7500

We claim:

1. A composition for treating a CAG repeat disorder comprising a compound which modulates PDE10A expression and a pharmaceutically acceptable carrier.
2. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of: quinpirole, alloxan, miconazole nitrate, MDL-12330A, and tetracycline derivatives such as demeclocycline.
3. A composition as claimed in claim 1, wherein said disorder is Huntington's disease.
4. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of:
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione.

5. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of: KS-505, IC224, SCH 51866, IBMX and Dipyridamole.
6. The use of a composition as claimed in claim 1 for treating a CAG repeat disorder comprising administering said composition to a subject in need of such treatment.
7. The use of a composition of claim 1 for treating Huntington's disease comprising administering said composition to a subject in need of such treatment.
8. A method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of:
 - (a) selecting a control animal having PDE10A and a test animal having PDE10A;
 - (b) treating said test animal using a compound; and,
 - (c) determining the relative quantity of RNA corresponding to PDE10A, as between said animals.
9. A method of claim 8, wherein said animal is a mammal.
10. A method of claim 9, wherein said mammal is a mouse.
11. A method of claim 10, wherein said mouse is R6/2 transgenic mouse.
12. A method of claim 8, wherein said CAG repeat disorder is Huntington's disease.

13. A method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of:

- (a) selecting a host cell containing PDE10A;
- (b) cloning said host cell and separating said clones into a test group and a control group;
- (c) treating said test group using a compound; and
- (c) determining the relative quantity of RNA corresponding to PDE10A, as between said test group and said control group.

14. A method of claim 13, wherein said CAG repeat disorder is Huntington's disease.

15. A method for detecting the presence of or the predisposition for a CAG repeat disorder, said method comprising determining the level of expression of RNA corresponding to PDE10A in an individual relative to a predetermined control level of expression, wherein a decreased expression of said RNA as compared to said control is indicative of a CAG repeat disorder.

16. A method of claim 15, wherein said CAG repeat disorder is Huntington's disease.

17. A method of claim 15, wherein said expression is measured by in situ hybridization.

18. A method of claim 15, wherein said expression is measured using a polymerase chain reaction.

19. A method of claim 15, wherein said expression is measured using a DNA fingerprinting

technique.